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Motivational symptoms such as fatigue, anergia, and amotivation are seen in depression, 
Parkinson’s disease, schizophrenia, and other disorders. These symptoms are often left untreated 
by the most frequently prescribed antidepressants, which typically block serotonin transport. 
Considerable evidence implicates brain dopamine (DA) in the regulation of behavioral activation 
and effort-related aspects of motivation. Animal studies of effort-based choice are being used to 
provide formal models of motivational dysfunctions in humans. Drugs that block DA transport 
(DAT) are able to reverse the effort-related effects of the vesicular monoamine transport 
inhibitor tetrabenazine, a drug that blocks DA storage and depletes DA. Many of the existing 
DAT inhibitor drugs are either classic DA blockers such as cocaine, or drugs that also stimulate 
release of DA. These drugs can produce a number of undesirable side effects, including 
psychotic symptoms and abuse liability. Thus, there is a need to develop and characterize novel 
atypical DAT inhibitors that are relatively selective and have unique binding profiles. The 
completed studies discussed here focus on the behavioral and neurochemical characterization of 
several recently synthesized atypical DAT inhibitors, with the aim of identifying a novel family 
of drugs that may be useful for the treatment of motivational dysfunctions in humans, and the 
development of physiological markers of the selection of high-effort instrumental behavior. In 
recent years, human imaging and neurophysiological studies have had sought to identify the 




Renee Rotolo, University of Connecticut, 2020 
depression and other disorders. Human studies have suggested that there is frontal 
electroencephalography (EEG) asymmetry in depressed patients, but physiological correlates of 
effort-related motivational dysfunction have not been identified in animals. To complement the 
investigation of effort-related impairments using pharmacological approaches, the final 
experiment involved the measurement of frontal cortex EEG activity of animals under 
pharmacological manipulation of DA transmission. Ultimately, the development of a 
physiological marker of effort-related dysfunction in a preclinical model may be critical for 
identifying the brain circuits involved in regulating these behaviors that can be readily translated 
to human studies. Together, results from these experiments may contribute to the identification 
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Chapter 1: Background 
Role of Dopamine (DA) in Motivated Behaviors 
Motivation has been defined as the process that allows organisms to regulate their 
internal and external environment, and control the probability, proximity, and availability of 
stimuli (Salamone et al. 2017). On a day to day basis, organisms continually make effort-related 
decisions based upon cost/benefit analyses of reinforcement preference vs. response costs such 
as effort requirements. Central dopamine (DA) has been identified as a significant regulator of 
motivated behaviors in both animal and human studies. Behavioral paradigms such as the T-
maze barrier and operant lever pressing tasks have been designed in order to measure effort-
related decision making in rodents. These tasks are useful for assessing the activational aspects 
of motivation, described as the speed, vigor, and persistence of motivated behavior (Salamone 
and Correa 2002; Salamone et al. 2016a), and for characterizing how those functions can be 
manipulated under different experimental conditions, such as depletion or antagonism of DA. 
Behavioral activation in these tasks is regularly driven by incentives and cost/benefit strategies 
that assess the perceived benefits to be gained by exerting effort to obtain a highly valued 
stimulus. When DA transmission is reduced, the typical patterns of behavior are altered, and 
animals tend to select options with lower physical effort requirements. It has been suggested that 
these behavioral effects resemble symptoms associated with human depression such as anergia 
and fatigue (Salamone et al. 2016a).  
Considerable evidence supports the role of DA in modulating the exertion of effort in 
rodents performing instrumental actions. For instance, interference with ventral striatal (i.e., 
accumbens) DA transmission preferentially affects high-effort instrumental activities elicited or 




behaviors, and reinforcer preference remain intact (Aberman and Salamone 1999; Salamone and 
Correa, 2012). Drugs that can reliably reverse the low-effort bias induced by DA antagonists or 
depletions, such as DA transport (DAT) inhibitors, act to increase extracellular DA in the 
nucleus accumbens, which supports the notion that mesolimbic DA plays a direct role in 
activational or effort-related aspects of motivated behaviors. 
 
Motivational Aspects of Depression 
Major depressive disorder (MDD) is a psychiatric illness that affects over 300 million 
people worldwide (WHO, 2018). This number has increased steadily over the past several 
decades, and has been accompanied by a dramatic increase in the number of antidepressants that 
are being prescribed. The most widely recognized symptoms of major depression are emotional 
and cognitive in nature, but patients also exhibit lassitude, lack of self-reported energy, fatigue, 
psychomotor retardation, and motivational dysfunction (Stahl, 2006; Treadway and Zald, 2011; 
Fava et al. 2014; Salamone et al. 2016a), which are often the most difficult symptoms to treat. 
The most commonly prescribed medications for MDD are selective serotonin reuptake inhibitors 
(SSRIs), which tend to improve mood and reduce rumination and anxiety, but have little to no 
effect on symptoms of motivational dysfunction and fatigue (Papakostas et al., 2006; Pae et al., 
2007; Cooper et al., 2014; Fava et al., 2014; Rothschild et al., 2014). Thus, these symptoms are 
often left untreated and can be severely debilitating.  
Patients with depression, as well as Parkinson’s disease and schizophrenia, show a low-
effort bias when tested on effort-related choice procedures (Treadway et al. 2012; Yang et al. 




individuals who report fatigue is two-fold greater compared to non-fatigued individuals (Corfield 
et al. 2016). These symptoms that involve amotivation and reductions in exertion of physical 
effort are commonly accompanied by elevated levels of pro-inflammatory cytokines such as IL-
6, IL-1β, IFN-alpha, and TFN-α (Raison et al., 2006; Dantzer et al., 2008; Dowlati et al. 2010; 
Cattaneo et al. 2013), and several of these cytokines are upregulated as a result of exposure to 
chronic stress in animals (Miller et al. 2009; Lopresti et al. 2012). Rodent studies of effort-based 
choice have paralleled results from human research on motivational dysfunction, underlining 
their utility as animal models useful in determining possible treatment strategies for these 
symptoms (Dantzer et al. 2008; Nunes et al. 2014; Yohn et al. 2016b,d). These rodent studies 
focusing on modeling of effort-related motivation symptoms are consistent with the NIMH 
Research Domain Criteria (RDoC) approach, which emphasizes the importance of characterizing 
the neural processes that underlie the development of specific psychiatric symptoms.  
 
Pharmacological Models of Fatigue and Anergia in Rats 
Pharmacological agents that reduce DA transmission are used to treat symptoms of 
disorders such as schizophrenia and Huntington’s disease, however, they have been shown to 
produce several undesirable side effects. For example, chronic treatment with DA antagonists 
such as haloperidol and other first-generation antipsychotics in schizophrenic patients is 
generally unsuccessful at treating negative symptoms such as lack of energy, fatigue, and 
amotivation (Harvey et al. 2016). In fact, drugs such as haloperidol can induce negative 
symptoms in healthy volunteers (Artaloytia et al. 2006). In addition, it has been reported that 
Huntington’s disease patients treated with tetrabenazine (TBZ), a VMAT-2 inhibitor which 




Guay, 2010; Chen et al. 2012). When animals are administered TBZ in tasks measuring effort-
related choice, high-effort baseline behavior is shifted towards a low-effort bias (Nunes et al. 
2013; Randall et al. 2012, 2014; Yohn et al. 2015a,b). These effects are not dependent upon 
changes in food intake or preference, or discrimination of reinforcement magnitude, and do not 
resemble the effects of reinforcer devaluation or appetite suppressant drugs (Nunes et al. 2013; 
Yohn et al. 2015b; Randall et al. 2012, 2014). Rodent studies have also shown that a low-effort 
bias can be induced by inflammatory challenges (Nunes et al. 2014; Yohn et al. 2016d). The 
most commonly prescribed antidepressants, which inhibit the transport of serotonin (SSRIs or 
SERT inhibitors), do not reverse the effects of TBZ when co-administered, and actually tend to 
worsen them (Yohn et al. 2016a,b). However, administration of DAT inhibitors such as 
bupropion, GBR12909, lisdexamfetamine, and methylphenidate are able to reverse the effects of 
TBZ (Nunes et al. 2013, Yohn et al. 2016a,b; Salamone et al. 2016b) and of pro-inflammatory 
cytokines (Yohn et al. 2016c). These findings emphasize the need to identify and characterize a 
group of atypical DAT inhibitor compounds that are able to reverse the effects of DA 
antagonists/depletions or pro-inflammatory cytokines. 
 
Classical vs. Atypical Dopamine Transport Inhibitors 
Several drugs that inhibit DA uptake, such as bupropion, amphetamines, 
methylphenidate, and modafinil, have demonstrated the ability to partially reverse motivational 
dysfunctions in human studies of depression and other psychiatric disorders (Stotz et al. 1999; 
Hanna et al. 2006; Pae et al. 2007; Papakostas et al. 2006; Cooper et al., 2014). However, many 
of the existing drugs that are labeled as DAT inhibitors are either classical DA uptake blockers 




effects such as psychotic symptoms and abuse liability (Wilcox et al. 2002; Todtenkopf and 
Carlezon 2006; Ostlund et al. 2014; Dong et al. 2017). Psychomotor stimulants such as 
amphetamines and cocaine are categorized as “classical” DAT inhibitors due to their action at 
the DAT and their substantial effects on extracellular DA levels (Ferris et al. 2011; Schmitt et al. 
2013; Tanda et al. 2013). When administered to rodents, both cocaine and amphetamine induce 
effects associated with recreational use and abuse liability, such as place conditioning (Tanda et 
al. 2013), conditioned DA release during self-administration (Phillips et al. 2003; Willuhn et al. 
2010; Ostlund et al. 2014), and cue-induced craving (Dong et al. 2017). Taken together, this 
evidence suggests that while yielding positive effects in some studies focusing on motivational 
symptoms, there is probably a limited therapeutic utility in psychiatry for most classical DAT 
inhibitors. This highlights the importance of investigating the effort-related motivational effects 
of drugs that inhibit the uptake of DA, but may not be as likely to promote abuse and 
dependence. 
A relatively new group of DA uptake inhibitors, known as atypical DAT inhibitors, has 
emerged over the last several years as a class of drugs that demonstrate distinct binding 
characteristics and different behavioral profiles from classical DAT inhibitors. These compounds 
are neither classified as cocaine-like DAT inhibitors nor amphetamine-like substrates and 
releasing agents due to their unique binding site and subsequent functional changes within the 
cell, resulting in a lack of cocaine-like subjective effects that result from binding (Schmitt et al. 
2008; Schmitt et al. 2013; Kohut et al. 2014). The behavioral assessment of atypical DAT 
inhibitors such as benztropine, modafinil, and vanoxerine (GBR12909), has led to the discovery 
that not all inhibitors of DA uptake show signs of abuse liability to the same extent as the 




et al. 2001; Loland et al. 2008; Schmitt et al. 2008; Tanda et al. 2013). For example, while 
modafinil inhibits DAT (Schmitt and Reith 2011), and elevates extracellular DA as measured by 
microdialysis (Mereu et al. 2017) and human imaging studies (Volkow et al. 2009), this drug in 
humans does not induce a powerful euphoria or ‘high’ at doses that increase motivation and 
enhance task engagement (Muller et al. 2013). Some evidence indicates that modafinil binds to 
the DAT with different characteristics than cocaine (Schmitt and Reith 2011). However, the 
neurochemical bases for these different functional outcomes are still not completely understood.  
Based upon all the studies reviewed above, it has become evident that there is a need to 
develop novel therapeutic strategies to treat motivational dysfunctions in humans. In order to be 
useful clinically, the behavioral and neurochemical profiles of novel drug targets need to be 
elucidated. The body of literature cited above outlines a class of drugs, known as atypical DAT 
inhibitors, which are currently being assessed for their ability to reverse motivational deficits 
induced by DA antagonists or depletions, and by pro-inflammatory cytokine challenges.  
 
Development of Physiological Measures of Effort-Related Aspects of Motivation  
Though the neural bases of the effort-related dysfunctions in psychopathology are still 
being characterized, considerable evidence indicates that the ability to exert effort and select 
high-effort options is dependent upon the functional integrity of forebrain circuits that involve 
mesolimbic DA inputs to nucleus accumbens, as well as the ventral pallidum, amygdala, and 
prefrontal cortex (Salamone et al. 1991, 1994; 2007, 2016a,b, 2018; Walton et al. 2003; Floresco 
and Ghods-Sharifi 2007; Mingote et al. 2008; Farrar et al. 2008, 2010; Winstanley and Floresco 




family receptors can induce a low-effort bias in rats tested on effort-based choice procedures 
(Cousins et al. 1994; Nowend et al. 2001; Salamone et al. 2002; Sink et al. 2008; Warden et al. 
2009; Nunes et al. 2010; Randall et al. 2014; Yohn et al. 2015b). While pharmacological 
manipulation of neural function remains an important tool in behavioral neuroscience, advances 
in molecular biology have led to the development of methods that allow for the silencing or 
activation of specific types of neurons, such as optogenetics and chemogenetics. Considerable 
evidence indicates that D1 and D2 receptors are predominantly localized on separate populations 
of neostriatal and accumbens medium spiny projection neurons, containing different peptide 
markers and distinct projection targets. Our laboratory has a long-range plan to investigate the 
role of accumbens neurons that express D1 and D2 receptors in effort-related function. Based 
upon circuitry models of basal ganglia, and the known signal transduction effects of stimulating 
D1 and D2 receptors (Mingote et al. 2008; Salamone et al. 2010; Farrar et al. 2010; Santerre et al. 
2012; Nunes et al. 2013; Pardo-Garcia et al. 2019; Carvalho Poyraz et al. 2016), it is 
hypothesized that chemogenetic inactivation of accumbens neurons that express DA D1 receptors 
will induce a low effort bias similar to that induced by TBZ. 
As discussed above, pharmacological conditions that induce a low-effort bias in humans 
can alter effort-related choice in rats, and bias animals towards low-effort options (Salamone et 
al. 2016a,b,c; Yohn et al. 2016a,b,c), and these effects can be reversed by co-administration of 
several drugs that facilitate DA transmission. What is missing from this body of animal studies is 
the identification of a physiological marker that can be readily translatable to human clinical 
research. Recent studies have demonstrated that there are electroencephalographic (EEG) 
markers of frontal cortex activity that are characteristic of engagement in motivated behavior and 




al. 2018; Gheza et al. 2019). Moreover, these effects are associated with clinically rated lassitude 
in depressed individuals (Nelson et al. 2018). Generally speaking, these studies have implicated 
striatal and frontal cortical processes in approach motivation and effort-based decision making, 
which is consistent with animal studies in this area (Winstanley and Floresco 2016). Therefore, 
there is a need to employ EEG methods to aid in the development of physiological markers 
associated with altered DA transmission and effort-related dysfunction in preclinical animal 
models that can be readily translated to human studies.  
 
Present Work 
The following set of experiments was undertaken to investigate the behavioral and 
neurochemical evidence of motivational dysfunctions in rats, to uncover potential treatments for 
the effort-related motivational symptoms of depression and other disorders. The experiments 
discussed in Chapter 2 aimed to evaluate the effects of the DA D2 receptor antagonist 
haloperidol, chronically administered via subdermal minipump, in rats tested on effort-related 
procedures. Several experiments in this dissertation employed the vesicular monoamine transport 
(VMAT-2) inhibitor tetrabenazine to induce effort-related motivational impairments in rats 
(Chapters 3-6). Experiments described in Chapters 3-5 aimed to characterize the effort-related 
and neurochemical effects of three recently synthesized atypical DA transport inhibitors. A 
critical goal of the final experiments in this dissertation (Chapters 6-7) was to employ a novel 
operant lever pressing task and EEG methods to aid in the development of physiological markers 
associated with altered DA transmission and effort-related dysfunction in preclinical animal 
models that can be readily translated to human studies. Appendices 1-3 provide the results from 




kappa opioid receptors). Results from these studies will contribute to the development and 
discovery of novel treatments for treating anergia, fatigue, and motivational symptoms of 



























Chapter 2: Evaluation of the effort-related effects of chronic administration of the DA D2 
receptor antagonist haloperidol via subcutaneous minipumps.  
 
2.1 Introduction 
Motivational/psychomotor symptoms such as response slowing, apathy, fatigue, and 
reduced exertion of effort are critical and debilitating features of major depressive disorder (Stahl 
2002; Demyttenaere et al. 2005; Salamone et al. 2006; Treadway and Zald 2011; Fava et al. 
2014). These symptoms, often classified as negative symptoms, are present in diverse psychiatric 
disorders in addition to depression, including schizophrenia, Parkinson’s disease, and bipolar 
disorder (Caligiuri and Ellwanger 2000; Salamone et al. 2006, 2010; Friedman et al. 2007; Horan 
et al. 2015; Reddy et al. 2015; Fervaha et al. 2015; Treadway et al. 2015). Chronic treatment 
with DA antagonists such as haloperidol and other first-generation antipsychotics in 
schizophrenic patients is generally unsuccessful at treating negative symptoms such as lack of 
energy, fatigue, and amotivation (Kelley et al. 1999; Harvey et al. 2016). In fact, drugs such as 
haloperidol can induce negative symptoms in healthy volunteers (Artaloytia et al. 2006), and 
thus it has been hypothesized that a subset of the most common negative symptoms might be 
induced, at least partially, by chronic exposure to antipsychotic treatments.  
In addition to physical symptoms of fatigue and amotivation, clinical reports indicate that 
chronic exposure to antipsychotics is often associated with adverse side effects such as dystonia, 
extrapyramidal symptoms, and sedation (Chouinard et al. 1993; Emsley et al. 2008; Essali et al. 
2019). Drug tolerance or sensitivity have been commonly reported as effects of chronic 
antipsychotic use, yet these characteristics remain difficult to predict and to regulate due to 




schizophrenia and other psychiatric disorders due to undesirable side effects, impaired cognition, 
and/or a general lack of insight, which may ultimately lead to severe negative consequences 
(Xiao et al. 2015; Bitter et al. 2015; Phan 2016). For these reasons, it has become increasingly 
common for clinicians to prescribe long-acting injectable antipsychotics, including haloperidol 
decanoate, which is a depot formulation of the DA D2 antagonist (Eklund and Forsman 1991; 
McEvoy et al. 2014; Brissos et al. 2015). Although long-acting depot formulations eliminate 
some of the medication adherence issues and decrease relapse rates (Brissos et al. 2015), the 
secondary negative effects of prolonged antipsychotic delivery can be debilitating and can 
severely impact daily functioning.  
Fatigue and amotivation have been documented in rodents through the use of acute 
administration of DA D2 antagonists in effort-related choice paradigms (Salamone et al. 1991; 
Salamone and Correa 2002, 2012a); however, the effects of chronic steady-state antipsychotic 
administration on effort-related processes are still unknown. Thus, assessing the behavioral 
changes that take place as a result of chronic DA D2 antagonist administration in rats could 
provide insight regarding the development of secondary negative symptoms and the development 
of drug tolerance in schizophrenic patients (Gold et al. 2013; Fervaha et al. 2013; Barnes et al. 
2013; Kring and Barch 2014; Barch et al. 2014; Reddy et al. 2015). The use of programmable 
infusion pumps has allowed researchers to implement continuous and controlled drug delivery 
which closely resembles long-acting and slow-release formulations of clinical drug therapies 
(Abe et al. 2010; Tan et al. 2011). The studies discussed below assessed the effects of chronic 
DA D2 receptor blockade via subdermal haloperidol infusions on effort-related choice behavior, 





2.2 Materials and Methods 
Animals 
Adult male Sprague Dawley rats (Envigo Sprague Dawley, Indianapolis, IN, USA; 
weights 275-299 g upon arrival) were pair-housed in a colony maintained at 23°C, with a 12-h 
light/dark cycle (lights on 07:00). Rats were food deprived to 85% of their free-feeding body 
weight for operant training and were fed supplemental chow as needed, allowing modest growth 
throughout the experiment. Water was available ad libitum in home cages. Animal protocols 
were approved by the University of Connecticut Institutional Animal Care and Use Committee, 
and the studies were conducted according to National Institutes of Health (NIH) guidelines. 
 
Behavioral Procedures 
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm3; Med 
Associates, Fairfax, VT) with 30 minute sessions 5 days/week. Rats were initially trained to 
lever press on a continuous reinforcement FR1 schedule (high-carbohydrate 45 mg pellets, Bio-
Serv, Frenchtown, NJ) and then shifted to the FR5 schedule. Rats in Exp 2.1 (n=15) remained on 
the FR5 schedule for four to five weeks, until a stable baseline was reached. Rats in Exp 2.2 
(n=17) underwent the same initial training, and after four weeks of FR5, were shifted to the 
concurrent FR5/chow feeding choice procedure for up to four additional weeks. Weighed 
amounts of laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000, Purina Mills, St. Louis, 
MO; typically 15-20 g) were concurrently available on the floor of the chamber during the 
FR5/chow feeding choice task sessions. At the end of each 30 minute session, rats were 




of chow consumed was determined by weighing the remaining food (including spillage from a 
tray beneath the floor of the chamber). On baseline and drug treatment days, rats consumed all of 
the operant pellets that were delivered during each session. After a stable baseline was reached 
on the FR5 or FR5/chow procedure, rats in both experiments underwent a surgical procedure.  
 
Surgeries 
All rats underwent a surgical procedure for implantation of iPRECIO infusion pumps 
(iPRECIO SMP-200, Alzet). Pumps were stored at 45°C for 36 h prior to the surgery in a heating 
cabinet. On the day of surgery, the temperature was reduced to 37°C. Antiseptic technique was 
used and all instruments were cleaned and autoclaved prior to the procedure. Anesthesia was 
induced with 4-5% isoflurane in oxygen (and maintained in 2-3% isoflurane). The desired 
incision site was shaved, and betadine solution was used to disinfect the shaved area. Local 
analgesia (topical lidocaine) was applied at the incision site. Using a size 10 scalpel blade, a 4-
cm midline incision was made approximately 8 cm from the top of the head. Blunt dissection 
was used, creating a pouch under the skin from the point of incision to the caudal area on the 
rat’s right side, by separating the skin from the underlying tissue with hemostats. The pump was 
then removed from the heating cabinet, filled with sterile 0.9% saline, and the outlet tube was cut 
to 4 cm prior to being placed within the pocket. Non-absorbable nylon sutures (5-0) were used to 
attach the pump to the muscle layer. A blunt scissor was used to form a small tunnel for the 
outlet tube between the muscle and skin layers in the rostral direction. The tube was then sutured 
to the muscle ~1 cm from the tip. The skin incision was closed using 5-0 non-absorbable suture 
with 5-8 simple interrupted stitches or metal wound clips. After surgery, the rats were single-




Behavioral Pharmacology Experiments 
These experiments assessed the effects of continuous infusion of haloperidol vs. vehicle 
on performance on effort-related choice behavior. After a seven day recovery period, rats were 
retrained on their respective behavioral tasks to reestablish their baseline responding rates. 
Pumps were pre-programmed to initiate an infusion rate of 3 µl/hour twelve days after surgery. 
As soon as animals reached stable baseline responding, pumps were filled with haloperidol (2.0 
mg/ml or 1.0 mg/ml) or 0.3% tartaric acid vehicle through a subcutaneous port. Infusion of 
haloperidol or vehicle occurred for four weeks, which was referred to as the ‘drug exposure’ 
phase, followed by a four-week ‘washout phase’. During both the drug exposure and washout 
phases, behavioral testing was conducted 5 days/week (19 days of data collection in each phase).  
 
Statistical Analysis 
The data for this experiment were analyzed in SPSS using a 3 × 4 factorial analysis of 
variance (ANOVA) with treatment group as the between-groups factor and week as the within-
groups factor. In the case of a significant interaction, simple effects of treatment group were 
assessed by computing between groups ANOVAs at each week. Dunnett’s tests using the error 
term from the between-subjects analysis were used to assess differences between each drug 
treatment and vehicle at each time point (weeks 1-4). A p value of <0.05 was considered 







Experiment 2.1: Ability of chronic DA D2 receptor antagonism by continuous subdermal 
infusion of haloperidol to suppress lever pressing on the FR5 operant procedure.  
Fifteen rats were treated with one of two doses of haloperidol (1.0 mg/ml or 2.0 mg/ml) 
or vehicle for four weeks and tested on the FR5 lever pressing task daily. At baseline, prior to 
drug exposure, there were no significant differences in lever pressing between the three groups 
according to one-way ANOVA (p=n.s.). During the drug exposure phase, repeated measures 
factorial ANOVA indicated a significant overall effect of treatment group [F(2,12)=36.172, 
p<0.001] and week [F(3,36)=3.434, p<0.05] on lever pressing (Figure 2.1). No week by 
treatment interaction was found (p=n.s.), but a linear trend for week approached significance 
[F(1,12)=3.617, p=0.08]. To make specific comparisons of the effects of each dose of 
haloperidol and assess effect size of treatments on lever pressing, factorial ANOVAs were 
performed comparing the vehicle vs. high dose group, and vehicle vs. low dose group. Treatment 
had a significant effect on high dose group lever pressing [F(1,9)=150.137, p<0.001] with a large 
effect size (ηp2 = 0.943). The low dose treatment did not have a significant effect on lever 
presses [F(1,8)=4.739, p>0.05] and the effect size for this analysis was relatively low (ηp2 = 
0.372). 
In the washout phase, factorial ANOVA revealed a significant effect of week 
[F(3,36)=18.255, p<0.001] and a significant week by treatment interaction [F(6,36)=6.073, 
p<0.001], and no significant overall effect of treatment on lever pressing during the washout 
phase (p=n.s.). Because of a significant week by treatment interaction, between groups overall 
ANOVAs were computed at each time point and post-hoc two-tailed Dunnett’s tests were 




lever presses was found only at week 1 [F(2,14)=4.297, p<0.05], and a Dunnett’s test revealed a 
significant difference only between the vehicle and high dose groups (p<0.05). No significant 
differences in lever pressing were seen in the remaining weeks of washout. In addition, a 
significant linear trend for week [F(1,12)=40.368, p<0.001], and for week by treatment 
interaction [F(2,12)=11.957, p<0.001] were found during washout. Thus, in summary, the high 
dose of haloperidol suppressed FR5 lever pressing, the lack of significant dose x treatment 
interaction indicates that there were no substantial signs of sensitization or tolerance during 
chronic drug treatment, and there was rapid return to pre-drug lever pressing during washout 
(Fig. 2.1). 
Experiment 2.2: Ability of chronic DA D2 receptor antagonism by continuous subdermal 
infusion of haloperidol to induce motivational impairments on the FR5/chow feeding choice 
procedure. 
Figure 2.2 shows the effects of chronic haloperidol treatment on lever pressing and chow 
intake on the FR5/chow feeding choice task in rats (n=17). During the drug exposure phase, 
there was a significant overall effect of treatment on lever presses [F(2,14)=20.498, p<0.001] 
(Fig. 2.2A) and chow intake [F(2,14)=18.574, p<0.001] (Fig. 2.2B), but no effect of week or 
week by treatment interaction for either lever presses or chow intake (p=n.s.). As with Exp 2.1, 
separate factorial ANOVAs were computed to assess the effect of treatment on lever pressing in 
the vehicle vs. high dose group and vehicle vs. low dose group. Significant effects of treatment 
on lever presses were found when comparing vehicle vs. high dose [F(1,9)=39.845, p<0.001; ηp2 
= 0.816], and vehicle vs. low dose [F(1,7)=20.359, p<0.01; ηp2 = 0.744], with large effect sizes 




 The total number of subjects was reduced to n=7 in the washout phase. Repeated 
measures ANOVA revealed a significant effect of week on lever presses [F(3,12)=11.088, 
p=0.001] and chow intake [F(3,12)=8.813, p<0.01]. The week by treatment interaction 
approached significance for lever presses (0.05<p<0.1), and was statistically significant for chow 
intake [F(6,12)=3.194, p<0.05]. Treatment did not have a significant overall main effect on lever 
presses or chow intake during the washout phase (p=n.s.).  
In summary, both the low and high doses of haloperidol shifted choice behavior, 
suppressing FR5 lever pressing while significantly and substantially increasing chow intake. As 
seen in the FR5 alone experiment, there was a lack of significant dose x treatment interaction 
during chronic drug treatment, indicating that there were no substantial signs of sensitization or 
tolerance. Although the n was very low during the washout period due to the COVID shutdown, 
it is evident that there was a rapid return to pre-baseline levels of lever pressing during the 







Figure 2.1. The effect of chronic haloperidol (HAL) administration on lever pressing on an FR5 
feeding task in rats (n=15). Mean (± SEM) number of lever presses during a 30-minute session. 
**p<0.001, significant between groups effect of treatment on lever presses between HAL 2.0 
mg/ml vehicle during drug exposure phase. *p<0.05, lever presses significantly differed between 







Figure 2.2. The effect of chronic haloperidol (HAL) administration on lever pressing and chow 
intake in rats (n=17) performing on an FR5/chow feeding choice task. (A) Mean (± SEM) 
number of lever presses in a 30-minute session. **p<0.001, significant between groups effect of 
treatment on lever presses between HAL 2.0 mg/ml and vehicle, *p<0.01 significant between 
groups effect of treatment on lever presses between HAL 1.0 mg/ml and vehicle during drug 




**p<0.001, significant between groups effect of treatment on chow intake between HAL 2.0 
mg/ml and vehicle, *p<0.01 significant between groups effect of treatment on chow intake 
between HAL 1.0 mg/ml and vehicle during drug exposure phase. There was a significant effect 
of week (p<0.01) and a significant week by treatment interaction (p<0.05) only during the 

















Chapter 3: The novel atypical dopamine uptake inhibitor (S)-CE-123 partially reverses the 
effort-related effects of the dopamine depleting agent tetrabenazine and increases 
progressive ratio responding. 
Published; Rotolo et al. 2019, Frontiers in Pharmacology 
 
3.1 Introduction 
Motivational symptoms such as fatigue, anergia, and psychomotor slowing are seen in 
depression, Parkinson’s disease, and other disorders.  These symptoms are often debilitating, and 
can severely limit long-term functional outcomes (Demyttenaere et al. 2005; Friedman et al. 
2007; Fava et al. 2014; Rothschild et al. 2014; Chong et al. 2015; Salamone et al. 2006, 
2016a,b,c, 2017).  Moreover, motivational symptoms can be highly resistant to treatment with 
common antidepressants such as serotonin transporter (SERT) blockers (Cooper et al. 2014; 
Fava et al. 2014; Rothschild et al. 2014).  The catecholamine uptake inhibitor bupropion has 
shown some success in treating motivational symptoms in depressed people (Papakostas et al. 
2006; Pae et al. 2006; Cooper et al. 2014), and reports indicate that treatment with drugs that 
inhibit dopamine transporter (DAT), such as d-amphetamine and methylphenidate, can improve 
motivational function (Stotz et al. 1999).  However, psychomotor stimulants that block DAT also 
can have undesirable effects, such as abuse liability and induction of psychotic symptoms. For 
these reasons, it is important to develop and assess drugs that are highly selective for DAT, but 
show atypical neurochemical characteristics that may lower the side effect profile.   
A recently synthesized and chromatographically separated analog of modafinil, (S)-CE-




cognitive flexibility and reduce impulsivity in rats (Nikiforuk et al., 2017). The present paper 
describes the enantioselective synthesis and initial characterization of (S)-CE-123.  In addition, 
(S)-CE-123 was assessed for its effects on effort-related aspects of motivation in rats. These 
behavioral pharmacology studies evaluated the motivational effects of (S)-CE-123 in rats using 
well characterized tests of effort-based choice behavior, the concurrent fixed ratio 5 (FR5)/chow 
feeding choice task, and the concurrent progressive ratio (PROG)/chow feeding choice task. 
Effort-related choice is studied using procedures that offer high effort options leading to highly 
valued reinforcers vs. low effort/low reward options (Salamone and Correa 2012; Salamone et al. 
2016a,b,c, 2017, 2018; Hart et al. 2017). Considerable research has implicated dopamine (DA) 
transmission, particularly in nucleus accumbens core, in the regulation of effort-based choice; 
animals with impaired DA transmission (i.e., DA antagonism or depletion) show a shift from the 
high-effort option to the low effort option, while enhancement of DA transmission reverses those 
effects (Sokolowski and Salamone 1998; Salamone et al. 2002, 2007, 2016a,b,c; Farrar et al. 
2010; Mai et al. 2012; Hosking et al. 2015). It has been suggested that animal models employing 
tests of effort-based decision making can be used to study functions that are related to aspects of 
human motivational dysfunction (Salamone et al. 2006, 2016a,b,c, 2018). This strategy has been 
validated by clinical research showing that patients with major depression, Parkinson’s disease, 
and other disorders show a low-effort bias when tested on effort-related choice procedures 
(Treadway et al. 2012; Yang et al. 2014; Chong et al. 2015; Barch et al. 2017).  
Studies have shown that a low-effort bias can be induced in rats by several conditions 
associated with depressive symptoms, including stress (Shafiei et al. 2012; Bryce and Floresco 
2016), inflammatory challenge (Nunes et al. 2014; Yohn et al. 2016e), withdrawal from 




2 (VMAT-2) inhibitor tetrabenazine (TBZ; Nunes et al. 2013; Randall et al. 2014; Yohn et al. 
2015a,b). TBZ induces depressive symptoms in people (Frank 2009, 2010; Guay, 2010), and has 
been used in classical animal models of depression (Tadano et al., 2000; Wang et al., 2010). By 
virtue of inhibiting VMAT-2, TBZ blocks DA storage, depletes brain DA, and reduces post-
synaptic DA receptor signaling (Nunes et al. 2013). Across a variety of behavioral tests, TBZ 
shifts choice behavior and induces a low-effort bias, and the reallocation of behavior from high 
to low-effort options that is produced by TBZ is not due to alterations in food preference or 
hedonic taste reactivity, reduced appetite, or impairments in reference memory (Randall et al. 
2012, 2014; Nunes et al. 2013; Correa et al. 2015; Pardo et al. 2015; Yohn et al. 2015a). On 
operant behavior tests that give animals the choice between lever pressing on a FR5 or PROG 
schedule for a preferred food vs. approaching and consuming a less preferred lab chow (Nunes et 
al. 2013; Randall et al. 2014; Yohn et al. 2016a,b,c) TBZ reliably decreases working for food by 
lever pressing, but actually increases consumption of the concurrently available chow.  TBZ in 
this dose range does not reduce consumption of either type of food that is used in these studies, 
nor does it affect preference as measured in free-feeding preference tests (Nunes et al. 2013). 
Also, the effects of TBZ on operant choice procedures differ substantially from the effects of 
reinforcer devaluation, as well as appetite suppressant drugs (Randall et al. 2013, 2014). These 
effects of TBZ are not reversed by the SERT blockers fluoxetine and citalopram, or by the 
norepinephrine transporter (NET) inhibitor desipramine (Yohn et al. 2016a,b), but they are 
attenuated by several drugs that block DAT, including bupropion, GBR12909, lisdexamfetamine, 
methylphenidate and modafinil (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2016a,b,c; 
Salamone et al. 2016a,b). Drugs that inhibit DAT, such as bupropion, lisdexamfetamine, and 




more highly demanding behavioral tasks, such as the PROG/chow feeding choice task (Randall 
et al. 2015; Yohn et al. 2016b,c,d). In view of these results, the present studies investigated the 
ability of (S)-CE-123 to attenuate the effort-related effects of TBZ in rats tested on the 
concurrent FR5/chow feeding choice task, and to enhance exertion of effort in rats assessed with 
the PROG/chow feeding choice task. An additional experiment studied the effects of the 
behaviorally effective dose of (S)-CE-123 (24.0 mg/kg) on extracellular DA in nucleus 
accumbens using microdialysis methods.  
 
3.2 Materials and Methods 
Synthesis of (S)-CE-123 
Refer to Rotolo et al. 2019 for details regarding synthesis and chemical structure (see Fig. 3.1). 
Synthesis was performed by the laboratory of Dr. Gert Lubec. 
 
In Vivo Behavioral Pharmacology  
Animals: 
For the behavioral pharmacology experiments, adult male Sprague Dawley rats (Envigo 
Sprague Dawley, Indianapolis, IN, USA; weights 275-299 g upon arrival) were pair-housed in a 
colony maintained at 23°C, with a 12-h light/dark cycle (lights on 07:00). Rats were food 
deprived to 85% of their free-feeding body weight for operant training and allowed modest 
growth throughout the experiment. Water was available ad libitum in the home cages. Animal 
protocols were approved by the University of Connecticut Institutional Animal Care and Use 
Committee, and the studies were conducted according to National Institutes of Health (NIH) 




Italy; weights 275-300 g upon arrival) were used. Rats were housed 4 per cage, in standard 
plastic cages with wood chip bedding, maintained at 22 ± 2 °C and 60% humidity with a 12-h 
light/dark cycle (lights on 07:00). Water and standard laboratory rodent chow (Mucedola, 
Settimo Milanese, Italy) were provided ad libitum in the home cage. All animal experiments 
were carried out in accordance with the Guidelines for the Care and Use of Mammals in 
Neuroscience and Behavioral Research according to Italian (D.L. 116/92 and 152/06) and 
European Council (609/86 and 63/2010) directives and in compliance with the approved animal 
policies by the Ethical Committee for Animal Experiments (CESA, University of Cagliari) and 
the Italian Ministry of Health (Aut. N. 162/2016- PR). All efforts were taken to minimize pain 
and suffering, and to reduce the number of animals used. 
 
Behavioral Procedures 
FR5/Chow Feding Choice Task: 
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm3; Med 
Associates, Fairfax, VT) with 30 minute sessions 5 days/week. Rats were initially trained to 
lever press on a continuous reinforcement FR1 schedule (high-carbohydrate 45 mg pellets, Bio-
Serv, Frenchtown, NJ) and then shifted to the FR5 schedule. After 5 weeks of training on the 
FR5 schedule, chow was introduced. Weighed amounts of laboratory chow (Laboratory Diet, 
5P00 Prolab RMH 3000, Purina Mills, St. Louis, MO; typically 15-20 g) were concurrently 
available on the floor of the chamber during the FR5/chow feeding choice task sessions. At the 
start of each session, it was confirmed that the pieces of weighed chow were larger than the 
spaces between the bars that make up the floor of the chamber, so they could not fall through. At 




of lever presses was recorded, and the amount of chow consumed was determined by weighing 
the remaining food (including spillage from a tray beneath the floor of the chamber). Rats were 
trained on the FR5/chow feeding choice procedure for 5 weeks, after which drug testing began. 
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered 
during each session. 
 
PROG/Chow Feeding Choice Task: 
Behavioral sessions were conducted in operant chambers with 30 minute sessions 5 
days/week. Rats were initially trained to lever press on a continuous reinforcement FR1 schedule 
(high-carbohydrate 45 mg pellets, Bio-Serv) and then shifted to the PROG schedule (Randall et 
al. 2012, 2014, 2015). For PROG sessions, the ratio started at FR1 and was increased by 1 
additional response every time 15 reinforcements were obtained (FR1×15, FR2×15, etc.). A 
“time-out” feature deactivated the response lever for the rest of the session whenever 2 minutes 
elapsed without a completed ratio. After 9 weeks of training on the PROG schedule, chow was 
introduced. Weighed amounts of laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000, 
Purina Mills; typically 15-20 g) were concurrently available on the floor of the chamber during 
the PROG/chow feeding choice task sessions. At the end of each 30 minute session, rats were 
immediately removed from the chambers, number of lever presses was recorded, and the amount 
of chow consumed was determined by weighing the remaining food (including spillage from a 
tray beneath the floor of the chamber). Rats were trained on the PROG/chow feeding choice 
procedure for 5 weeks, after which drug testing began. On baseline and drug treatment days, rats 





Drug Treatments and Dose Selection 
(S)-CE-123 ((S)-5-((benzhydrylsulfinyl)methyl)thiazole) was obtained from the Lubec 
Laboratory (University of Vienna, Austria) and dissolved in dimethyl sulfoxide (DMSO) (10%), 
Tween 80 (15%), and 0.9% saline (75%). The DMSO/Tween 80/saline solution was 
administered as the vehicle control. TBZ (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b 
hexahydrobenzo[a]quinolizin-2-one) was obtained from Tocris Bioscience (Ellisville, MO) and 
was dissolved in DMSO (20%), 0.9% saline (80%), and was titrated with microliter quantities of 
1.0 N HCl until the solid drug was in solution at a pH of 4.0-4.5. The DMSO/saline solution was 
administered as the vehicle control. The dose of 1.0 mg/kg TBZ was based on extensive piloting 
in our laboratory. The doses of (S)-CE-123 were selected based on extensive pilot studies and 
information about its relative affinity for DAT.  
 
Behavioral Pharmacology Experiments  
Trained rats (n=8) were administered either TBZ (1.0 mg/kg) or vehicle, and (S)-CE-123 
(6.0, 12.0, and 24.0 mg/kg) or vehicle, via intraperitoneal (IP) injections on drug testing days. 
Rats received TBZ or vehicle 120 minutes before testing and (S)-CE-123 or vehicle 30 minutes 
before testing. The experiment used a within-groups design, with each rat receiving each drug 
treatment in a randomly varied order (one treatment per week, with none of the treatment 
sequences repeated across different animals). Sample size was determined based on information 
obtained from pilot studies done in our laboratory. Experimenter blinding was not necessary due 
to the objective nature of the data collection. The following five treatment combinations were 
given: TBZ vehicle + (S)-CE-123 vehicle; 1.0 mg/kg TBZ + (S)-CE-123 vehicle; 1/0 mg/kg TBZ 




mg/kg (S)-CE-123. The endpoint of the experiment was marked by the completion of the last 
scheduled drug treatments for each rat, after having received each drug treatment in a randomly 
varied order. 
Following the initial behavioral experiment, (S)-CE-123 was tested on a different group 
of rats (n=7) to assess whether it had a behavioral effect when administered alone. Rats were 
trained on the FR5/chow feeding choice task as described previously. Thirty minutes prior to the 
testing session, rats were administered either vehicle or 24.0 mg/kg (S)-CE-123. One week later, 
rats received either vehicle or 24.0 mg/kg (S)-CE-123 so that the treatment orders were 
counterbalanced. Only the highest dose of (S)-CE-123 (24.0 mg/kg) was chosen for testing in 
this paradigm. 
A third behavioral experiment was conducted to determine if (S)-CE-123 had an effect on 
rats’ behavior on the PROG/chow feeding choice task when administered alone. Thirty minutes 
prior to the testing session, trained rats (n=15) were administered either vehicle or 6.0, 12.0, or 
24.0 mg/kg (S)-CE-123. This experiment used a within-groups design, with each rat receiving 
each drug treatment in a randomly varied order. Treatments were administered once per week 
over the course of four weeks.  
 
In Vivo Microdialysis  
Surgery: 
Male Sprague Dawley rats (275-300 g; Harlan, Italy) were anaesthetized with fentanyl 
(0.06 mg/kg IP), placed in a stereotaxic apparatus, and implanted with vertical dialysis probes 
prepared as previously described (De Luca et al., 2016) with 1.5 mm dialyzing portion.  




in the nucleus accumbens shell (A +2.2, L +1.0 from bregma, V -7.8 from dura; n=10) or nucleus 
accumbens core (A +1.4; L +1.6 from bregma, V -7.6 from dura; n=7).  
 
Analytical Procedure: 
On the day following surgery, animals were connected to an infusion pump and probes 
were perfused with Ringer's solution (147 mM NaCl, 4 mM KCl, 2.2 mM CaCl2) at a constant 
rate of 1 µl/min. After rinsing for at least 1 h, dialysate samples (20 µl) were collected every 20 
minutes and injected into an HPLC equipped with a reverse phase column (C8 3.5 µm, Waters, 
USA) and a coulometric detector (ESA, Coulochem II) to quantify DA. The electrodes of the 
analytical cell were set at +125 mV (oxidation) and −175 mV (reduction) to detect dopamine. 
The mobile phase composition was: 50 mM NaH2PO4, 0.1mM Na2EDTA, 0.5 mM n-octylsulfate 
and 15% (v/v) methanol. The sensitivity of the assay for DA was 5 fmol/sample. When the DA 
did not differ more than 10% in three consecutive samples, the average value was considered as 
the basal level of DA. The animals were treated with vehicle or (S)-CE-123 24.0 mg/kg IP, and 
monoamine levels were monitored for 3 h from the start of the treatment.  
 
Histology: 
At the end of the experiment, animals were sacrificed and brains were removed and 
stored in formalin (8%). Brains were sliced and stained with Nissl stain for histological 
examination in order to verify the correct placement of the microdialysis probes. Histology work 








Behavioral Pharmacology Experiments: 
 
Total number of lever presses and gram quantity of chow intake from the 30 minute 
sessions were analyzed using repeated measures ANOVA. A statistical program (SPSS, Version 
25) was used to perform all analyses. Since there were significant overall F values for the three 
behavioral measures being used, nonorthogonal planned comparisons were performed, using the 
overall error term to assess differences between each treatment and the control condition. The 
number of comparisons was restricted to the number of treatments minus one (Keppel, 1991). 
Statistical outliers were predefined as any point that is more than two standard deviations from 
the mean. No data from this study were excluded as outliers. Microdialysis data were expressed 
as percent of the last 3 baseline samples, and were analyzed by a 4 group x 12 sample factorial 
analysis of variance (ANOVA) with repeated measures on the sample factor. Since there was a 
significant group x sample interaction, so subsequent analysis of simple main effects examined 
the effect of the sample factor for each of the 4 groups. Results from treatments showing 
significant overall changes were subjected to Tukey’s tests for post hoc comparisons, with 
significance at p<0.05. 
 
3.3 Results  
FR5/Chow Feeding Choice task 
Figure 3.2 shows the results of the FR5/chow feeding choice experiment. TBZ shifted 
effort-based choice, decreasing lever pressing and increasing chow intake. Repeated measures 
ANOVA revealed that there was an overall significant effect of drug treatment on lever pressing 




decreased lever pressing compared to vehicle treatment (TBZ/Veh vs. Veh/Veh [F(1,28) = 
105.87, p<0.001]). There also was a significant overall effects of drug treatment on chow intake 
[F(4,28)=27.280, p<0.001], and TBZ alone significantly increased chow intake relative to 
vehicle treatment (TBZ/Veh vs. Veh/Veh [F(1,28) = 66.625, p<0.001]) (Fig. 3.2B). Additional 
planned comparisons revealed that co-administration of the dose of 24.0 mg/kg (S)-CE-123 with 
TBZ significantly attenuated the effects of TBZ on lever pressing (TBZ plus 24.0 mg/kg vs. 
TBZ/Veh [F(1,28) = 13.2866, p<0.01]) and chow intake (TBZ plus 24.0 mg/kg vs. TBZ/Veh 
[F(1,28) = 61.014, p<0.001]). 
As shown in Figure 3, there was no effect of drug treatment relative to vehicle on lever 
pressing or chow intake on the FR5/chow feeding choice task when 24.0 mg/kg (S)-CE-123 was 
administered alone prior to testing. Repeated measures ANOVA indicated no significant 
difference between rats treated with 24.0 mg/kg (S)-CE-123 and vehicle-treated rats on lever 
pressing [F(1,6)=0.012, p=n.s.] (Fig. 3.3A) or chow intake [F(1,6)=0.030, p=n.s.] (Fig. 3.3B). 
 
PROG/Chow Feeding Choice Task 
(S)-CE-123 was tested for its behavioral effect on the PROG/chow feeding choice task 
when administered alone (i.e., in the absence of TBZ). Repeated measures ANOVA revealed an 
overall main effect of drug treatment on lever pressing [F(3,42)=3.165, p<0.05], and planned 
comparisons demonstrated that lever presses were significantly increased at 24.0 mg/kg (S)-CE-
123 compared to vehicle treatment (Veh vs. 24.0 mg/kg (S)-CE-123 [F(1,42)=4.061, p<0.05] 
(Fig. 4.4A). Drug treatment with (S)-CE-123 also had a significant effect on chow intake during 




with a significant reduction in chow intake at the 24.0 mg/kg dose compared to vehicle (Veh vs. 
24.0 mg/kg (S)-CE-123 [F(1,42)=28.107, p<0.001] (Fig. 3.4B). 
 
Microdialysis 
One-way ANOVA revealed no differences in basal DA levels between nucleus 
accumbens shell vehicle (Mean 130.46 fmoles DA/20 µl; SEM 19.01) and nucleus accumbens 
shell 24.0 mg/kg (S)-CE-123 (Mean 90.65 fmoles DA/20 µl; SEM 12.17) conditions 
[F(1,9)=2.411, p=n.s.], or nucleus accumbens core vehicle (Mean 91.28 fmoles DA/20 µl; SEM 
27.37) and nucleus accumbens core 24.0 mg/kg (S)-CE-123 (Mean 90.25 fmoles DA/20 µl; SEM 
17.12) conditions [F(1,6)=0.001, p=n.s.]. A repeated measures factorial ANOVA revealed a 
significant overall effect of treatment group [F(3,13)=29.680, p<0.001], a significant effect of 
sample [F(11,143)=6.756, p<0.001], and a significant treatment x sample interaction 
[F(33,143)=8.019, p<0.001] (Fig. 3.5). Analysis of simple effects in which each condition was 
analyzed separately showed that there was a significant increase in extracellular DA in the 
nucleus accumbens core in the group that received 24.0 mg/kg (S)-CE-123 [F(11,33)=11.950, 
p<0.001]. Tukey tests indicated that 24.0 mg/kg (S)-CE-123 administration increased nucleus 
accumbens core DA significantly from baseline at samples taken 40-180 minutes after injection 
(p<0.05). Analysis of simple effects also showed that there was a significant difference in 
extracellular DA in the nucleus accumbens shell in the group treated with 24.0 mg/kg (S)-CE-
123 [F(11,33)=7.049, p<0.001] from baseline, and a Tukey test indicated a significant reduction 
at 100 minutes after injection (p<0.05). Injections of vehicle had no significant effect on 








Figure 3.1. Structure of the novel atypical dopamine reuptake inhibitor  









Figure 3.2. The effects of the DAT blocker (S)-CE-123 on TBZ-induced changes in 
performance on the concurrent lever pressing/chow-feeding choice procedure. (A) TBZ plus 
vehicle significantly differed from vehicle plus vehicle (#p<0.001); TBZ plus 24.0 mg/kg (S)-
CE-123 significantly differed from TBZ plus vehicle (*p< 0.01). (B) TBZ plus vehicle 
significantly differed from vehicle plus vehicle (#p<0.001); TBZ plus 24.0 mg/kg (S)-CE-123 








Figure 3.3. The effects of 24.0 mg/kg (S)-CE-123 or vehicle on performance on the concurrent 
FR5/chow feeding choice task. There was no effect of drug treatment on lever pressing or chow 
intake on the FR5/chow feeding choice task when rats (n=7) were administered (S)-CE-123 or 




rats treated with 24 mg/kg (S)-CE-123 and vehicle-treated rats on lever pressing [F(1,6)=0.012, 








Figure 3.4. The effects of the DAT blocker (S)-CE-123 on performance on the concurrent 
PROG/chow feeding choice procedure. Rats (n=15) received intraperitoneal injections of vehicle 
(Veh), 6.0, 12.0, or 24.0 mg/kg doses of (S)-CE-123. (A) 24.0 mg/kg (S)-CE-123 significantly 




Figure 3.5. Effect of vehicle or 24.0 mg/kg (S)-CE-123 on extracellular DA in the nucleus 
accumbens core and shell measured by microdialysis. Mean (±SEM) extracellular DA (expressed 
as percent baseline) in 20 minute samples across 180 minutes. Three baseline samples were 
collected prior to injection, followed by nine post-injection samples. *significantly different from 




Chapter 4: Behavioral and dopamine transporter binding properties of the modafinil 
analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and 
enhancement of progressive ratio responding. 
Submitted; Rotolo et al., Psychopharmacology 
 
4.1 Introduction 
Motivational symptoms such as anergia, fatigue, and effort-related dysfunctions are 
common and debilitating features of major depressive disorder, schizophrenia, Parkinson’s 
disease and other psychiatric and neurological disorders (Tylee et al. 1999; Demyttenaere et al. 
2005; Treadway et al. 2012; Barch et al. 2014; Chong et al. 2015). Motivational symptoms are 
not well treated by many of the most commonly prescribed antidepressant drugs (Tylee et al. 
1999; Demyttenaere et al. 2005; Cooper et al. 2014; Fava et al. 2014; Ghanean et al. 2018). 
Patients treated with drugs that block the serotonin transporter (SERT), such as fluoxetine, 
sertraline, paroxetine or escitalopram, often suffer from residual symptoms of apathy, fatigue, 
and a lack of energy (Katz et al. 2004; Padala et al. 2012; Rothschild et al. 2013; Cooper et al. 
2014; Ferguson et al. 2014), which can be detrimental to daily functioning. Clinical reports have 
revealed a critical link between symptoms related to fatigue and energy expenditure and the 
overall severity of depressive symptoms (Gullion and Rush 1998; Fava et al. 2014; Chung et al. 
2015; Ghanean et al. 2018). Moreover, self-reported fatigue is correlated with global functioning 
deficits and reduced likelihood of remission (Ferguson et al. 2014). The array and prevalence of 




animal models of fatigue and anergia to aid in the development of new and more effective 
treatments.  
In order to conduct preclinical studies of motivational dysfunctions using animal models, 
tasks have been developed to evaluate effort-based decision making in rodents (Salamone et al. 
2006, 2007, 2016a,b, 2018; Mai et al. 2012; Nunes et al. 2013; Sommer et al. 2014; Winstanley 
and Floresco 2016; Bailey et al. 2016, 2020; Hart et al. 2017; Stutz et al. 2019). With these tasks, 
animals are offered the choice between lever pressing for a highly valued reinforcer vs. 
approaching and consuming a freely available but less preferred reinforcer. Tasks such as the 
concurrent fixed ratio 5 (FR5)/chow feeding choice task and the concurrent progressive ratio 
(PROG)/feeding choice task are useful for measuring effort-related choice behavior (Salamone et 
al. 2002, 2007, 2016a; Salamone and Correa, 2012; Randall et al. 2012). Several studies have 
shown that selection of the high-effort alternative is reduced when animals are exposed to 
manipulations associated with depression and negative motivational symptoms, such as stress 
(Shafiei et al. 2012; Bryce and Floresco, 2016; Dieterich et al. 2020), proinflammatory cytokine 
administration (Nunes et al. 2014; Yohn et al. 2015; Rotolo et al. 2020, in prep), and dopamine 
(DA) depletion or antagonism (Nunes et al. 2013; Randall et al. 2012, 2014; Yohn et al. 2015a; 
Hosking et al. 2015; Pardo et al. 2015; Yohn et al. 2016a,b,c; Rotolo et al. 2019; Yang et al. 
2020; Bailey et al. 2020). For example, rats treated with the vesicular monoamine transport 
(VMAT-2) inhibitor tetrabenazine (TBZ) demonstrate a low-effort bias across several tasks, 
shifting choice away from the high-effort alternative (Nunes et al. 2013; Randall et al. 2014; 
Yohn et al. 2015a; Pardo et al. 2015). When administered to humans, TBZ induces depressive 
symptoms including fatigue (Chitnis and Karunapuzha, 2009; Frank, 2010; Chen et al. 2012). 




inhibitors of SERT or norepinephrine transport (NET) (Yohn et al. 2016a,b). Unlike drugs that 
inhibit SERT or NET, several inhibitors of the DA transporter (DAT), including bupropion, 
vanoxerine (GBR12909), lisdexamfetamine, PRX-14040, methylphenidate, and modafinil, can 
reverse the low-effort bias induced by TBZ (Nunes et al. 2013, Yohn et al. 2016a,b,c; Salamone 
et al. 2016b) and by pro-inflammatory cytokines (Yohn et al. 2016b,d). Moreover, several DAT 
inhibitors have demonstrated the ability to increase motivation to exert high levels of effort, 
increasing selection of lever pressing in rats tested on the PROG/chow feeding choice task when 
administered alone (Sommer et al. 2014; Randall et al., 2015; Yohn et al., 2016b,c,d).  
The ability of drugs that block DAT to reverse effort-related impairments and increase 
selection of high-effort activities in rodents is consistent with clinical studies showing that DAT 
inhibitors, including bupropion, amphetamine, and methylphenidate, can improve motivational 
function in people (Stotz et al. 1999; Papakostas et al. 2006; Pae et al. 2007; Blockmans and 
Persoons 2016). The wakefulness agent modafinil, which inhibits DAT (Schmitt and Reith 
2011), and elevates extracellular DA as measured by microdialysis (Mereu et al. 2017) and 
human imaging studies (Volkow et al. 2009), has been shown to improve motivational function 
in people with depression (Fava et al. 2007; Lam et al. 2007) and multiple sclerosis (Shangyan et 
al. 2018). Moreover, modafinil reduces perception of physical task demands during exercise 
(Rattray et al. 2019), and increases motivation and enhances task engagement in humans at doses 
that do not produce a powerful euphoria or ‘high’ (Müller et al. 2013). Modafinil has atypical 
DAT binding characteristics and behavioral effects (Schmitt and Reith 2011; Mereu et al. 2013, 
2017; Cao et al. 2016; Nikiforuk et al. 2017), and is part of an emerging class of drugs (e.g. 
benztropine and GBR12909 analogs) that have binding properties and behavioral effects that are 




analog CE-123 were demonstrated to have pro-cognitive effects in both rats and mice (Nikiforuk 
et al. 2017; Kristofova et al. 2018; Camats-Perna et al. 2019), as well as the ability to reverse the 
effort-related effects of TBZ in rats at doses that increase extracellular DA in nucleus accumbens 
core (Rotolo et al. 2019). While CE-123 has shown preclinical effectiveness across a variety of 
rodent behavioral tasks without adverse toxic effects (Kalaba et al. 2017), and has a higher 
specificity for the DAT than other commercially available drugs (Kalaba et al. 2020), it is 
important to provide a detailed characterization of a broad range of modafinil analogs to identify 
the most promising candidate for treating motivational dysfunctions and fatigue. The present 
study investigated a novel modafinil analog, (S, S)-CE-158, for its ability to bind to DAT, the 
specificity of its inhibition of DAT, and its ability to reverse the effort-related effects of TBZ, 




Adult male, drug-naïve, Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were 
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats (n=23 
for the behavioral pharmacology experiments; n=9 for the microdialysis experiment) weighed 
275–299 g at the beginning of the study, and were initially food restricted to 85% of their free-
feeding body weight for operant training. Rats were fed supplemental chow to maintain weight 
throughout the study, with water available ad libitum. Rats were allowed modest weight gain 
throughout the experiment. Animal protocols were approved by the University of Connecticut 






In Vitro Binding Experiment 
To determine binding specificity, in vitro binding assays were conducted using 
transfected HEK293 cells with stable expression of human DAT with [N-Methyl-3H]-
WIN35,428 = [3H]CFT = 2ß-carbomethoxy-3ß-(4-fluorophenyl) tropane. Cells were seeded in 
poly-D-lysine-coated 24-well plates (3 x 104 HEK293 cells/well) and, 2 days later, binding on 
whole cells was performed as described previously (Pifl et al., 2009). Cells were incubated on ice 
for 2 h in 0.25ml buffer (mmol/l: 4 Tris–HCl; 6.25 4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES); 120 NaCl; 5 KCl; 1.2 CaCl2; 1.2 MgSO4; 5 D-glucose; 0.5 
ascorbic acid; pH 7.1) containing 6 nM [3H]CFT and various concentrations of (S, S)-CE-158. 
Non-specific binding was measured in the presence of 10 µM mazindol. Binding experiments 
were performed by the laboratory of Dr. Gert Lubec. 
 
In Vitro Monoamine Transporter Reuptake Inhibition 
Monoamine transporter reuptake inhibition was outsourced to Eurofins DiscoverX 
Corporation (Fremont, CA) and performed according to the standard company protocol for the 
Neurotransmitter Transporter Uptake Assay (Molecular Devices). In short, (S, S)-CE-158 was 
tested for monoamine reuptake inhibition using a fluorescence-based assay. Fluorescent 
substrates mimicking amine neurotransmitters were taken up into HEK293 cells with stable 






Pharmacological Agents and Selection of Doses 
(S, S)-CE-158 (5-(((S)-((S)-(3-bromophenyl)(phenyl)methyl)sulfinyl)methyl)thiazole) 
(Fig. 4.1) was obtained from the Lubec Laboratory (University of Vienna, Austria) and dissolved 
in dimethyl sulfoxide (DMSO), Tween 80, and 0.9% saline. The DMSO/Tween 80/saline 
solution was administered as the vehicle control. TBZ (9,10-dimethoxy-3-(2-methylpropyl)-
1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one) was obtained from Tocris Bioscience 
(Ellisville, MO) and was dissolved in DMSO, 0.9% saline, and titrated with HCl. The 
DMSO/saline solution was administered as the vehicle control. The dose of 1.0 mg/kg TBZ was 
based on extensive piloting in our laboratory. The doses of (S, S)-CE-158 were selected based on 
extensive pilot studies and information about its relative affinity for DAT.  
 
Behavioral Procedures 
Concurrent FR5/Chow Feeding Choice Task: 
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm; Med 
Associates, Fairfax, VT). Sessions lasted 30 minutes a day for 5 days/week. First, rats were 
trained to lever press on a continuous reinforcement schedule to receive 45 mg high-
carbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for one week, then were shifted to the 
FR5 schedule. After 5 weeks of FR5 training, chow was introduced. During each FR5/chow 
feeding choice task session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000, 
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. Rats were 
trained on this FR5/chow feeding choice procedure for 5 weeks, after which drug testing began. 
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered 




Concurrent PROG/Chow Feeding Choice Task: 
A second behavioral experiment was conducted to determine if (S, S)-CE-158 had an 
effect on rats’ behavior on the PROG/chow feeding choice task when administered alone. 
Sessions were conducted in operant chambers (28 x 23 x 23 cm; Med Associates, Fairfax, VT) 
with 30-minute sessions 5 days/week. Rats were initially trained to lever press on a continuous 
reinforcement FR1 schedule (high-carbohydrate 45 mg pellets, Bio-Serv) and then shifted to the 
PROG schedule (Randall et al. 2012, 2014, 2015). For PROG sessions, the ratio started at FR1 
and was increased by 1 additional response every time 15 reinforcements were obtained 
(FR1×15, FR2×15, etc.). A “time-out” feature deactivated the response lever for the rest of the 
session whenever 2 minutes elapsed without a completed ratio. After 9 weeks of training on the 
PROG schedule, chow was introduced and was concurrently available on the floor of the 
chamber during the PROG/chow feeding choice task sessions as previously described. Rats were 
trained on the PROG/chow feeding choice procedure for 5 weeks, after which drug testing 
began. On baseline and drug treatment days, rats consumed all of the operant pellets that were 
delivered during each session. 
 
Surgical Implantation of Dialysis Guide Cannulae 
Animals were anesthetized with an intraperitoneal injection of 100.0 mg/kg ketamine 
hydrochloride and 10.0 mg/kg xylazine prior to placement in a stereotaxic device (incisor bar 5.0 
mm above interaural line). Microdialysis guide cannulae (Bioanalytical Systems) were implanted 
2.0 mm dorsal to the accumbens core (AP +2.8 mm, ML +1.8 mm, DV −6.8 mm from bregma). 




placements were counterbalanced, with four rats implanted on the left and five rats implanted on 
the right. After placement, guide cannulae were secured to the skull by stainless steel screws and 
cranioplastic cement. A stainless-steel stylet was inserted through each cannula while not in use. 
Rats were allowed 7 days to recover from surgery before undergoing dialysis procedures.  
 
DA Microdialysis and High Performance Liquid Chromatography 
On sample collection days, dialysis probes (Bioanalytical Systems; 2.0 mm active 
surface) were inserted through the microdialysis guide cannulae. Artificial CSF (aCSF; 147.2 
mm NaCl, 2.4 mm CaCl2, 4.0 mm KCl) was continuously perfused through the probe at a rate of 
2.0 µl/min. Neurochemical samples were collected every 30 min in tubes containing 2.0 μl of 
ascorbic acid and sodium metabisulfite to prevent oxidation of DA. Up to 7 baseline samples 
were collected before an intraperitoneal injection of 8.0 mg/kg (S, S)-CE-158 to establish a stable 
DA level. The last three of those baseline samples were used as the statistical baseline. Samples 
were either immediately frozen or analyzed fresh using reverse-phase high-performance liquid 
chromatography (HPLC) with electrochemical detection (ESA Coulochem II system). The 
electrochemical parameters were as follows: channel 1 = −100 mV, channel 2 = +200 mV, and 
guard cell = +350 mV. Each liter of mobile phase contained 27.5 g sodium phosphate 
monobasic, 7.0 % methanol, 750 μl of 0.1 m EDTA, and 2200 μl of 0.4 m sodium octyl sulfate 
dissolved in deionized ultrapure H2O with a final pH of 4.5. The flow rate was 1.0 ml/min. DA 
standards were run each day before the dialysate samples. Probe placements were verified with 





Nissl Staining for Identifying Probe Placements 
At the completion of behavioral testing in the intracranial injection and microdialysis 
experiments, each animal was anesthetized with CO2 and then perfused intracardially with 
physiological saline followed by a 3.7 % formaldehyde solution. The brains were removed and 
stored in formaldehyde and then sliced with a vibratome in 60 μm sections, which were mounted 
on glass microscope slides. After mounting, slides were stained with cresyl violet for 
microscopic observation by a blind observer. Any animal with improper cannulae placement or 
significant damage around the injection site was excluded from the statistical analyses of 
behavioral data. 
 
Experimental Procedures  
Effects of systemic administration of TBZ on the concurrent FR5/chow feeding choice procedure 
and reversal with (S, S)-CE-158: 
Trained rats (n=7) were administered either TBZ (1.0 mg/kg) or vehicle, and (S, S)-CE-
158 (2.0, 4.0, 8.0 mg/kg) or vehicle, via intraperitoneal (IP) injections on drug testing days. Rats 
received TBZ or vehicle 120 minutes before testing and (S, S)-CE-158 or vehicle 30 minutes 
before testing. The experiment used a within-groups design, with each rat receiving each drug 
treatment in a randomly varied order. The following five treatment combinations were given: 
TBZ vehicle + (S, S)-CE-158 vehicle; 1.0 mg/kg TBZ + (S, S)-CE-158 vehicle; 1.0 mg/kg TBZ + 
2.0 mg/kg (S, S)-CE-158; 1.0 mg/kg TBZ + 4.0 mg/kg (S, S)-CE-158; 1.0 mg/kg TBZ + 8.0 




Effects of systemic administration of (S, S)-CE-158 on the concurrent PROG/chow feeding 
choice procedure: 
Thirty minutes prior to the testing session, trained rats (n=16) were administered either 
vehicle or 2.0, 4.0, or 8.0 mg/kg (S, S)-CE-158. This experiment used a within-groups design, 
with each rat receiving each drug treatment in a randomly varied order, once per week over the 
course of four weeks.  
Effects of (S, S)-CE-158 on extracellular DA in the nucleus accumbens: 
Rats were implanted with dialysis probes in nucleus accumbens core as described earlier. 
On the test day, after baseline dialysis samples were collected, rats received intraperitoneal 
injections of either vehicle (n=4) or 8.0 mg/kg (S, S)-CE-158 (n=5). Seven post-injection 
samples were collected.  
 
Statistical Analysis 
Repeated measures ANOVA was used to determine the effect of drug treatment on lever 
pressing and chow intake in the behavioral pharmacology experiments. Since there were 
significant overall F values for the two behavioral measures being used, nonorthogonal planned 
comparisons were performed, using the overall error term to assess differences between each 
treatment and the control condition. The number of comparisons was restricted to the number of 
treatments minus one (Keppel, 1991). Statistical outliers were predefined as any point that is 





Changes in extracellular DA levels in the microdialysis experiment were calculated as the 
percent change from baseline, with the mean of the three samples immediately preceding the 
drug injections serving as the 100% baseline level. A 2 × 7 factorial ANOVA with the treatment 
(drug vs. vehicle) factor being between groups, and the sample factor (samples collected after 
drug injection) being repeated measures, was used to test for post-injection differences in 
extracellular levels of DA. The raw DA levels of the baseline samples were analyzed using t test 
to verify that the baseline DA levels were not different between conditions. Nonorthogonal 
planned comparisons were performed using the error term from the between-subjects analysis to 
assess differences between the two treatments at each particular sample.   
 
4.3 Results  
Binding experiments on DAT expressing cells and inhibition of monoamine transporters (DAT, 
NET, SERT) by (S, S)-CE-158:   
(S, S)-CE-158 concentration-dependently displaced [3H]CFT from human DAT with an 
IC50 of 0.052 ± 0.017 µM (Fig. 4.2). As shown in Figure 4.3, (S, S)-CE-158 selectively and 
potently blocked DAT (IC50 = 0.2271 µM), while having a weak effect on NET (IC50 = 11.97 







Ability of (S, S)-CE-158 to reverse the effects of TBZ on the concurrent FR5/chow feeding choice 
procedure: 
As shown in Figure 4.4, a repeated measures ANOVA revealed that there was an overall 
significant effect of drug treatment on lever pressing [F(4,24)=34.940, p<0.001]. Planned 
comparisons showed that TBZ significantly decreased lever pressing compared to vehicle 
treatment [F(1,24)=63.675, p<0.001], and that co-administration of the dose of 8.0 mg/kg (S, S)-
CE-158 with TBZ significantly attenuated the effects of TBZ on lever pressing [F(1,24)=39.06, 
p<0.001]. A two-tailed t-test revealed no difference in lever pressing between the vehicle plus 
vehicle and TBZ plus (S, S)-CE-158 8.0 mg/kg treatments (p=0.17) (Fig. 4.4a). There was also a 
significant overall effect of drug treatment on chow intake [F(4,24)=22.086, p<0.001]. 
Additional planned comparisons revealed that TBZ alone significantly increased chow intake 
relative to vehicle treatment [F(1,24)=38.098, p<0.001], and that co-administration of 8.0 mg/kg 
(S, S)-CE-158 with TBZ significantly reduced chow intake compared to the TBZ plus vehicle 
condition [F(1,24)=21.786, p<0.001]. Furthermore, a two-tailed t-test revealed no difference in 
chow intake between the vehicle plus vehicle and TBZ plus 8.0 mg/kg (S, S)-CE-158 treatment 
groups (p=0.42) (Fig. 4.4b). 
 
Ability of (S, S)-CE-158 to increase high-effort responding on the concurrent PROG/chow 
feeding choice procedure: 
Repeated measures ANOVA revealed an overall main effect of drug treatment on lever 
pressing [F(3,45)=3.583, p<0.05], and planned comparisons demonstrated that lever presses were 




S)-CE-158 [F(1,45)=5.54, p<0.05] compared to vehicle treatment (Fig 4.5a). Drug treatment 
with (S, S)-CE-158 also had a significant effect on chow intake during the PROG/chow session 
[F(3,45)=3.686, p<0.05], with a significant reduction in chow intake at the 4.0 mg/kg dose 
[F(1,45)=7.118, p<0.05] and at the 8.0 mg/kg dose [F(1,45)=5.613, p<0.05] compared to vehicle 
(Fig. 4.5b). 
 
Systemic administration of (S, S)-CE-158 increased extracellular DA in the nucleus accumbens: 
Administration of 8.0 mg/kg (S, S)-CE-158 significantly increased extracellular DA 
content in the nucleus accumbens (Fig. 4.6). Factorial ANOVA with repeated measures on the 
sample factor demonstrated that there was a significant overall difference across samples 
[F(6,42)=3.339, p<0.01] and a significant sample x treatment interaction [F(6,42)=3.011, 
p<0.05]. The factorial ANOVA also revealed a significant quadratic trend for the sample x 
treatment interaction [F(1,7)=912.422, p<0.01], which statistically characterized the tendency for 
DA levels to show a transient increase, followed by a decrease, after injection of (S, S)-CE-158. 
In addition, there was a significant overall difference between treatment groups across the seven 
samples [F(1,7)=703.162, p<0.001], showing that (S, S)-CE-158 produced a significant overall 
difference in DA across samples relative to vehicle injection. Nonorthogonal planned 
comparisons assessing the difference between the two treatments at each sample revealed 















Figure 4.2. Effect of (S, S)-CE-158 on binding to DAT expressing cells. HEK293 cells with 
stable expression of the human DAT and seeded in 24-well plates were incubated with [3H]CFT 
for 2 hrs in the absence (dashed line) or presence of (S, S)-CE-158 at the concentration indicated 




determined as described under “Experimental procedures”. Symbols represent means of binding 














Figure 4.3. In vitro monoamine transporter reuptake inhibition of (S, S)-CE-158 using HEK293 
cells with stable expression of DAT, NET, and SERT. (S, S)-CE-158 selectively and potently 
blocked DAT (IC50 = 0.2271 µM), while having a weak effect on NET (IC50 = 11.97 µM) and no 
effect on SERT. Symbols represent means of uptake inhibition ± standard error of three 








Figure 4.4. The effects of the DAT blocker (S, S)-CE-158 on TBZ-induced changes in 
performance on the concurrent lever pressing/chow-feeding choice procedure. (a) There was an 
overall significant effect of drug treatment on lever pressing (p<0.001). TBZ significantly 
decreased lever pressing compared to vehicle treatment (#p<0.001). (b) There was a significant 




chow intake relative to vehicle treatment (#p<0.001). Co-administration of the dose of 8.0 mg/kg 
(S, S)-CE-158 with TBZ significantly attenuated the effects of TBZ on lever pressing (*p<0.001) 







Figure 4.5. The effects of the DAT blocker (S, S)-CE-158 on performance on the concurrent 
lever pressing/chow-feeding choice procedure. (a) There was an overall main effect of drug 
treatment on lever presses (p<0.05). Lever presses were significantly increased at 4.0 mg/kg (S, 
S)-CE-158 (**p<0.01) and at 8.0 mg/kg (S, S)-CE-158 (*p<0.05) compared to vehicle treatment. 
(b) Drug treatment with (S, S)-CE-158 had a significant effect on chow intake during the 
PROG/chow session (p<0.05), with a significant reduction in chow intake at the 4.0 mg/kg dose 
(*p<0.05) and at the 8.0 mg/kg dose (*p<0.05) compared to vehicle. 
 
  
Figure 4.6. Effect of (S, S)-CE-158 on extracellular DA in the nucleus accumbens. Left: 
Photomicrograph and schematic showing a representative probe placement in nucleus 
accumbens. Abbreviations: acb: nucleus accumbens; cpu: caudate nucleus-putamen 
(neostriatum) (Pellegrino et al. 1979). Right: Mean (± SEM) extracellular DA (expressed as 




injection of vehicle or 8 mg/kg (S, S)-CE-158, followed by seven post-drug samples (S1-7). 
**p<0.001, (S, S)-CE-158 significantly differs from vehicle at S2. *p<0.05, (S, S)-CE-158 
significantly differs from vehicle at S3. #p<0.05 significant overall difference between vehicle 



















Chapter 5: The Novel Atypical Dopamine Transport Inhibitor CT-005404 Reverses the 
Effort-Related Motivational Effects of Tetrabenazine and Interleukin-1β and Increases 
Progressive Ratio Responding 
Submitted; Rotolo et al., Neuropharmacology 
 
5.1 Introduction 
Patients with major depressive disorder (MDD), Parkinsonism, schizophrenia, multiple 
sclerosis (MS) and other psychiatric or neurological disorders commonly experience 
motivational symptoms such as fatigue and loss of energy (Feinstein, 2007; Fava et al., 2014). 
According to the DSM-V, one of the nine core symptoms of MDD is “fatigue or loss of energy 
nearly every day”, and this is the second most frequently reported symptom (Zimmerman et al. 
2015; Tolentino and Schmidt, 2018). Fatigue and anergia are demonstrated by an individual’s 
lack of energy or willingness to work for something that is significant (Treadway et al. 2012; 
Yang et al. 2014; Zimmerman et al. 2015; Corfield et al. 2016), which has been demonstrated by 
the tendency of individuals with depression, Parkinsonism, and schizophrenia to show a low-
effort bias when tested on effort-related choice procedures (Treadway et al. 2012; Yang et al. 
2014; Chong et al. 2016; Barch et al. 2017). The risk of depression in individuals who report 
fatigue is two-fold greater compared to non-fatigued individuals (Corfield et al. 2016). 
Historically, serotonin transport (SERT) inhibitors have been the most commonly prescribed 
drugs for treating MDD patients, but SERT blockers are relatively ineffective at improving 
anergia or fatigue-related aspects of motivation (Cooper et al., 2014; Fava et al. 2014; Rothschild 




(Pae et al., 2007; Papakostas et al., 2006; Cooper et al., 2014), and drugs that inhibit the 
dopamine (DA) transporter (DAT) such as d-amphetamine and methylphenidate (Stotz et al., 
1999; Hanna et al. 2006), can partially alleviate these symptoms in depressed patients. 
Bupropion also was reported to reduce fatigue associated with MS (Duffy and Campbell 1994).  
Given the clinical importance of motivational dysfunctions in psychopathology, it is vital 
to employ animal models that are useful for drug development. Thus, several recent studies have 
focused on rodent tasks involving effort-related choice behavior. For assessment of effort-based 
choice, animals are offered the option of a high-effort instrumental action leading to highly 
valued reinforcer (preferred, or higher magnitude) vs. a low effort/low reward choice.  A low-
effort bias in rodents can be induced by several conditions associated with motivational 
dysfunction in depression and other disorders, including stress (Shafiei et al. 2012; Bryce and 
Floresco 2016) and inflammatory challenge (Nunes et al. 2014; Yohn et al. 2016b,d). DA 
antagonists or depletions reliably produce a low-effort bias in rodents (Salamone et al. 1991, 
2002; Mai et al. 2012; Pardo et al. 2012; Nunes et al. 2013; Randall et al. 2014; Yohn et al. 
2015a,b; Yang et al. 2020). Tetrabenazine (TBZ) is an inhibitor of the vesicular monoamine 
transporter type-2 (VMAT-2), which blocks vesicular storage and depletes monoamines, though 
its greatest effects at low doses are on striatal and accumbens DA (Pettibone et al. 1984; Tanra et 
al. 1995; Nunes et al. 2013).  TBZ has been shown to produce depressive symptoms including 
anergia and fatigue in humans (Frank 2009, 2010; Guay 2010; Chen et al. 2012), and thus it has 
been used in numerous preclinical experiments involving effort-based choice to induce a low-
effort bias (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015, 2016a,b,c; Salamone et al. 
2016b; Carratala-Ros et al. 2020). TBZ-induced shifts in effort-based choice are not due to 




reference memory, and the effects of TBZ do not resemble those produced by appetite 
suppressant drugs or reinforcer devaluation (Nunes et al. 2013; Randall et al. 2014; Pardo et al. 
2015; Yohn et al. 2015, 2016a,b,c; Salamone et al. 2016b; Yang et al. 2020; Carratala-Ros et al. 
2020). The low-effort bias induced by TBZ in rats was not reversed by the commonly prescribed 
SERT inhibitors fluoxetine or citalopram (Yohn et al. 2016a,b), but it was attenuated by several 
drugs that block DAT, including bupropion, GBR12909, PRX-14040, lisdexamfetamine, (S)-CE-
123, methylphenidate, and modafinil (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015, 
2016a,b,c; Salamone et al. 2016a,b; Rotolo et al. 2019).  
Although there are classical DAT inhibitors such as cocaine, and drugs that block DAT 
and release DA such as amphetamines and methylphenidate, there is an emerging interest in the 
neurochemical and behavioral characteristics of novel atypical DAT blockers, such as N-
substituted benztropine analogs and modafinil analogs (Schmitt and Reith, 2011; Zhang et al. 
2017; Rotolo et al. 2019). In contrast to cocaine and amphetamines, which rapidly increase 
extracellular DA in nucleus accumbens (Tanda et al. 1997; Desai et al. 2010), GBR 12909 and 
some benztropine analogs induce a relatively slow increase in extracellular DA over a broad time 
course (Raje et al. 2003; Desai et al. 2005a,b, 2010; Tanda et al, 2005, 2009, 2013; Kohut et al. 
2014), which may offer advantages in terms of clinical utility.  In view of the potential 
importance of DAT inhibition as a target for developing drugs to treat motivational dysfunction, 
the present paper provides an initial characterization of the neurochemical and effort-related 
behavioral effects of a novel atypical DAT inhibitor, CT-005404. As well as providing data on 
DAT binding and alterations in extracellular DA as measured by microdialysis, the present 
studies evaluated the ability of CT-005404 to reverse the effort-related impairment induced by 




rats tested on the concurrent fixed ratio 5 (FR5)/chow feeding choice task. Furthermore, CT-
005404 was assessed for its ability to increase selection of high-effort lever pressing in rats 
tested on the progressive ratio (PROG)/chow feeding choice task.  
 
5.2 Materials and Methods 
Animals 
Sprague Dawley rats were obtained from Charles River Laboratories (Germany) and 
divided into 6 groups (n=4/group; 220-250 g) for the in vivo receptor occupancy experiment. 
Fifteen adult males (328-485 g) were used for the microdialysis experiments. Experiments were 
conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National 
Research Council 2011), European Union directive 2010/63, and Dutch law. Experiments were 
licensed by the national committee for animal experiments (AVD247002015341; Centrale 
Commissie Dierproeven) and approved by the Animal Care and Use Committee of Charles River 
Discovery Groningen. Animals were housed in groups of 5 in polypropylene cages (40 X 50 X 
20 cm) with wire mesh tops in a temperature (22 ± 2 °C) and humidity (55 ± 15%) controlled 
environment (12-h light/dark cycle, lights on 07:00). Standard diet (SDS Diets, RM1 PL) and 
water were available ad libitum. 
For the behavioral pharmacology experiments, adult male Sprague Dawley rats (Envigo, 
Indianapolis, IN, USA; 279-299 g) were pair-housed in a colony maintained at 23°C (12-h 
light/dark cycle, lights on at 07:00). Rats were initially food restricted to 85% of their free-
feeding body weight for operant training and then allowed modest growth, with water available 




University of Connecticut Institutional Animal Care and Use Committee, and studies were 
conducted according to NIH guidelines. 
 
CT-005404 In Vivo Receptor Occupancy 
Rats were treated with either vehicle (0.5% (w/v) (hydroxypropyl)methyl cellulose 
(HPMC) in 0.9% saline) or CT-005404 (1.0, 3.0, 10.0, 30.0, or 100.0 mg/kg), and 100 minutes 
later were given [18F]FECNT (8-(2-[18F]fluroethyl)-2betacarbomethoxy-3beta-(4-
chlorophenyl)nortropane) (i.v. 3.0 µg/kg, 0.5 ml/kg). After the tracer survival interval, rats were 
euthanized by cervical dislocation. Trunk blood was collected in K2-EDTA coated tubes and 
stored on ice. Whole brains were removed and rinsed with sterile water. Target tissues (striatum 
and cerebellum), were dissected, weighed, and stored in 1.5 ml tubes on dry ice at -80°C until 
tissue extraction. Blood samples were centrifuged at 1650 x g for 16 minutes, and serum was 
pipetted into tubes and stored at -80°C. Receptor occupancy experiments were performed by 
Chronos Therapeutics laboratories. 
 
In Vivo Microdialysis 
Surgical Implantation of Dialysis Guide Cannulae: 
Rats were anesthetized using isoflurane (2% and 500 mL/min O2). Before surgery, 
Finadyne analgesia (1.0 mg/kg, s.c.) was administered. A bupivacaine/epinephrine mixture was 
used for local analgesia of the incision site. Animals were placed in a stereotaxic apparatus (Kopf 
instruments, USA) with the incisor bar at -3.0 mm, and guides for I-shaped microdialysis probes 
with 2.0 mm exposed surface (polyacrylonitrile membrane; CRL, the Netherlands) were 




mm (from midline), ventral -7.7 mm (from dura), based on Paxinos and Watson (2008)). 
Cannulae were attached to the skull with stainless steel screws and dental cement.  
 
DA Microdialysis: 
Experiments were initiated one day after cannulae implantation. Microdialysis probes 
were connected with PEEK tubing (Western Analytical Products Inc. USA; PK005-020) to a 
microperfusion pump (Harvard Apparatus) and perfused with artificial CSF (aCSF: 147 mM 
NaCl, 3.0 mM KCl, 1.2 mM CaCl2 and 1.2 mM MgCl2) at 1.5 µl/min flow rate. After two hours 
of stabilization, microdialysis samples were collected in 20-minute intervals. After the third basal 
sample (t=0 minutes) vehicle or 10.0 or 30.0 mg/kg CT-005404 (0.5% (w/v) 
(hydroxypropyl)methyl cellulose (HPMC) in 0.9% saline) were orally administered. 
Microdialysates were collected for 360 minutes after compound administration. Samples were 
collected into polystyrene microvials (Microbiotech/se AB, Sweden; 4001029) using an 
automated collector (UV 8301501, TSE, Univentor, Malta). The vials contained 10 μL 
stabilization fluid (0.02 M formic acid + 0.04% ascorbic acid in ultrapurified water). Samples 
were stored at -80 °C. After the experiment animals were sacrificed, and brain tissue was 
collected for verification of probe placements. Microdialysis experiments were performed by 
Chronos Therapeutics laboratories. 
 
Analytical Procedure: 
The volume for the microdialysis samples was 40 μL. Concentrations of DA were 
determined by HPLC with tandem mass spectrometry (MS/MS) detection using the following 




each sample. The resulting mixture was derivatized with SymDAQ™ automatically in the 
autosampler and then injected onto the HPLC by an automated sample injector (Shimadzu, 
Japan). Chromatographic separation was performed with a Phenomenex, Synergi MAX-RP 
column (100 x 3 mm, 2.5 µm; 35 °C). The mobile phases consisted of A: ultrapurified 
water+0.2% acetonitrile+0.1% formic acid and B: 70% acetonitrile in ultrapurified water+0.1% 
formic acid. Elution of compounds proceeded using a linear gradient (flow rate- 0.3 mL/min).  
The MS analyses were performed using an API 4000 MS/MS system (API 4000 MS/MS 
detector, Turbo Ion Spray interface, Applied Biosystems, The Netherlands). The acquisitions 
were performed in positive ionization mode with the instrument operated in multiple-reaction-
monitoring mode. 
 
Behavioral Pharmacology Procedures 
FR5/Chow Feeding Choice Task: 
Behavioral sessions (30 minutes/day, 5 days/week) were conducted in operant chambers 
(28 x 23 x 23 cm; Med Associates, Fairfax, VT). First, rats were trained to lever press on a FR1 
schedule reinforced by 45 mg high-carbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for 
one week, then were shifted to the FR5 schedule. After 5 weeks of FR5 training, chow was 
introduced. During FR5/chow feeding choice sessions, 15-20 g of lab chow (Laboratory Diet, 
5P00 Prolab RMH 3000, Purina Mills, St. Louis, MO) was concurrently available on the floor of 
the chamber. At the end of each session, rats were removed from operant chambers, the number 
of lever presses was recorded, and the remainder of chow and spillage in the chamber floor was 




drug testing began. On baseline and drug treatment days, rats consumed all the operant pellets 
that were delivered during each session. 
 
PROG/Chow Feeding Choice Task: 
Behavioral sessions (30 minutes/day, 5 days/week) were conducted in operant chambers. 
Rats were initially trained to lever press on a FR1 schedule on Bio-Serv pellets as described 
above, then were shifted to the PROG schedule. For PROG sessions, the ratio started at FR1 and 
was increased by one additional response every time 15 reinforcers were obtained. A “timeout” 
feature deactivated the response lever and turned off the house light for the rest of the session 
whenever 2 min elapsed without a completed ratio. After 9 weeks of PROG training, chow was 
introduced. During each session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000, 
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. At the end 
of each session, rats were removed from operant chambers, the number of lever presses was 
recorded, and the chow intake was determined. Rats were trained on this PROG/chow feeding 
choice procedure for 5 weeks, after which drug testing began. On baseline and drug treatment 
days, rats consumed all of the operant pellets that were delivered during each session. 
 
Behavioral Pharmacology Experiments 
Drug Treatments and Dose Selection: 
CT-005404 was obtained from Chronos Therapeutics (Oxford, UK), and was dissolved in 
dimethylsulfoxide (DMSO) (1%) and hydroxypropyl methylcellulose (HPMC) (99%). The 
DMSO/HPMC solution was administered as the vehicle control. For Exp. 1, TBZ (9,10-




obtained from Tocris Bioscience (Ellisville, MO), and was dissolved in DMSO (20%) and 0.9% 
sterile saline (20%). Once partially dissolved, the TBZ solution was titrated with microliter 
quantities of 1.0 N HCl to fully dissolve the drug at a pH of 4.0-4.5. The dose of 1.0 mg/kg TBZ 
was based on previous studies (Rotolo et al. 2019). For Exp. 2, IL-1β was obtained from R&D 
Systems (Minneapolis, MN, USA), and was dissolved in 0.9% saline, which also served as the 
vehicle control. The dose of IL-1β was based on previously published data (Merali et al., 2003; 
Nunes et al. 2014) and pilot studies. The doses of CT-005404 were selected based on target 
engagement pilot studies (e.g. time course of receptor occupancy and receptor occupancy by 
dose) conducted by Chronos Therapeutics (see Figure 1). 
 
Behavioral Pharmacology Experiments: 
Rats (n=15) trained on the FR5/chow choice feeding procedure were administered either 
TBZ (1.0 mg/kg i.p.) or vehicle and CT-005404 (7.5, 15.0, and 30.0 mg/kg p.o.) or vehicle on 
drug testing days. CT-005404 or vehicle was administered 240 min (n=7) or 180 min (n=8) 
before testing, and TBZ or vehicle was administered 120 min before testing. A within-subjects 
design was used, with each animal receiving each drug treatment in a randomly varied order. 
Treatment combinations were as follows: TBZ vehicle + CT-005404 vehicle (control); 1.0 mg/kg 
TBZ + CT-005404 vehicle; 1.0 mg/kg TBZ + 7.5 mg/kg CT-005404; 1.0 mg/kg TBZ + 15.0 
mg/kg CT-005404; 1.0 mg/kg TBZ + 30.0 mg/kg CT-005404. Drug treatments were given once 
per week, with none of the treatment sequences repeated across different animals.  
For the CT-005404/IL-1β reversal study, a second group of trained rats (n=11) were 
administered either IL-1β (4.0 µg/kg i.p.) or vehicle and CT-005404 (7.5, 15.0, and 30.0 mg/kg 




testing, and IL-1β or vehicle was administered 90 min before testing. A within-subjects design 
was used, with each animal receiving each drug treatment in a randomly varied order. Treatment 
combinations were: IL-1β vehicle + CT-005404 vehicle (control); 4.0 μg/kg IL-1β + CT-005404 
vehicle; 4.0 μg/kg IL-1β + 7.5 mg/kg CT-005404; 4.0 μg/kg IL-1β + 15.0 mg/kg CT-005404; 4.0 
μg/kg IL-1β + 30.0 mg/kg CT-005404. Drug treatments were given once per week, with none of 
the treatment sequences repeated across different animals. 
For the CT-005404 PROG/chow feeding choice study, a group of rats (n=16) trained on 
the PROG/chow feeding choice procedure received 7.5, 15.0, or 30.0 mg/kg CT-005404 or 
vehicle 240 min before testing. Treatments were given once per week, in a randomly varied 
order, over the course of 4 weeks.  
 
Statistical Analysis 
For evaluation of the in vivo receptor occupancy data, a [agonist] vs. response variable 
slope model was used. The dose required to produce 50% occupancy (Occ50) and SEM was 
calculated using GraphPad Prism 8.4.1. 
Changes in extracellular DA levels in the microdialysis experiment were calculated as the 
percent change from baseline, with the mean of the three samples immediately preceding the 
drug injections serving as the 100% baseline level. Data from one rat was excluded due to 
interrupted sample collection. Data from a total of 14 rats were included in the analysis (vehicle 
n=4, 10.0 mg/kg n=5, 30.0 mg/kg n=5). All post-administration samples were expressed as a 
percentage of basal level within the same subject. A 3 × 17 factorial ANOVA with the treatment 
(two doses of CT-005404 vs. vehicle) factor being between groups, and the sample factor 




injection differences in extracellular levels of DA. The raw DA levels of the baseline samples 
were analyzed using t tests to verify that the baseline DA levels were not different between 
conditions. Dunnett’s tests using the error term from the between-subjects analysis were used to 
assess differences between each drug treatment and vehicle at each particular sample.  
For the behavioral pharmacology experiments, total number of lever presses and gram 
quantity of chow intake were analyzed using repeated measures ANOVA. Nonorthogonal 
planned comparisons restricted to the number of treatments minus 1 (Keppel, 1991) using the 
overall error term were performed when the repeated measures ANOVA yielded a significant F 
value, to assess differences between each treatment and the control condition. The level of 
statistical significance was defined a priori at p<0.05. SPSS Statistics (Version 25), was used to 
perform all statistical analyses. 
 
5.3 Results 
CT-005404 In Vivo Receptor Occupancy: 
In vivo receptor occupancy studies were performed. Occupancy of the DAT as it relates 
to dose was calculated for CT-005404. It was determined that the Occ50 of CT-005404 was 
8.224 mg/kg (± SEM 1.646) (Fig. 5.1A). Receptor occupancy was measured after CT-005404 
administration at 0.5, 1, 2, 4, 8, 12, and 24 hours. The peak receptor occupancy percentage was 
observed 4 hours post-treatment with a 78% occupancy (± 2.2 SEM) (Fig. 5.1B). Table 5.1 
shows the in vitro binding affinities for CT-005404 at DAT, NET, and SERT binding sites. CT-
005404 showed an 80-fold selectivity for binding to the DAT relative to the NET, and a 1600-





In Vivo Microdialysis: 
Administration of CT-005404 significantly increased extracellular DA content in the 
nucleus accumbens (Fig. 5.1C). Factorial ANOVA with repeated measures on the sample factor 
demonstrated that there was a significant overall difference across samples [F(16,176)=13.58, 
p<0.001] and a significant sample x treatment interaction [F(32,176)=2.90, p<0.001]. In 
addition, administration of CT-005404 yielded a significant overall main effect of treatment 
group on extracellular DA across the seventeen post-injection samples [F(2,11)=7.03, p<0.05]. 
Simple effects of treatment group were assessed by computing between groups ANOVAs at each 
time point. For each significant between groups overall ANOVA, post-hoc two-tailed Dunnett’s 
tests were performed, which revealed significant differences in extracellular DA for both the 
10.0 mg/kg and 30.0 mg/kg treatment groups compared to vehicle from 80-280 min post-
injection (with the exception of the 180-minute time point due to increased error).  
 
Behavioral Pharmacology Experiments 
FR5/Chow Feeding Choice Task: 
Figure 5.2 shows the effects of CT-005404 on TBZ-induced changes in rats tested on the 
FR5/chow feeding choice procedure. CT-005404 was administered either 3 hours or 4 hours 
prior to testing in two different groups of rats. In both groups, TBZ shifted effort-based choice, 
decreasing lever pressing and increasing chow intake. A treatment x lead time repeated measures 
factorial ANOVA revealed a significant overall main effect of treatment on lever pressing 
[F(4,52)=32.28, p<0.001], but no effect of lead time on lever pressing [F(1,13)=0.39, p=n.s.], 
and no significant treatment x lead time interaction [F(4,52)=0.824, p=n.s.] (Fig. 5.2A). Due to a 




across the 3- and 4-hour lead times. TBZ+vehicle significantly reduced lever presses relative to 
the vehicle+vehicle treatment [F(1,52)=102.682, p<0.001]. Planned comparisons revealed a 
significant increase in lever presses for both the TBZ+15.0 mg/kg CT-005404 [F(1,52)=9.844, 
p<0.01] and TBZ+30.0 mg/kg CT-005404 [F(1,56)=9.068, p<0.01] relative to the TBZ+vehicle 
treatment (Fig. 5.2A). Factorial ANOVA assessing chow intake revealed a significant treatment 
effect [F(4,52)=15.399, p<0.001], but no effect of lead time on chow intake [F(1,13)=2.268, 
p=n.s.], and no significant treatment x lead time interaction [F(4,52)=0.800, p=n.s.] (Fig. 5.2B). 
TBZ+vehicle significantly increased chow intake relative to vehicle+vehicle treatment 
[F(1,52)=47.645, p<0.001]. Planned comparisons revealed a significant decrease in chow intake 
for both the TBZ+15.0 mg/kg CT-005404 [F(1,52)=4.829, p<0.05] and TBZ+30.0 mg/kg CT-
005404 [F(1,52)=18.495, p<0.001] relative to the TBZ+vehicle treatment (Fig. 5.2B).  
For the CT-005404/IL-1β reversal study, repeated measures ANOVA demonstrated a 
significant overall treatment effect on lever presses [F(4,40)=12.504, p<0.001] (Fig. 5.3A). IL-
1β+vehicle significantly reduced lever presses compared to vehicle+vehicle [F(1,40)=40.759, 
p<0.001]. Planned comparisons revealed that treatment with both 15.0 mg/kg CT-005404 and 
30.0 mg/kg CT-005404 were able to significantly increase lever presses from IL-1β plus vehicle 
treatment [F(1,40)=4.180, p<0.05; F(1,40)=8.992, p<0.01, respectively] (Fig. 5.3A). There was 
no overall treatment effect for chow intake [F(4,40)=1.558, p=n.s.] (Fig. 5.3B). 
 
PROG/Chow Feeding Choice Task 
Repeated measures ANOVA revealed for the effect of CT-005404 on lever pressing 
closely approached statistical significance [F(3,45)=2.628, 0.1 < p > 0.05] (Fig. 5.4A), and a 




(Fig. 5.4B). However, orthogonal analysis of trend showed that there were significant linear 
dose-related effects for lever presses [F(1,15)=6.632, p<0.05] and chow intake [F(1,15)=12.035, 
p<0.01]. Because the linear dose-related trend was significant, planned comparisons were 
computed for number of lever presses. Rats treated with 30.0 mg/kg CT-005404 lever pressed 
significantly more [F(1,45)=6.617, p<0.05] and consumed less chow [F(1,45)=11.240, p<0.01] 
than rats treated with vehicle. Rats treated with 15.0 mg/kg CT-005404 also consumed 
significantly less chow during the session compared to vehicle [F(1,45)=7.911, p<0.01]. 
Moreover, a significant negative correlation was found when the percent change in lever presses 
was compared to the percent change in chow intake from vehicle at the 15.0 mg/kg treatment 





Table 5.1. Binding affinity of CT-005404 to the DA transporter (DAT), the norepinephrine 
transporter (NET), and the 5-HT transporter (SERT). Values represent IC50s calculated from 














Figure 5.1. DAT occupancy and extracellular levels of DA in nucleus accumbens after oral 
administration of CT-005404. (A) DAT occupancy as it relates to dose (mg/kg). The dose of CT-
005404 required to produce 50% occupancy (Occ50) of the DAT was 8.224 mg/kg (± 1.6 SEM). 
(B) DAT occupancy over time (hours). DAT occupancy was measured after CT-005404 
administration at 0.5, 1, 2, 4, 8, 12, and 24 hours. The peak % DAT occupancy was observed 4 
hours post-treatment with a 78% occupancy (± 2.2 SEM). (C) Microdialysis data showing 
extracellular DA in nucleus accumbens after p.o. administration of CT-005404. Mean (± SEM) 
extracellular DA (expressed as percent baseline) in 20-min samples. Three baseline samples 
were collected prior to injection of vehicle or 10.0 or 30.0 mg/kg CT-005404, followed by 17 
post-injection samples. There was a significant overall effect of treatment group across the 17 
post-drug samples, and a significant group x sample interaction. †p<0.05, 30.0 mg/kg CT-








Figure 5.2. The effects of the DAT inhibitor CT-005404 on TBZ-induced changes in 
performance on the FR5 concurrent lever pressing/chow feeding choice procedure. (A) Lever 
presses during the 30-minute session. #p<0.001, TBZ plus vehicle significantly differed from 
vehicle plus vehicle; **p<0.01, TBZ plus 15.0 mg/kg CT-005404 (3 hours) significantly differed 
from TBZ plus vehicle; *p<0.05, TBZ plus 30.0 mg/kg CT-005404 significantly differed from 
TBZ plus vehicle. (B) Gram quantity of chow intake. #p<0.001, TBZ plus vehicle significantly 
differed from vehicle plus vehicle; **p<0.01, TBZ plus 30.0 mg/kg CT-005404 significantly 






Figure 5.3. The effects of the DAT inhibitor CT-005404 on IL-1β-induced changes in 
performance on the FR5 concurrent lever pressing/chow-feeding choice procedure. (A) Lever 
presses during the 30-minute session. #p<0.001, IL-1β plus vehicle significantly differed from 




significant difference from IL-1β plus vehicle; **p< 0.01, IL-1β plus 30.0 mg/kg CT-005404 
significantly differed from IL-1β plus vehicle.  (B) Gram quantity of chow intake. IL-1β plus 






Figure 5.4. The effects of the DAT inhibitor CT-005404 on performance on the Progressive 
Ratio/chow-feeding choice procedure. (A) Lever presses during the 30 minute session. Rats 
treated with 30.0 mg/kg CT-005404 lever pressed significantly more than vehicle-treated rats 
(*p<0.05). (B) Gram quantity of chow intake. Rats treated with 15.0 mg/kg and 30.0 mg/kg CT-

















Chapter 6: Effort-related effects of altering lever pressing ratio requirements, and of 
tetrabenazine administration, on progressive ratio work output. 
 
6.1 Introduction  
Motivation has been defined as the set of processes through which organisms regulate the 
probability, proximity, and availability of significant stimuli (Salamone 1992; Salamone and 
Correa 2002; Salamone 2010; Salamone et al. 2016a). Motivated behaviors are characterized by 
a high degree of behavioral activation, which is manifested as the vigor and persistence of work 
output (Salamone 1988, 1992; Salamone and Correa 2002, 2012; Croxson et al. 2009; McGinty 
et al. 2013; Salamone et al. 2016a). These features facilitate the exertion of effort during the 
instigation and maintenance of instrumental responding, allowing organisms to overcome effort-
related response costs in order to obtain something valued by the organism (e.g. food). 
Considerable research has shown that mesolimbic dopamine (DA) plays an important role in 
regulating motivated behaviors (Salamone et al. 1997, 2007, 2012; Salamone and Correa, 2002, 
2012; Robbins and Everitt, 2007). More specifically, interference with nucleus accumbens DA 
can affect the willingness of animals to exert high levels of effort to obtain food reinforcers, 
while leaving primary aspects of motivation such as appetite and the direction and acquisition of 
food intact (Salamone and Correa 2002, 2012).  
A growing body of clinical neuroscience research emphasizes the importance of effort-
related symptoms, such as fatigue, anergia, and psychomotor retardation in major depression, 
multiple sclerosis, chronic fatigue syndromes, schizophrenia, Parkinson’s disease, and other 




2006; Treadway and Zald 2011; Fava et al. 2014; Chong et al. 2015). Human tests of effort-
related decision making are increasingly being employed for characterizing the motivational 
impairments seen in people with Parkinsonism, schizophrenia, and depression (Treadway et al. 
2012a; Gold et al. 2013, 2015; Chong et al. 2015; Green et al. 2015; Green and Horan 2015; 
Reddy et al. 2015). Patients with major depression have a reduced likelihood of selecting high 
effort alternatives when assessed in tests of effort-related decision making (Treadway et al. 
2012a; Yang et al. 2014). Furthermore, Guillion and Rush (1998) conducted a factor analytic 
study of patients with major depression and identified a “lack of energy” factor (i.e., problems 
with energy/fatigability, psychomotor retardation, inability to work), which was the factor that 
loaded most strongly onto a second order general depression factor. These symptoms can 
strongly interfere with daily living, and can be difficult to treat (Tylee et al. 1999; Stahl 2002; 
Fava et al. 2014). Moreover, it has been suggested that fatigue could be used as a predictor of 
clinical depression, and can contribute to deficits in global functioning (Corfield et al. 2016), 
highlighting its importance as a critical feature in animal research. Thus, it is important to study 
the neural and behavioral processes related to the exertion of effort to better understand the 
physiological underpinnings of these symptoms. 
In view of the clinical relevance of motivational dysfunctions related to deficits in 
behavioral activation and exertion of effort, it is critical to develop animal models that focus 
specifically on effort-related motivational symptoms. Animal studies of effort-based choice have 
been developed as formal models to study motivational dysfunctions. In these tasks, animals are 
offered a choice between high-effort instrumental actions leading to highly valued reinforcers, 
versus low-effort options leading to less valued reinforcers. Fixed ratio (FR) reinforcement 




reinforcer (high-carbohydrate pellets), or to choose a concurrently available but less preferred 
option (standard laboratory chow). DA D1 and D2 family antagonists decrease food-reinforced 
FR5 lever pressing but substantially increase chow intake (Salamone et al., 1991, 2002; Sink et 
al. 2008). The shift from lever pressing to chow intake is not produced by neostriatal DA 
depletions or antagonism (Cousins et al. 1993; Farrar et al. 2010), but instead results from 
accumbens DA depletions, and intra-accumbens injections of D1 or D2 antagonists (Cousins et al. 
1993; Nowend et al. 2001; Farrar et al. 2010). Drug treatments that produce the shift in choice 
behavior did not alter food intake or preference in free-feeding choice tests (Salamone et al. 
1991; Koch et al. 2000; Farrar et al. 2008), and did not resemble the effects of appetite 
suppressant drugs (Salamone et al. 2002; Sink et al. 2008; Randall et al. 2012, 2013).  
The Salamone lab also has employed a progressive ratio (PROG)/chow feeding 
concurrent choice task (Salamone 2006; Randall et al. 2012, 2014, 2015; Yohn et al. 2016b,c,d, 
2018), which offers the choice of lever pressing on a PROG schedule reinforced by the preferred 
high carbohydrate pellets vs. approaching and consuming the less preferred chow. The PROG 
schedule requires that the rat repeatedly make within-session choices between lever pressing and 
chow intake under conditions in which the ratio requirement is gradually incrementing. DA D1 
and D2 family antagonists decreased PROG lever pressing (e.g., number of lever presses, highest 
ratio achieved, and time spent responding), but rats maintained normal levels of chow intake, 
indicating that their appetite for food was still intact (Randall et al. 2012, 2014). Importantly, the 
effects of DA antagonism or depletion differed markedly from those of reinforcement or 
appetite-related manipulations (reinforcer devaluation by pre-feeding, the cannabinoid CB1 
antagonist/inverse agonists AM251 and AM4113), which decrease both lever pressing and chow 




local antagonism or depletion of DA in nucleus accumbens, do not affect primary food 
motivation or appetite when access to food is unconstrained, but instead make it less likely that 
animals will work for food. These findings demonstrate that interference with DA transmission 
causes animals to reallocate their instrumental actions based on the response requirements of the 
task, and select lower cost alternatives to obtain food (Salamone et al. 2007, 2009b, 2012, 
2016a,b,c; Salamone and Correa 2002, 2012).  
Due to the prevalence of effort-related dysfunctions observed in human 
psychopathologies, it is critical to characterize the impact of varying response costs on an 
organism’s willingness to exert high levels of effort. Human clinical research has shown that 
willingness to work for monetary reward on a PROG task was impaired in people with 
depression (Hershenberg et al. 2016), and in schizophrenics with high levels of negative 
symptoms (Wolf et al. 2014). PROG schedules can also be used to measure exertion of high-
effort behavior in rats (Salamone 2006; Randall et al. 2012, 2014, 2015; Yohn et al. 2016b,c,d, 
2018). Typically, animals tested on PROG schedules will lever press until the work requirement, 
or the ‘cost’, becomes too high, while others will continue responding throughout the entire 
session. The point at which an animal ceases high-effort responding is referred to as the 
breakpoint, and can be used as a measure of maximal effort exertion. In the concurrent 
PROG/chow feeding choice procedure described above, the freely available lab chow acts as a 
‘magnet’, effectively pulling the animal away from high-effort lever pressing towards a low-
effort alternative, as soon as the animal perceives the work requirement as too difficult to 
overcome. In the present experiment, rats were trained on a PROG reinforcement schedule 
without the option of freely available lab chow, so the only way to receive food was to lever 




increase in order to shift animals’ breakpoint earlier in order to be observed within a 30-minute 
session.  
The present studies were conducted to evaluate the effects of altering ratio requirements 
on a PROG schedule of reinforcement, and to establish a PROG schedule that is difficult enough 
to cause animals to exhibit a breakpoint during a 30-minute session. It was predicted that altering 
the number of reinforcers delivered at each ratio (N), and the increment at which the ratio 
requirement increases after N reinforcers are delivered (I), would produce a drastic change to the 
total number of lever presses and breakpoint exhibited during a session. It also was hypothesized 
that the VMAT-2 inhibitor TBZ, which pharmacologically depletes DA, would decrease the 
number of lever presses, the time of last response, and the breakpoint during the modified PROG 
session. Ultimately, the PROG schedule determined by these experiments will be used in future 
electrophysiological recording experiments to assess frontal cortex electroencephalography 
(EEG) changes under baseline and pharmacological conditions in which animals shift their 
behavior away from high-effort instrumental responding towards the low effort-alternative (see 
Chapter 7 for initial development of recording techniques and effects of TBZ in untrained 
animals).  
 
6.2 Materials and Methods 
Animals 
Sixteen adult male Sprague Dawley rats were obtained from Envigo (Indianapolis, IN, 
USA), and were housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 




to 85% of their free-feeding body weight for operant training. Rats were fed supplemental chow 
to maintain weight throughout the study, with water available ad libitum. Rats were allowed 
modest weight gain throughout the experiment. Animal protocols were approved by the 
University of Connecticut Animal Care and Use Committee, and followed NIH guidelines.  
 
PROG Lever Pressing Task and Schedule Modifications 
Rats were initially trained to lever press for 45 mg high-carbohydrate pellets (Bio-Serv) 
on an FR1 (continuous reinforcement) schedule for one week or until a stable baseline was 
reached. Then, rats were switched to a PROG schedule (Randall et al. 2012, 2014, 2015), in 
which the number (N) of pellets delivered at each ratio was equal to 15, and the increment (I) at 
which the ratio increased after the delivery of each reinforcer was equal to 1 (e.g. FR1 x 15 
reinforcers, FR2 x 15 reinforcers, FR3 x 15 reinforcers, and so on) for nine weeks (30 min 
sessions, 5 times/week). The PROG schedule was then modified so that N = 1 and I = 1 (e.g. 
FR1 x 1 reinforcer, FR2 x 1 reinforcer, FR3 x 1 reinforcer, and so on), and rats were trained on 
this schedule for six and a half weeks. After a stable baseline was reached, the PROG schedule 
was further modified to change the ratio increase increment after each reinforcer delivery, so that 
N = 1 and I = 2 (e.g. FR1 x 1 reinforcer, FR3 x 1 reinforcer, FR5 x 1 reinforcer, and so on). After 
three days of training on the modified PROG schedule, a stable baseline was reached. Then, the 
schedule underwent a final modification, increasing the ratio increment to I = 4 (e.g. FR1 x 1 
reinforcer, FR5 x 1 reinforcer, FR9 x 1 reinforcer, and so on). Rats remained on this training 
schedule for three weeks before drug testing began. At the end of each 30 minute session, rats 
were immediately removed from the chambers and number of lever presses, time of last 




recorded for each rat. On baseline training and drug treatment days, rats consumed all of the 
operant pellets that were delivered during each session.  
 
Drug Treatments and Dose Selection 
Tetrabenazine (TBZ) (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b 
hexahydrobenzo[a]quinolizin-2-one) was obtained from Tocris Bioscience (Ellisville, MO) and 
was dissolved in DMSO (20%), 0.9% saline (80%), and was titrated with microliter quantities of 
1.0 N HCl until the solid drug was in solution at a pH of 4.0-4.5. The DMSO/saline solution was 
administered as the vehicle control. The dose of 1.0 mg/kg TBZ was selected based on extensive 
piloting in our laboratory.  
 
Behavioral Pharmacology Experiment 
Fifteen out of sixteen trained rats were used for the behavioral pharmacology experiment. 
One rat was excluded from the experiment due to an unstable baseline. On drug testing days, 
trained rats were administered either TBZ (1.0 mg/kg) or vehicle via intraperitoneal (IP) 
injections 120 minutes before testing. The experiment used a within-groups design, with half of 
the rats receiving a vehicle treatment on the first day of drug testing, while the other half 
received TBZ, and vice versa on the second drug testing day. The only PROG schedule used for 
the behavioral pharmacology experiment was the schedule where N = 1 and I = 4, which was the 






 For the PROG training progression, differences in lever presses across time within each 
phase of training was analyzed using repeated measures ANOVA. For the behavioral 
pharmacology experiment, number of lever presses, time of last response, and breakpoint ratio 
were all analyzed using paired-samples t tests. Factorial ANOVA was used to determine an 
overall main effect of treatment on the three behavioral measures during the PROG session as a 
percentage of their baseline performance. A statistical program (SPSS, Version 25) was used to 
perform all analyses. 
 
6.3 Results 
Rats underwent a training progression on various schedules of PROG reinforcement over 
a time period of 20 weeks. Shown in Figure 6.1, a repeated measures ANOVA demonstrated a 
statistically significant main effect of week on average lever presses during the ‘N=15; I=1’ 
phase [F(8,120)=69.626, p<0.001] and a significant linear trend [F(1,15)=147.635, p<0.001]. 
There was no significant effect of week on lever presses in the second phase, ‘N=1; I=1’ 
(p=n.s.), or final phase, ‘N=1; I=4’ (p=n.s.) (Fig. 6.1).  
TBZ was administered to rats trained on the modified PROG reinforcement schedule 
(N=1; I=4). The mean number of lever presses under vehicle conditions was 1853.2 ± 259.5. 
TBZ administration yielded an average of 982.3 ± 194.8 lever presses, equating to a 47% 
reduction compared to the vehicle-treated group. Paired-sample t test indicated a statistically 
significant difference in lever presses between the vehicle and TBZ treatment groups 




were also compared. Paired-sample t test indicated that TBZ significantly reduced the time of 
last response during the session [t(14)=4.588, p<0.001] (Fig. 6.2B). There was also a significant 
reduction of breakpoint ratio as a result of TBZ administration, as demonstrated by a paired-
sample t test [t(14)=4.885, p<0.001] (Fig. 6.2C). TBZ administration resulted in a 29-30% 
reduction of both time of last response and breakpoint ratio measures. 
 Figure 6.3 shows the effects of TBZ on PROG lever presses, time of last response, and 
breakpoint ratio during a 30-minute session in rats as a percentage of baseline performance. 
Factorial ANOVA indicated an overall significant main effect of treatment [F(1,42)=39.283, 
p<0.001] and a non-significant interaction between treatment and any of the dependent variables 
(p=n.s.). After reaching a stable baseline in the final phase, average baseline values were 
calculated for lever presses, time of last response, and breakpoint ratio. Prior to the first day of 
drug testing, the average number of lever presses was 1752.1 ± 310.5, average time of last 
response was 1371.0 ± 93.0 seconds, and average breakpoint ratio was 111.3 ± 10.6. Prior to the 
second day of drug testing, the average number of lever presses was 1803.9 ± 255.7, average 
time of last response was 1324.8 ± 86.4 seconds, and average breakpoint ratio was 114.3 ± 8.4 
(data not shown). Paired sample t tests indicated no statistically significant differences between 
any of the baseline measures from the first to second drug testing day. These averages were used 






Figure 6.1. Progressive ratio (PROG) training procedure. Rats (n=16) were trained on various 
PROG schedules over the course of 20 weeks. Each point (•) represents weekly average lever 
presses ± SEM. Dashed lines represent training phase transitions, each phase labeled accordingly 
as ‘PROG (N=X; I=X)’. Overall effect of week on lever presses during the first training phase 











Figure 6.2. Effects of tetrabenazine (TBZ) on PROG lever presses, time of last response, and 
breakpoint ratio during a 30-minute session in rats (n=15). (A) Mean ± SEM number of lever 
presses after treatment with vehicle or 1 mg/kg TBZ. *p<0.001, difference between vehicle and 
TBZ. (B) Mean ± SEM time of last response (sec) in a 30-minute session after treatment with 
vehicle or 1 mg/kg TBZ. *p<0.001, difference between vehicle and TBZ. (C) Mean ± SEM 
breakpoint ratio in a 30-minute session after treatment with vehicle or 1 mg/kg TBZ. *p<0.001, 






Figure 6.3. Effects of tetrabenazine (TBZ) on PROG lever presses, time of last response, and 
breakpoint ratio during a 30-minute session in rats (n=15) as a percentage of baseline 
performance. Factorial ANOVA indicated an overall significant main effect of treatment 










Chapter 7: Exploration of frontal cortex electrophysiology in freely moving untrained rats: 
effects of TBZ. 
 
7.1 Introduction 
Motivational symptoms such as psychomotor slowing, fatigue, lassitude, loss of energy 
and reduced exertion of effort are critical and debilitating features of psychopathology (Stahl 
2002; Demyttenaere et al. 2005; Salamone et al. 2006; Treadway and Zald 2011; Treadway et al. 
2012a; Fava et al. 2014). Effort-related motivational symptoms are present in major depressive 
disorder, bipolar disorder, schizophrenia, Parkinsonism, chronic fatigue syndrome and multiple 
sclerosis (Salamone et al. 2006, 2010, 2016b; Friedman et al. 2007; Tellez et al. 2008; Green et 
al. 2015). The neural basis of the effort-related dysfunctions in psychopathology are still being 
characterized, nevertheless, considerable evidence shows that the selection of high-effort 
activities is dependent upon forebrain mesolimbic DA circuitry as well as integrity of the 
circuitry connecting ventral striatum, ventral pallidum, and prefrontal cortex (Salamone et al. 
1991, 1994; 2007, 2016a,b, 2018; Walton et al. 2003; Floresco and Ghods-Sharifi 2007; Mingote 
et al. 2008; Farrar et al. 2008, 2010; Winstanley and Floresco 2016).  
Our laboratory has demonstrated that tests of effort-based choice can be used as animal 
models of effort-related motivational symptoms in psychopathology (Salamone and Correa 2002; 
Salamone et al. 2007, 2016a,b,c, 2018). Pharmacological conditions that induce a low-effort bias 
in humans can alter effort-related choice in rats, and bias animals towards low-effort options 
(Salamone et al. 2016a,b,c; Yohn et al. 2016a,b,c). For example, rats treated with vesicular 
monoamine transport type-2 inhibitor tetrabenazine (TBZ), which induces or exacerbates anergia 




effort alternative. These effects can be reversed by co-administration of the established 
antidepressant bupropion (Wellbutrin), which inhibits catecholamine uptake, and the DA 
transport (DAT) blockers GBR12909, PRX-14040, lisdexamfetamine, methylphenidate, and 
modafinil. This pattern of effects is consistent with data from human clinical neuroscience on 
effort-related motivational dysfunctions in psychopathology, and the effects of drugs that act on 
DA. Though the neurochemical changes underlying these effects have been characterized 
through the use of animal studies, electrophysiological markers of the selection of high or low 
effort activity have not been defined.  Moreover, it is unclear if such markers developed from 
animal studies can be readily translatable to human psychopathologies.  
Recent evidence has indicated that there are electroencephalographic (EEG) markers of 
frontal cortex activity that are characteristic of engagement in motivated behavior and 
anticipation of reinforcement, and that these markers are reduced in depressed people (Nelson et 
al. 2018; Gheza et al. 2019). These findings are consistent with well characterized role of frontal 
cortex, including prefrontal areas, in regulating decision making processes (Winstanley and 
Floresco 2016). Preclinical tests using rodent effort-based choice tasks can serve as valuable 
models of motivational dysfunction in humans, since human tests of effort-related decision 
making derived from animal studies are increasingly being employed for characterizing the 
motivational impairments seen in people with Parkinsonism, schizophrenia, and depression 
(Treadway et al. 2012a; Gold et al. 2013, 2015; Chong et al. 2015; Green et al. 2015; Green and 
Horan 2015; Reddy et al. 2015). Patients with major depression have a reduced likelihood of 
selecting high effort alternatives when assessed in tests of effort-related decision making 




tests of effort-based decision making as animal models of the effort-related symptoms in 
psychopathology. 
A number of imaging papers have aimed to identify the neural correlates of psychomotor 
retardation, anergia, and lassitude in depression and other disorders (Hickie et al. 1999; Capuron 
et al. 2007), and several recent studies have reported on the brain areas involved in effort-related 
decision making (Wardle et al. 2011; Schouppe et al. 2014; Huang et al. 2016; Hogan et al. 
2018; Aridan et al. 2019). Generally speaking, these studies have implicated striatal and frontal 
cortical processes in approach motivation and effort-based decision making, which is consistent 
with the animal studies reviewed above. Additional lines of inquiry have employed EEG 
methods to characterize alterations in approach motivation. One psychophysiological marker of 
instrumental approach motivation in humans is an asymmetry in EEG activity between left and 
right frontal brain regions (Allen, Coan, & Nazarian, 2004; Coan & Allen, 2004). Pizzagalli et al. 
(2005) observed that higher task-independent alpha EEG activity in left dorsolateral prefrontal 
and medial orbitofrontal cortices was associated with a stronger tendency to respond to reward-
related cues, supporting the idea that frontal EEG asymmetry modulates the propensity to engage 
in appetitively motivated behavior. Moreover, several papers have reported that people with 
major depressive disorder, as well as individuals with high levels of depressive symptoms, 
exhibit decreased relative left frontal cortical activity at rest (Bruder et al., 1997; Henriques & 
Davidson, 1991; Diego, Field, & Hernandez-Reif, 2001; Feng et al., 2012; see Thibodeau, 
Jorgensen, & Kim, 2006 for a meta-analysis). A recent study by Nelson et al. (2018) investigated 
the association between multiple depression symptom dimensions and asymmetrical frontal 
cortical activity in people with major depression as well as two different control groups. EEG 




machine task, during which participants anticipated possible monetary reward in some 
conditions, or no reward in others. In undergraduates with low depression symptoms and control 
participants that had no history of depression, reward trials induced greater relative left frontal 
cortical activity relative to no incentive trials. Furthermore, in both samples across all 
participants, increased presentation of lassitude symptoms was associated with decreased relative 
left frontal cortical activity while anticipating reward. The authors concluded that “depression 
symptoms consistent with motivational disengagement are associated with decreased relative left 
frontal cortical activity” (Nelson et al. 2018). These results are consistent with a recent report by 
Gheza et al. (2019), who recorded frontal EEG activity from a large cohort of depressed patients 
that were performing a reinforcement learning task. Although depressed participants showed 
intact reinforcement learning compared to control participants, they had greater alpha EEG 
power asymmetry, consistent with the results of Nelson et al. (2018) and potentially reflecting 
lower approach motivation. 
Although the precise relationship between frontal EEG in rats and humans is uncertain, 
the goal of this experiment was to characterize frontal and parietal cortex EEG activity from both 
left and right hemispheres in awake rats under baseline conditions, and then under 
pharmacologically-induced DA depletion conditions by administration of tetrabenazine (TBZ). 
This experiment was intended to be the first step in a larger project focusing on the development 
of physiological markers associated with altered DA transmission and effort-related dysfunction 
in preclinical animal models that can be readily translated to human studies. It was hypothesized 
that frontal cortex activity will provide a correlate of the pharmacological manipulations that 
affect the functions of ventral striatum and striatopallidal circuits that are known to be involved 




frontal EEG markers can be developed that also are sensitive to the selection of high and low 
effort instrumental activities. Frontal cortex was selected as a region of interest because of the 
extensive animal and human literatures linking prefrontal cortex to executive function, decision 
making, and effort-based choice. Parietal cortex recordings were conducted to provide a 
comparison with the frontal recordings, and also to determine if other cortical areas are 
responsive to TBZ. 
 
7.2 Materials and Methods 
Surgeries 
One cohort of untrained male (n=8) rats were used for the initial EEG recordings. Rats 
were anesthetized with an intraperitoneal injection of 100.0 mg/kg ketamine hydrochloride and 
10.0 mg/kg xylazine prior to placement in a stereotaxic device. Up to six stainless-steel skull 
screw EEG electrodes were implanted adjacent to the frontal and parietal cortices, and as ground 
and reference electrodes. Rats were given seven days to recovery from surgery before recording 
took place.  
 
Electrophysiological Recording Experiment 
A Digital Lynx SX Electrophysiology System (Neuralynx) was used to acquire EEG 
activity from awake rats. Rats were connected to the electrophysiology system using a tethered 
cable. Wide-band activity (1-2000 Hz, 4006 samples/sec) will be recorded using the Neuralynx 
system and analyzed offline using MATLAB software (MathWorks Inc, Natick, MA). After a 




rats were injected with vehicle or TBZ (1.0 mg/kg). EEG activity was recorded immediately after 
injection for up to five minutes. A lead time of 120 minutes elapsed before resuming recordings. 
Each rat was exposed to vehicle and TBZ treatments, counterbalanced, over the course of two 
separate testing days (one treatment per week). 
 
Data Preprocessing 
 All signal processing and related procedures were performed using the FieldTrip software 
package (Oostenveld et al. 2011; http://www.fieldtriptoolbox.org/) and custom scripts in 
MATLAB (The MathWorks, Natick, MA). EEG data were preprocessed as follows: 1) data were 
down-sampled from 32 kHz to 1 kHz; 2) data were mean subtracted; 3) data were split into 1-s 
epochs to remove the epochs with artifacts; and 4) the first epoch and the last epoch were 




To assess how the power spectral density (PSD) of each frequency varied across time, a 
time frequency analysis was conducted using short-time Fourier transform. We segmented the 
preprocessed EEG data into 10-s epochs with 5-s overlap. Each epoch is windowed with a 





For power spectral analysis, the preprocessed EEG data were segmented into 1-s epochs 
with 0.5-s overlap. We estimated the PSDs using Welch’s overlapped averaged periodogram 
method (Welch, 1967) with a Hamming window on each epoch. We estimated the PSDs over 
frequencies from 1 Hz to 50 Hz (0.5 Hz resolution).  
In addition to power in specific sub-bands, EEG signals throughout frontal cortex were 
also analyzed to assess coherence and phase relationships. Coherence values (see Bullock et al, 
1990) for each channel pair will be computed using the Welch periodogram estimation procedure 
with a spectral resolution of ~ 2 Hz. Coherence is a measure of the linear association between 
two signals as a function of frequency. In this experiment, the consistency of the relative 
amplitude and phase between interhemispheric channels at each frequency was quantified. To 
ensure that the measured coherence values were not due to chance alone, a significance 
estimation procedure was used where the coherence estimate is compared to that of signals with 
identical magnitude spectrum but with zero phase coherence. For each channel pair, the 
cumulative distribution of the frequency-specific coherence values is created by circularly phase-
shifting one signal in the pair randomly, calculating the coherence and bootstrapping the 
procedure 250 times (Efron and Tibshirani, 1993). This procedure guarantees that the signal 
spectrums are identical but have no linear association (because the phase information is 
removed). Coherence values for each pair were then analyzed using univariate analysis of 
variance (ANOVA) followed by Tukey tests. 
The preprocessed EEG data were segmented into 1-s epochs with 0.5-s overlap. We 
estimated the coherence using Welch’s overlapped averaged periodogram method (Welch, 1967) 




the following formula, where P_xx and P_yy are the estimated power spectral densities of the 








We estimated the coherences over frequencies from 1 Hz to 50 Hz (0.5 Hz resolution).  
 
7.3 Results 
 For the recording experiments, a power spectral analysis was performed to quantify the 
effects of TBZ (1.0 mg/kg IP) or vehicle treatment on EEG activity recorded from awake rats 
(n=6) (Fig. 7.1). At baseline, EEG spectral analysis showed the highest peak PSD at 7.5 Hz. This 
effect was detectable in frontal and parietal channels, but was more robust in the parietal 
channels. In general, TBZ caused a reduction in EEG power in a frequency range of 7-8 Hz in all 
four channels relative to baseline (Fig. 7.1B). Also, PSD was slightly reduced at higher 
frequencies (e.g. >25 Hz in frontal channels; >35 Hz in parietal channels) in the TBZ condition 
compared to vehicle.  
 Analyses of inter-hemispheric EEG signal coherence revealed much stronger coherence 
measurements from electrodes that were placed in the same position on either side of the midline 
(e.g. left and right frontal electrodes) compared to electrodes that were placed in different 
positions on either side of the midline (e.g. left frontal and right parietal electrodes). Specifically, 
on a scale of 0-1, coherence was greater than 0.5 for congruous electrode placements at baseline 




electrode placements remained below 0.5 in both treatment conditions across frequencies. Data 








Figure 7.1. Effects of TBZ on power spectral density (PSD) (dB/Hz) of frequency (Hz) 
measured by EEG in left and right frontal and parietal electrodes. (A) PSD of EEG signal under 




Figure 7.2. Effects of TBZ on inter-hemispheric coherence by frequency (Hz) measured by EEG 
in left and right frontal and parietal electrodes. (A) Coherence analysis of EEG signal under 







Chapter 8: Discussion 
 
8.1 Summary of Results 
The major objectives of the present research outlined in this dissertation were to investigate the 
role of DA in a model of effort-related motivational dysfunction in rats, to explore novel 
treatment options for motivational symptoms of depression and other disorders through the use 
of effort-based choice paradigms, and to identify physiological biomarkers related to 
motivational dysfunctions. 
The first set of experiments, outlined in Chapter 2, assessed the effects of chronic 
subcutaneous administration of the DA D2 antagonist haloperidol on effort-based choice. This 
specific procedure was used to mimic the development of secondary negative symptoms which 
can be induced by long-term drug treatment. The results showed that chronic haloperidol 
administration significantly and dose-dependently reduced lever presses and increased chow 
intake during the FR5/chow feeding choice task and that continuous infusion of haloperidol via 
subdermal pumps provided a translatable model of chronic slow-release DA D2 antagonist 
administration.  
The experiments described in Chapters 3 and 4 provided an initial characterization of 
the effort-related behavioral effects of the novel atypical DAT inhibitors that are analogs of 
modafinil, (S)-CE-123 and (S, S)-CE-158.  Co-administration of 24.0 mg/kg (S)-CE-123 
(Chapter 3) with TBZ produced a significant but partial reversal of the effects of TBZ and 
significantly increased PROG lever pressing, accompanied by a decrease chow intake. 
Furthermore, the effective dose of (S)-CE-123 in both the TBZ reversal and PROG/chow feeding 




by microdialysis. The experiments in Chapter 4 demonstrated the ability of the modafinil analog 
(S, S)-CE-158 to reverse the effort-related effects of TBZ, increase PROG/chow lever pressing, 
and decrease chow intake during PROG/chow sessions. In addition, systemic administration of 
(S, S)-CE-158 increased extracellular DA in the nucleus accumbens during the behaviorally 
active time course. Ultimately, this research will guide future studies to advance target 
identification for treatments of motivational dysfunction.  
The experiments discussed in Chapter 5 provided a characterization of the effort-related 
effects of another recently synthesized DAT inhibitor known as CT-005404. This compound was 
assessed for its ability to reverse the effort-related effects of TBZ, and the suppression of lever 
pressing induced by the pro-inflammatory cytokine IL-1β. CT-005404 also produced a 
significant increase in lever pressing and decrease in chow intake when administered to rats on 
the PROG/chow procedure, and significantly increased extracellular accumbens DA over the 
course of >340 minutes. Collectively, results from Chapters 3-5 suggest that novel atypical 
DAT inhibitors such as (S)-CE-123, (S, S)-CE-158, and CT-005404 may ultimately be useful as 
compounds that are suitable for treating motivational dysfunction. 
A critical goal of the final experiments in this dissertation (Chapters 6-7) was to employ 
a novel operant lever pressing task and EEG methods to aid in the development of physiological 
markers associated with altered DA transmission and effort-related dysfunction in preclinical 
animal models that can be readily translated to human studies. In Chapter 6 experiments, the 
PROG operant reinforcement schedule was modified to increase the overall work requirement. 
After achieving a steady baseline level of responses on the modified PROG schedule, TBZ was 
administered, which significantly reduced number of lever presses, time of last response in the 




outlined in Chapter 7. The final experiments (Chapter 7) employed frontal cortex skull screw 
EEG activity recordings in behaving rats under baseline and pharmacological DA manipulations. 
Results from this experiment suggested several notable differences in relative frequency band 
power and inter-hemispheric coherence as a result of TBZ administration, which can be used as 
an initial step towards identifying a physiological biomarker of a low-effort bias and 
motivational dysfunctions as seen in clinical depression.  
 
8.2 Chapter 2 Discussion: 
The experiments described in Chapter 2 were conducted to evaluate the effects of 
chronic DA D2 antagonism in an animal model of effort-related choice behavior in rats. A 
chronic subcutaneous infusion of either vehicle, a high dose (HAL 2.0 mg/ml, 3.0 µl/hour), or a 
low dose (HAL 1.0 mg/ml, 3.0 µl/hour) of haloperidol was delivered via minipump for a period 
of four weeks, followed by a four-week washout. Consistent with previous work involving acute 
haloperidol administration (Salamone et al. 1991, 2009; Yohn et al. 2017), our results 
demonstrated that continuous chronic infusions of haloperidol to rats produced significant 
reductions of high-effort lever pressing on the FR5 procedure (Fig. 2.1), and a shift from lever 
pressing to chow intake on the concurrent FR5/chow feeding choice task (Fig. 2.2).  
The effects of haloperidol in rats performing on the FR5 lever pressing schedule are 
depicted in Figure 2.1. In the drug exposure phase, significant overall effects of week and 
treatment group were found. Across weeks, drug treatment produced a significant overall effect 
on FR5 lever pressing, which was evident when the high dose was compared to vehicle, but not 
when the low dose was compared to vehicle, demonstrating that only the high dose rats lever 




very little carry over of the drug effect into the washout phase, as demonstrated by a significant 
reduction in lever presses in the high dose group relative to vehicle at only at week 1. This effect 
was completely washed out by the second week. During the washout phase of Exp 2.1, a 
significant effect of week and week x treatment interaction were found, with no overall 
significant effect of treatment group, as the average number of lever presses returned to baseline. 
Haloperidol produced a different pattern of dose-related effects on lever pressing in Exp 
2.2. As shown in Figures 2.1 and 2.2A, rats in the high dose groups in both studies showed 
substantial and significant reductions in lever pressing, which were marked by very large effect 
sizes. However, the effects of the low dose were very different in the two studies. While the low 
dose did not significantly suppress lever pressing when the FR5 schedule was the only path to 
obtain food, and the effect size was relatively low (0.372), there was a significant suppression of 
lever pressing in the low dose group that was seen when animals were tested on the FR5/chow 
feeding choice task, and the effect size was much larger (0.744). This difference can be attributed 
to having the option of freely available lab chow offered in the FR5/chow feeding choice task. 
When a substitute food source was available (FR5/chow, Exp 2.2), rats treated with the low as 
well as the high dose of haloperidol shifted away from FR5 lever pressing and towards 
consumption of the freely available lab chow. However, when the only way to obtain the food 
reinforcer was to press the lever (FR5 alone, Exp 2.1), the low dose of haloperidol did not 
significantly reduce the tendency of rats to engage in FR5 lever pressing. These findings are 
consistent with the results of Cousins and Salamone (1994), who compared the effects of nucleus 
accumbens DA depletions induced by 6-hydroxydopamine on FR5 lever pressing vs. 
performance on the FR5/chow feeding choice task. They reported that while moderate depletions 




task, decreasing lever pressing and increasing chow intake, the same animals showed no 
significant suppression of FR5 responding when no concurrent chow was available. Similar 
findings were described by Yohn et al. (2015a), in which the DA depleting agent TBZ was 
assessed for its effort-related effects on a T-maze barrier choice task in rats. TBZ reduced 
selection of the high-effort behavior when there was a low-effort option, but did not affect high 
density vs. low density arm selection when there was no barrier, or when there were only pellets 
in one arm. Such an effect on T-maze performance was also seen after administration of 
haloperidol and nucleus accumbens DA depletions induced by 6-hydroxydopamine (Salamone et 
al. 1994). In mice tested on the T-maze barrier choice task, haloperidol reduced selection of the 
arm with the high density of food reinforcement when that arm was blocked by a barrier, but 
when both arms had a barrier, haloperidol did not affect choice (Pardo et al. 2012). Taken 
together, these results indicate that the effects of haloperidol and accumbens DA depletions are 
not simply due to an effect on primary food reinforcement, appetite, or discrimination of 
reinforcement magnitude. In this regard, it is worth emphasizing the effects of DA antagonism 
via chronic infusion of haloperidol in this experiment produced effects that do not resemble the 
effects of reinforcement or appetite-related manipulations (reinforcer devaluation by pre-feeding, 
administration of cannabinoid CB1 antagonist/inverse agonists) in rats (Randall et al. 2012, 
2014), or in mice (Pardo et al. 2012; Yang et al. 2020), which decreased both lever pressing and 
chow intake. Nevertheless, instrumental responding is consistently impaired by manipulations 
that interfere with DA transmission when either there is a very high effort-related challenge (e.g. 
Aberman and Salamone 1999; Salamone et al. 2001) or when animals have a low-cost alternative 




After prolonged exposure to a drug, changes in the effects of the drug, termed ‘tolerance’ 
or ‘sensitization,’ can occur due to physiological or psychological factors. These phenomena are 
often difficult to measure in humans due to extreme variability in an individual’s previous drug 
exposure and medication compliance, genetic factors, comorbidities, concomitant treatment 
regimens, etc., and are often overlooked by clinicians (Li 2016). Animal research has suggested 
that the frequency of repeated antipsychotic dosing (e.g. intermittent vs. continuous) can 
influence a drug’s behavioral effects, including potential tolerance and sensitization (Kurachi et 
al. 1995; Trevitt et al. 1998; Gao and Li 2014; Sebel et al. 2017). The present experiments were 
designed to assess the effects of continuous exposure to haloperidol at two different doses over 
the course of four weeks, and to observe for signs of tolerance or sensitization, demonstrated by 
either an increase or decrease in the effects of the drug across weeks. In these experiments, there 
was clearly an overall significant effect of haloperidol treatment, but the lack of a week x 
treatment interaction indicates that rats did not develop tolerance or sensitization to haloperidol 
at either dose. Nevertheless, the response to acute haloperidol after washout from a period of 
chronic administration demands further exploration in order to elucidate the possible roles of 
drug exposure duration and concentration on the development of tolerance. 
In addition to effects such as drug tolerance or sensitization, prolonged drug exposure can 
produce other undesirable effects. Previous work has demonstrated that repeated daily dosing of 
haloperidol over the course of 14 days significantly reduced lever pressing and increased chow 
intake, without producing a sedative (i.e., drowsiness) effect in the dose range tested (0.05-0.15 
mg/kg) (Salamone et al. 1996). In contrast, the atypical antipsychotic drug clozapine clearly 
produced sedation (i.e. drowsiness and sleepiness as observed with a reliable rating scale), and 




while some antipsychotic drugs show a dissociation between sedative effects and the suppression 
of lever pressing, with other drugs these actions appear to be related to each other. The present 
studies did not assess sedation or reinforcer preference in the absence of a work component, but 
our results suggest that possible sedative effects were unlikely, due to the very substantial intake 
of chow consumption observed during the concurrent FR5/chow feeding choice task in Exp 2.2. 
This effect was steady over the course of four week drug exposure phase (see Fig. 2.2), and no 
overt behavioral differences or drowsiness were observed. Moreover, animals in this study were 
able to maintain their target weights throughout the experiment (supplemental chow was given as 
needed), whereas rats in a previous pilot experiment given a higher concentration of haloperidol 
(3.0 mg/ml) were unable to maintain target weights. Therefore, a ‘high dose’ of 2.0 mg/ml was 
determined to be effective at suppressing lever pressing and increasing chow consumption by 
altering effort-related choice behavior without any apparent sedation. Moreover, the low dose 
was even more selective, in that it clearly suppressed lever pressing and shifted animals to chow 
intake when there was a choice, but failed to significantly suppress lever pressing when the only 
way to obtain food was to press the lever (i.e., FR5 alone). 
This work has important implications for advances in clinical drug therapies for 
schizophrenia and related disorders. At baseline, individuals with schizophrenia exhibit effort-
related impairments and other negative symptoms (Gold et al. 2013; Strauss et al. 2014; 
Treadway et al. 2015). As described earlier, some of the most common antipsychotics do not 
treat these symptoms, and may even induce or exacerbate them. The present findings highlight 
the effort-related motivational impairments that can be produced by antipsychotic medications 
such as haloperidol. Several types of drugs such as adenosine A2A receptor antagonists, glycine 




motivational effects of DA D2 antagonists and DA depleting agents in animals with limited signs 
of potential side effects (Salamone et al. 2009; Yohn et al. 2017; Rotolo et al. 2019), however, 
these potential treatments have not yet been assessed in chronic administration models. Future 
studies should assess whether chronic co-administration of drugs in these classes reduces the 
effects of reduced DA transmission, which may ultimately improve clinical therapeutic strategies 
for the negative symptoms of schizophrenia and other affective disorders.  
 
8.3 Chapter 3 Discussion: 
The synthesis of (S)-CE-123 afforded highly pure desired enantiomer, and NMRs and 
mass spectroscopy methods yielded spectra unambiguously identifying the compound (see 
supplementary materials of Rotolo et al. 2019). In previous studies, the absolute configuration 
was characterized as the (S)-enantiomer which was shown to be stronger at inhibiting DAT than 
the (R)-enantiomer (Nikiforuk et al. 2017). In uptake inhibition assays conducted in HEK293 
cells stably expressing human isoforms of DAT, NET and SERT, the EC50 for inhibition of DAT 
by (S)-CE-123 was reported to be 2.76 x 10-6M, which was 30-fold selective relative to 
inhibition of NET and more than 400-fold selective compared to SERT inhibition (Nikiforuk et 
al. 2017, supplementary figure 17A). Thus, we present the first enantioselective synthesis of (S)-
CE-123. 
The behavioral studies sought to provide an initial characterization of the behavioral 
effects of the novel atypical DAT inhibitor, (S)-CE-123, in terms of its ability to alter effort-
related choice behavior in rats. Specifically, one of the experiments employed a task designed to 




effort-related effects of TBZ. In this experiment, rats trained on the FR5/chow feeding choice 
task shifted from the high effort option (FR5 lever pressing) to the low-effort option (chow 
intake) when treated with TBZ, consistent with previous findings (Nunes et al. 2013; Randall et 
al. 2014; Yohn et al. 2015a,b,c). Several previous studies with TBZ have shown that these shifts 
in effort-based choice are not due to changes in food intake, food preference, sucrose preference, 
motor incapacity, or reference memory, and do not resemble the effects of appetite suppressant 
drugs or reward devaluation by pre-feeding (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 
2015a; Pardo et al. 2015). Co-administration of 24.0 mg/kg (S)-CE-123 with TBZ produced a 
significant but partial reversal of the effects of TBZ, as indicated by an increased selection of 
FR5 lever pressing (Fig. 3.2A) and a decrease in chow intake (Fig. 3.2B) compared to TBZ plus 
vehicle. In a parallel control experiment in rats tested on the same task, 24.0 mg/kg (S)-CE-123 
administered in the absence of TBZ did not did not have any effect on lever pressing (Fig. 3.3A) 
or chow intake (Fig. 3.3B). 
In order to develop a more comprehensive characterization of the effort-related actions of 
monoamine uptake inhibitors, it also is important to administer them alone, in the absence of a 
drug like TBZ, because that would allow for the assessment of both increases and decreases in 
performance, in the absence of a drug condition like TBZ, which induces an impairment. In 
previous studies, the PROG/chow feeding choice task has been used to assess the ability of drugs 
to enhance selection of high effort PROG lever pressing (e.g. Randall et al. 2012, 2015). This 
task is especially well suited for such an assessment because unlike the FR5/chow feeding choice 
task, baseline lever pressing rates are relatively low on the PROG component due to the 
increasing response requirement of the PROG schedule. Thus, as the ratio work requirement gets 




2015). Previous research has demonstrated that the NET inhibitors desipramine and atomoxetine, 
as well as the SERT inhibitor fluoxetine, all fail to increase PROG lever pressing in rats tested on 
the PROG/chow feeding choice procedure (Yohn et al. 2016d). In contrast, drugs that inhibit 
DAT, including bupropion, lisdexamfetamine, PRX-14040, MRZ-9547, and GBR 12909 all have 
been shown to increase selection of PROG responding on this task (Sommer et al. 2014; Randall 
et al. 2015; Yohn et al. 2016b,c,d). In the present studies, (S)-CE-123 was shown to significantly 
increase PROG lever pressing and decrease chow intake in rats tested on the PROG/choice 
procedure (Fig. 3.4). Furthermore, the effective dose of (S)-CE-123 in both the TBZ reversal and 
PROG/chow feeding choice studies, 24.0 mg/kg, significantly increased extracellular DA in 
nucleus accumbens core as measured by microdialysis (Fig. 3.5).  The magnitude of the 
increases in PROG lever pressing and accumbens core DA shown in the present studies with (S)-
CE-123 are comparable to those reported previously for 20.0 mg/kg bupropion (Randall et al. 
2015). It is not clear why extracellular DA did not increase in the nucleus accumbens shell after 
injections of (S)-CE-123, however, DA did substantially increase in the core, and previous work 
has shown that the core subregion is a critical site at which effort-based choice is regulated 
(Sokolowski and Salamone 1998; Ghods-Sharifi and Floresco 2010; Farrar et al. 2010; Randall 
et al. 2012; Nunes et al. 2013).  
Several lines of evidence indicate that DAT blockers can have pro-motivational effects in 
animal models (Nunes et al. 2013; Randall et al. 2015; Sommer et al. 2014; Yohn et al. 
2016a,b,c,d). Although DAT inhibition is a commonly used descriptor for a broad class of drugs, 
there is considerable heterogeneity within this group of compounds. For example, amphetamines 
such as d-amphetamine and methamphetamine are not only competitive inhibitors of DAT; they 




al. 2011). Cocaine is a classical DAT inhibitor with a rapid onset and offset of action (Tanda et 
al. 2013). Unfortunately, most classical DAT inhibitors and releasing agents have a well 
characterized abuse liability (Todtenkopf and Carlezon 2006; Ostlund et al. 2014; Dong et al. 
2017), which limits their therapeutic utility for treating motivational dysfunction in psychiatry. 
However, not all drugs that bind to the DAT share cocaine’s behavioral profile or have a high 
potential for abuse. Over the last several years, atypical DAT inhibitors have been under 
development, which have characteristics that differ from cocaine. GBR12909 was developed as a 
potential treatment for cocaine addiction (Rothman et al. 2008). GBR12909 blocks many of the 
effects of cocaine, and on its own has produced mixed effects in terms of cocaine-like actions; it 
did not produce psychostimulant effects in people in the dose ranges tested (Sogaard et al. 1990; 
Preti 2000), and although it supported self-administration in primates, its efficacy was lower than 
that of cocaine (Woolverton et al. 2001). Although GBR12909 was discontinued as a potential 
treatment for cocaine abuse due to its cardiac effects, analogs of GBR12909 have been studied 
for their atypical binding characteristics (Rothman et al. 2008). The DAT has multiple functional 
conformations, and several benztropine analogs have been shown to bind to the DAT in a 
manner that is distinct from that of cocaine (Schmidt et al. 2008; Kohut et al. 2014). Some of 
these benztropine analogs have been shown to increase extracellular DA in nucleus accumbens, 
albeit over a much longer time course than cocaine (Tanda et al. 2013). Unlike cocaine, these 
drugs failed to induce conditioned place preference (Tanda et al. 2013).   
(S)-CE-123 is an analog of modafinil, which also binds to the DAT with an atypical 
profile (Schmitt and Reith 2011; Cao et al. 2016). Modafinil inhibits DAT and increases 
extracellular DA over a broad time course (Mereu et al. 2017), and while this drug has been 




liability (Müller et al. 2013; Mereu et al. 2013). Modafinil has been reported to improve fatigue 
symptoms in depressed patients (Lam et al. 2007), and recent studies from our laboratory have 
shown that modafinil can reverse the low-effort bias induced by TBZ in rats (Yohn et al. 2016c; 
Salamone et al. 2016a). When bound to the DAT, (S)-CE-123 also has an atypical pattern 
compared to cocaine, in that it interacts with the negatively charged ASP79 locus (Kristofova et 
al., 2018). Moreover, (S)-CE-123 acts as a highly selective atypical inhibitor of DAT relative to 
NET and SERT, and is more selective for DAT than modafinil (Kristofova et al. 2018). (S)-CE-
123 has been shown to enhance cognitive flexibility, improve memory acquisition and retrieval, 
and reduce impulsivity in rats (Nikiforuk et al. 2017; Kristofova et al. 2018), and in the present 
studies, it reverses the motivational impairments induced by TBZ and increases selection of 
high-effort PROG lever pressing.  
In the present studies, a partial reversal of the effort-related motivational dysfunction 
induced by TBZ was achieved with (S)-CE-123 administration in a dose range of 6.0-24.0 
mg/kg. The efficacy of (S)-CE-123 at restoring lever pressing appears to be lower than that of 
bupropion, GBR12909, lisdexamfetamine, methylphenidate and modafinil in rats tested on 
similar procedures (Nunes et al. 2013; Yohn et al. 2016a,b,c; Salamone et al. 2016a), although 
most drugs that block DAT tend to produce only partial reversals of the effects of TBZ (i.e., 
approximately 60-85% restoration of responding). Nevertheless, (S)-CE-123 was highly 
efficacious at reversing the TBZ-induced increase in chow intake (Fig. 3.2B), which may 
indicate that this drug also has appetite suppressant actions. These potential appetite suppressant 
effects of (S)-CE-123 would suggest that the increases in lever pressing seen in the FR5 and 
PROG/chow feeding choice studies are not due to an increase in appetite. Drugs that inhibit DAT 




in behavioral experiments. High affinity drugs such as d-amphetamine, methylphenidate, PRX-
14040, and GBR12909 have a relatively high potency for reversing the effects of TBZ (Yohn et 
al. 2016a,b,c,d; Salamone et al. 2016a). In contrast, compounds with lower DAT binding 
affinities such as bupropion, modafinil and (S)-CE-123 tend to be less potent at reversing the 
effects of TBZ (i.e., they require higher doses; Nunes et al. 2013; Salamone et al. 2017a; present 
studies).  
Future studies should examine a larger group of atypical DAT blockers to determine the 
overall relation between the neurochemical characteristics of these compounds (e.g. DAT 
affinity, selectivity and binding locus, effects on DAT trafficking (Mash et al., 2002; Vaughan et 
al., 2013), dynamics of effects on extracellular DA) and their effort-related behavioral effects. 
Furthermore, behavioral studies should be extended to include tasks that provide information 
about other behavioral effects, including locomotor activity, and most importantly, potential 
abuse liability. Drugs such as amphetamine and methylphenidate can increase selection of high-
effort activity in humans (Wardle et al. 2011), and can improve motivational function in 
depressed patients (Stotz et al. 1999), but they also are well known for their abuse liability. In 
contrast, the atypical DAT blocker modafinil has been reported to improve motivational function 
in depressed patients (Lam et al. 2007), albeit without a strong abuse liability. The molecular 
interactions that occur as a result of the particular functional configuration of the DAT as it binds 
to drugs that block its action may be related to the diversity of patterns of abuse potential seen 
across multiple drugs (Tanda et al. 2013). Thus, the binding characteristics of drugs like 
modafinil and its analogs, such as (S)-CE-123, suggest that novel compounds may ultimately be 
identified that are suitable for treating motivational dysfunction, and future studies should 




8.4 Chapter 4 Discussion:  
DAT inhibitors with atypical binding characteristics are being studied for their ability to 
ameliorate effort-related symptoms of fatigue and motivational dysfunction in rodents. The 
present work focused on the pharmacodynamic, neurochemical, and behavioral profile of the 
recently synthesized modafinil analog, (S, S)-CE-158. To determine the selectivity of (S, S)-CE-
158 for the DAT, in vitro binding and monoamine transporters reuptake inhibition experiments 
were conducted using transfected HEK293 cells expressing human isoforms of DAT, NET, and 
SERT. In the present study, the IC50 of (S, S)-CE-158 binding to the DAT was reported to be 
0.052 µM, while its DAT inhibition was greater than 50-fold selective relative to NET (SERT 
reuptake inhibition was undetected; Fig. 4.2, 4.3). These patterns are consistent with results from 
inhibition assays measuring the EC50 for inhibition of monoamine transporters of the previously 
synthesized compound, (S)-CE-123, which revealed a 30-fold selective inhibition of DAT 
relative to NET and more than 400-fold selective compared to SERT (Nikiforuk et al. 2017). By 
direct comparison, (S, S)-CE-158 is even more selective for the DAT than (S)-CE-123, 
supporting its potential use as a DAT inhibitor with limited off-target effects. 
The FR5/chow feeding choice experiment was performed to investigate the effects of (S, 
S)-CE-158 for its ability to reverse the effort-related effects of TBZ. Consistent with previous 
findings (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015a,b,c; Rotolo et al. 2019), 
administration of 1.0 mg/kg TBZ shifted choice behavior, decreasing high effort lever pressing 
and increasing low-effort chow intake (Fig. 4.4). Previous research has shown that the effects of 
TBZ on effort-related choice are not due to actions on the intake of or preference for the two 
foods used in the FR5/choice task (Nunes et al. 2013), discrimination of reinforcer magnitude or 




2015). Furthermore, the effects of TBZ on effort-based tasks do not resemble the effects of 
reinforcer devaluation by reduction in food motivation, or appetite suppressant drugs (Randall et 
al. 2012, 2014; Yang et al. 2020). For these reasons, and also because TBZ induces motivational 
symptoms such as fatigue in humans (Chitnis and Karunapuzha, 2009; Frank, 2010; Chen et al. 
2012), TBZ was used in the present experiment to provide a challenge to the tendency of rats to 
exert physical effort when given a choice. 
Co-administration of 8.0 mg/kg (S, S)-CE-158 with TBZ resulted in a significant reversal 
of the effects of TBZ on both lever pressing and chow intake. The magnitude of this effect can 
be observed by comparing the average number of lever presses at the dose that produced a 
significant reversal to the number of lever presses in the vehicle group. Here, the co-
administration of 8.0 mg/kg (S, S)-CE-158 with TBZ yielded a lever pressing average which was 
85% of the vehicle/vehicle average (Fig. 4.4a), whereas Rotolo et al. (2019) reported only a 40% 
restoration of the vehicle/vehicle lever pressing average when the highest dose of (S)-CE-123 
(24.0 mg/kg) was co-administered with TBZ. The ability of (S)-CE-123 to only partially reverse 
the effects of TBZ was attributed to possible appetite suppressant actions, which were not 
observed in the present experiment. Moreover, the efficacy of (S, S)-CE-158 for reversing the 
effort-related motivational dysfunction induced by TBZ is comparable to a group of DAT 
inhibitors including GBR12909, lisdexamfetamine, and methylphenidate in terms of their 
relatively large effects in terms of reversing the effects of TBZ (Salamone et al., 2016a; Yohn et 
al., 2016a,b,c). 
To measure its effect when administered alone, (S, S)-CE-158 was administered to rats 
trained on the concurrent PROG/chow feeding choice task. This task is well suited for assessing 




levels of effort on a more highly demanding task. In the present study, (S, S)-CE-158 
significantly increased the selection of the high-effort option (lever pressing) and a reduced 
selection of the low-effort option (chow intake) at both the 4.0 mg/kg and 8.0 mg/kg doses (Fig. 
4.5). These results are consistent with previous experiments demonstrating that DAT inhibitors 
such as bupropion, lisdexamfetamine, MRZ-9547, and PRX-14040 significantly increased 
PROG lever pressing and decreasing chow consumption (Sommer et al. 2014; Randall et al., 
2015; Yohn et al., 2016b,c,d), whereas drugs that inhibit NET and SERT did not (Yohn et al. 
2016d). These results also are consistent with the findings of Cagniard et al. (2006), who 
reported that DAT knockdown increased selection of lever pressing in mice tested on an effort-
based choice task, and with Wardle et al. (2011), who reported that amphetamine increased 
selection of high-effort activity in human participants. Furthermore, it was shown that systemic 
administration of (S, S)-CE-158 at a dose of 8.0 mg/kg significantly increased extracellular DA 
in the nucleus accumbens core as measured by microdialysis (Fig. 4.6). The peak increase in DA 
at 30-90 minutes post-injection is aligned with the time course used for the behavioral 
pharmacology experiments (i.e. 30 min injection lead time prior to a 30 min task). Systemic 
administration of DAT inhibitors in rodents has been reported to increase extracellular DA in the 
nucleus accumbens core, which has been associated with increased motivation (Yohn et al. 
2016d; Rotolo et al. 2019) and pro-cognitive effects such as enhanced recognition memory 
(Carnats-Perna et al. 2019). 
The ability of (S)-CE-123 and (S, S)-CE-158 to increase motivation and ameliorate effort-
related impairments can be seen as complimentary to the known effects of their parent 
compound, modafinil. In addition to its prescribed indication as a treatment for narcolepsy, 




cognitive enhancement (Sahakian and Morein-Zamir, 2011; Battleday and Brem, 2015; Sousa 
and Dinis-Oliveira, 2020; Teodorini et al. 2020). Memory and cognitive flexibility have been 
described as effects of both the S-configuration and the racemic mixture of the thiazole-
containing modafinil analog, CE-123 (Nikiforuk et al. 2017; Kristofova et al. 2018; Carnats-
Perna et al. 2019). Interestingly, it has been suggested that modafinil’s effects related to 
cognitive processes and task engagement may be dependent on fronto-striatal circuitry, rather 
than hippocampal (Müller et al. 2013), which further supports the utility of these drugs as 
treatments for effort-related dysfunction. Moreover, it has been suggested that modafinil and its 
derivatives possess anti-inflammatory properties in vitro (Jung et al. 2012) and in vivo (Zager et 
al. 2017; Han et al. 2018; Brandão et al. 2019), and may reduce multiple sclerosis fatigue in 
humans (Shangyan et al. 2018), underlying possible utility of these compounds to attenuate 
symptoms of various disorders that are propagated by inflammatory cascades. Therefore, results 
from the current studies may be useful to guide future assessments of atypical DAT inhibitors to 
expand the clinical indications for modafinil and similar compounds. 
In summary, these experiments contributed to the characterization of a recently 
developed group of atypical DAT inhibitor compounds, by demonstrating the ability of (S, S)-
CE-158 to reverse the effort-related effects of TBZ, and increase high-effort responding in tasks 
measuring effort-based choice. Additionally, it was shown that systemic administration of (S, S)-
CE-158 increased extracellular DA in the nucleus accumbens during the behaviorally active time 
course. The behavioral assessment of atypical DAT inhibitors such as analogs of benztropine, 
GBR12909 and modafinil has led to the discovery that not all inhibitors of DA uptake show 
signs of abuse liability to the same extent as the classical DAT inhibitors that are major 




Loland et al. 2008; Schmitt et al. 2008; Esumi et al. 2012; Tanda et al. 2013; Mereu et al. 2013). 
These results suggest it is possible that atypical DAT inhibitors may be effective at reducing 
motivational impairments with minimal induction of major psychomotor side effects or abuse 
liability. Ultimately, this research will guide future studies to advance target identification for 
treatments of motivational dysfunction. These and other similar findings could lead to the 
development of atypical DA uptake blockers that could potentially treat motivational symptoms 
of depression, chronic fatigue syndrome, or other disorders, while reducing undesirable side 
effects. 
 
8.5 Chapter 5 Discussion: 
Motivational dysfunctions such as anergia, fatigue, and low-effort bias are debilitating 
treatment-resistant psychiatric symptoms that span multiple disorders, including MDD, PD, 
schizophrenia and MS (Treadway et al. 2012; Yang et al. 2014; Zimmerman et al. 2015; Corfield 
et al. 2016; Chong et al. 2016; Barch et al. 2017; Le Heron et al. 2019). In view of data from 
animal models and human studies indicating that DA systems regulate behavioral activation and 
effort-related function, DAT inhibitors considerable potential as treatment targets. The present 
studies showed that the novel compound CT-005404 selectively binds to DAT relative to NET 
and SERT (Table 5.1), and also increases extracellular DA with a prolonged time course as 
measured by microdialysis (Fig. 5.1). Furthermore, CT-005404 reversed the low-effort bias 
induced by the VMAT-2 inhibitor TBZ (Fig. 5.2), as well as the suppression of lever pressing 
induced by the pro-inflammatory cytokine IL-1β (Fig. 5.3). When administered alone, CT-
005404 increased the tendency to select high-effort PROG lever pressing (Fig. 5.4). Taken 
together, these results suggest that CT-005404 has the profile of a drug that could be useful for 




Consistent with previous studies (Nunes et al. 2013), 1.0 mg/kg TBZ shifted effort-based 
choice, significantly decreasing FR5 lever pressing while increasing intake of the concurrently 
available chow. The ability of TBZ to induce this effect is not dependent on changes in food 
intake or food preference, and does not resemble the effects of appetite suppressant drugs or 
reinforcer devaluation on this task (Salamone et al. 1991, 2002; Sink et al. 2008; Nunes et al. 
2013). Co-administration of CT-005404 with TBZ led to a significant but partial reversal of the 
effects of TBZ. Compared to TBZ alone, rats administered TBZ plus 15.0 and 30.0 mg/kg doses 
of CT-005404 showed significant increases in lever pressing and decreases in chow intake (Fig. 
5.2). Consistent with the gradual and prolonged elevations in extracellular DA that were seen in 
the microdialysis experiment, CT-005404 was able to reverse the effects of TBZ over the period 
of 3-4.5 hours after its p.o. administration. The ability of CT-005404 to show positive effects in 
the TBZ model is consistent with previously published studies showing that a variety of 
compounds that block DAT, including the catecholamine uptake inhibitor bupropion (Nunes et 
al. 2013; Yohn et al. 2016b), and the DAT inhibitors lisdexamfetamine, GBR 12909, and PRX-
14040 (Yohn et al. 2016a,b,c,d), all act to reverse the effort-related effects of TBZ.  
Pro-inflammatory cytokines play a significant role in mediating central and peripheral 
immune responses, but it has become evident that these proteins also are involved in the 
manifestation of psychopathological symptoms including anergia, fatigue, and amotivation 
(Dantzer 2001; Dantzer et al. 2009; Felger and Miller 2012; Felger and Treadway 2017). 
Increased expression of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-
α), interleukin 6 (IL-6), interferon alpha (IFN-α), and IL-1β in patients with major depression 
(Yang et al. 2007; Dantzer et al. 2008; Dowlati et al. 2010; Cattaneo et al. 2013; Rossi et al. 




and TNF-α, were reported to be negatively correlated with antidepressant treatment response 
(Cattaneo et al. 2013). TNF-α, IL-6, and IL-1β are also elevated in patients with MS, and 
increased levels of TNF-α and IL-1β are correlated with clinical depression symptom severity in 
MS patients (Rossi et al. 2017). IL-1β was shown to decrease lever pressing and slightly increase 
chow intake in rats tested on the FR5/chow feeding choice task (Nunes et al. 2014). In the 
present studies, IL-1β was used to provide an inflammatory challenge, which may be relevant for 
understanding disorders associated with elevated inflammation including MDD and MS. CT-
005404 was co-administered with IL-1β (4.0 µg/kg) at doses ranging from 7.5-30.0 mg/kg i.p. 
IL-1β administration significantly decreased lever pressing, without altering chow intake. The 
15.0 and 30 mg/kg doses of CT-005404 partially but significantly reversed the effects of IL-1β, 
significantly increasing lever pressing compared to treatment with IL-1β alone (Fig. 5.3). 
Evidence indicates that brain DA transmission interacts with the effects of pro-inflammatory 
cytokines. Pro-inflammatory cytokine signaling has a modulatory effect on some aspect of 
monoamine synthesis and/or transmission (Rossi et al. 2010; Gentile et al. 2015; Felger and 
Treadway 2017). Extracellular levels of DA in nucleus accumbens were reduced by 
administration of IL-6 in rats at a dose that suppressed lever pressing, and the DAT inhibitor 
methylphenidate reversed the lever pressing suppression induced by IL-6 (Yohn et al. 2016), 
which is consistent with the ability of CT-005404 to reverse the suppression of lever pressing 
induced by IL-1β. 
The PROG/chow feeding choice task provides a stronger effort-related challenge than the 
FR5/chow choice task, because the lever pressing work requirement gradually increments 
throughout the session. This task generates substantial variability in PROG lever pressing output 




of CT-005404 alone led to a significant linear dose-related increase in PROG lever pressing, as 
well as a decrease in chow intake. The highest dose of CT-005404 significantly increased PROG 
lever pressing and decrease chow intake relative to vehicle (Fig. 5.4), suggesting that the 
administration of this novel DAT inhibitor increased the tendency of animals to select the high-
effort lever pressing component of the task. This finding is consistent with previous studies 
showing that selection of PROG lever pressing relative to chow intake was increased by several 
drugs that inhibit DAT, including bupropion, lisdexamfetamine, GBR 12909, and PRX-14040 
(Randall et al. 2015; Yohn et al. 2016b,c,d). Taken together, these studies demonstrate that DA 
transmission exerts a bi-directional control over effort-based decision making, i.e., that 
interference with DA transmission induces a low-effort bias, while augmentation of DA 
transmission by blockade of DAT increases selection of high-effort lever pressing. These 
findings also are consistent with Wardle et al. (2011), who reported that amphetamine increased 
selection of high-effort activity in human participants. 
In summary, CT-005404 is a novel DAT inhibitor that binds selectively to DAT 
compared to NET and SERT, increases extracellular DA in nucleus accumbens, reverses the 
suppression of lever pressing induced by TBZ and IL-1β, and when administered alone, 
increases the tendency to select high-effort PROG lever pressing. Thus, CT-005404 has a profile 
similar to that shown by bupropion, modafinil, and methylphenidate, which are drugs that have 
been shown to improve motivational function in humans.  Future research should determine if 
CT-005404 shows signs of abuse liability. It is possible that CT-5404 or other novel DAT 
inhibitors could ultimately be useful as treatments for motivational dysfunction in humans 





8.6 Chapter 6 Discussion: 
This experiment was undertaken to develop a modified PROG task to be used for 
assessments of effort-based decision making in rats, and to assess the effects of DA depletions on 
several measures of high-effort responding during the PROG session. Although most studies 
with PROG schedules are relatively open ended in terms of session times, this specific task was 
developed in order to obtain break points from animals during a 30-minute session, so that in the 
future recording experiments can readily be done during the period of time in which rats show 
break points.  Although it has sometimes been thought that PROG break points are measures of 
“reward” or “reinforcement efficacy”, PROG break points are most directly a measure of how 
much work an organism will do to obtain reinforcement (Stewart 1974; Salamone 2006). For 
example, increasing the work requirement by increasing the height of the lever has been reported 
to decrease progressive ratio break points (Skjoldager, Pierre and Mittlman 1993; Schmelzeis 
and Mittleman 1996). Thus, PROG tasks are useful in studying the activational aspects of 
motivation and the tendency to work for food reinforcement (Salamone 2006; Salamone and 
Correa 2002; Salamone et al. 2016a), and how those the tendency to work for reinforcement is 
sensitive to various pharmacological manipulations. Though the PROG/chow feeding choice task 
has been used as a reliable model of effort-related choice behavior in animals for a number of 
years (Randall et al. 2012, 2014, 2015; Sommer et al. 2014; Yohn et al. 2016b,c,d, 2018), this 
study was the first to examine the effects of altering ratio requirements on PROG work output 
(e.g. lever pressing, time of last response, and breakpoint ratio) through distinct training phases 
in the same cohort of rats over a number of weeks, and the first to examine the effects of TBZ on 




By separating the training into separate phases, we were able to determine the point at 
which the parameter modifications were difficult enough to cause the majority of rats to cease 
responding, or ‘break’ during a 30-minute session. As depicted in Figure 6.1, the PROG (N=1; 
I=4) schedule was chosen as the schedule to be used for the behavioral pharmacology 
experiments. A four-day sample of baseline data taken from the ‘N=1; I=4’ training phase 
indicated that only three of sixteen rats did not break prior to the end of the 30-minute session. It 
was also observed that the rats that demonstrated breakpoints prior to the session end typically 
ceased responding within the first three quarters of the session. These data should be used to 
inform future studies of effort-related choice, ultimately allowing for direct observations of the 
behavioral and electrophysiological changes that are taking place as an animal shifts away from 
engaging in a high-effort task. 
The behavioral pharmacology experiment assessed the effects of tetrabenazine 
administration on total lever presses, time of last response, and break point ratio. Tetrabenazine 
administration resulted in significant reductions of all three measures (Fig. 6.2). These findings 
indicate that reduced DA transmission causes animals to exert less effort to overcome an 
instrumental response cost, effectively modeling the motivational deficits observed in individuals 
with neurological or psychiatric disorders. While treatment with DA antagonists or depleting 
agents causes animals to shift from choosing high- to low-effort options in tasks motivated by 
food, previous research has shown that this is not due to reduced appetite or alterations in 
preference or hedonic taste reactivity as the animals’ preference for the high-density arm or high 
carbohydrate pellet is still intact (Salamone et al. 1994; Berridge and Robinson, 1998; Randall et 
al. 2012, 2014; Nunes et al. 2013; Pardo et al. 2015; Yohn et al. 2015a). Similarly, it is important 




stimuli, but lack the drive to exert the effort required to obtain it (Treadway and Zald, 2011; 
Treadway, 2012).  When administered a drug that blocked catecholamine synthesis, human 
subjects were still able to detect the hedonic properties of cigarette smoking, and still 
experienced feelings of craving, but demonstrated lower response break points on the PROG 
schedule, indicating a reduced willingness to work for cigarettes (Venugopalan et al. 2011). In 
summary, DA depletions cause reductions in rats’ willingness to exert effort on the PROG lever 
pressing procedure, which can be compared to human studies of psychopathology related to the 
exertion of physical effort. In this regard, it is interesting to note that clinical studies have shown 
that willingness to work for monetary reward on a PROG task was impaired in people with 
depression and bipolar depression (Hershenberg et al. 2016). 
 The development of behavioral tasks that requires high levels of effort is critical for 
inducing a low-effort bias in animals. The systematic adjustments that were made to the PROG 
reinforcement schedule in this study have provided useful information about the effects of 
increasing: a) the number of reinforcers delivered at each ratio requirement (N); and b) the 
increment at which the ratio requirement increases after N reinforcers are delivered (I). In 
addition, the modified PROG task developed here will foster the study of EEG activity in 
behaving rats as they shift from high-effort lever pressing to the low-effort alternative, which 
will serve as a pre-clinical model of the physiological and neural changes that are relevant in 
human fatigue, anergia, and psychomotor slowing. Ultimately, these studies may allow for the 
assessment of identifiable patterns of prefrontal/frontal activity that may be relatable to the 






8.7 Chapter 7 Discussion: 
Our initial studies involving EEG recording have focused on conducting power spectral 
density analyses of signals obtained from frontal and parietal cortex, and determining the effects 
of TBZ, in untrained freely moving animals. These experiments were intended to be preliminary 
studies that allow for the development of EEG and data analysis methods that could lay the 
groundwork for future studies performed on trained animals performing on effort-related choice 
tasks. Ultimately, this research could allow for the development of EEG markers of effort-based 
choice that are translatable to humans. Furthermore, future research will study the behavioral and 
EEG effects of pharmacological manipulations that affect effort-based choice in trained animals, 
so that we can create larger, more robust variations in approach motivation that will potentially 
allow us to identify more sensitive electrophysiological biomarkers.  
Results from the Chapter 7 studies identified at least one major difference in relative 
frequency band power as a result of TBZ administration, and also focused on inter-hemispheric 
coherence based on electrode placements. Data from six rats treated with 1.0 mg/kg TBZ 
demonstrated a reduction of power in a range of 7-8 Hz relative to baseline (Fig. 7.1). Although 
8 Hz frequency bands can be categorized as within the alpha frequency range, theta oscillations 
have been reported within a frequency range of 4-12 Hz (Buzsaki et al. 1983; Penley et al. 2011). 
Theta and gamma oscillations originating from hippocampal structures have been implicated in 
activities such as locomotion and task engagement in the awake rat (Penley et al. 2011; Hinman 
et al. 2013; Jacobson et al. 2013; Schmidt et al. 2013), and thus should be considered as possible 
contributors to the cortical EEG signals observed in the present studies. Furthermore, our results 
suggested that TBZ did not seem to affect inter-hemispheric coherence of EEG signal from skull 




relative beta, theta, and gamma frequency power as well as measures of coherence as measured 
by EEG and LFP signals in the rat brain (Pálenícek et al. 2011, 2013; Hinman et al. 2013; West 
et al. 2018). For example, the DAT inhibitor amphetamine caused an increase in theta and alpha 
band coherence and a decrease in beta coherence, which was linked to an increase in locomotion 
and extracellular accumbens DA (Pálenícek et al. 2013). These studies emphasize the importance 
of studying both intra- and inter-hemispheric coherence in future studies assessing the effects of 
TBZ in behaving rats. Nevertheless, the data shown in Figure 7.2 suggest that the position of 
electrodes greatly affected the signal coherence, as demonstrated by the strongest signal 
coherence between two frontal electrodes positioned on either side of the midline, and two 
parietal electrodes positioned on either side of the midline, regardless of drug treatment. Results 
from this initial study demonstrate the feasibility of doing recording experiments with a 
relatively high degree of spatial resolution (i.e. differentiating prefrontal and parietal cortical 
areas) and a notable sensitivity to changes induced by pharmacological manipulations.  
Considering that the data reported here reflect EEG activity in an awake rat under 
baseline conditions, it is expected that rats behaving on the PROG task will show marked 
differences in EEG activity across multiple frequency bands. For example, animals engaging in 
high-effort PROG lever pressing may demonstrate lower frontal-frontal coherence, as human 
studies have posited a relation between frontal alpha asymmetry and motivated behaviors, as 
well as a reduced propensity to exhibit depressive symptoms (Pizzagalli et al. 2005; Nelson et al. 
2018; Gheza et al. 2019). Furthermore, changes to beta power may be observed in animals 
engaging in the PROG task under baseline (non-drug) conditions and after treatment with TBZ. 
Beta oscillations in cortical-basal ganglia circuits have been highlighted as a critical modulator 




abnormal beta rhythms have been linked to the motor impairments seen in Parkinson’s disease 
(Levy et al. 200l; West et al. 2018) and to pathological motor output in animals during task 
engagement (Leventhal et al. 2012). Therefore, the reduction of DA transmission in striatal areas 
caused by TBZ may result in alterations in beta power in rats that are correlates of a low-effort 
bias during PROG performance. Although TBZ primarily affects subcortical DA transmission in 
DA-rich striatal areas (Pettibone et al. 1984; Tanra et al. 1995), a sparse DA innervation also is 
present in areas of cortex other than prefrontal regions, with an anterior/posterior gradient (Vitrac 
and Benoit-Marand 2017), and thus TBZ may affect cortical DA transmission in ways that have 
not yet been elucidated. 
The initial step in this study was to establish reliable procedures for recording frontal 
cortex EEG signals in awake rats. Now that initial procedures have been established, future work 
will aim to record EEG activity while rats are performing on a high-effort lever pressing task 
(PROG) under baseline conditions and after pharmacological challenges that produce 
motivational deficits. Since PROG responding is characterized by initial periods of responding 
followed by a cessation of responding (i.e., “breaking” or ratio strain), a major goal of this future 
work will be to determine if there are differences in frontal cortical EEG activity during the 
initial period of responding vs. the period during and after the breakpoint. Ideally, this 
experiment will involve cohorts of male and female rats that will be trained on the modified 
PROG task developed in the studies outlined in Chapter 6. Once sufficiently trained, rats will be 
surgically implanted with up to six cortical EEG electrodes adjacent to the frontal cortex and 
parietal cortex as additional reference points. After recovery, rats will be tested on their 
respective behavioral tasks under baseline (non-drug) conditions and EEG activity will be 




behavioral tasks under pharmacological challenge with the VMAT-2 inhibitor TBZ. Additional 
studies will involve administration of TBZ to induce lower breakpoints, in order to determine if 
the changes in PROG responding induced by TBZ covary with changes in EEG activity. Based 
upon the Pizzagalli et al. (2005), Nelson et al. (2018), and Gheza et al. (2019) papers, as well as 
the present studies, it is hypothesized that engagement in high-effort lever pressing activity in the 
PROG will be marked by changes in frontal EEG activity, and possibly changes in parietal 
cortex, and in frequency bands other than alpha, such as theta beta, and gamma, as well. 
Furthermore, it is hypothesized that when animals trained on the PROG task reach their break 
point ratio, stop lever pressing, and shift to chow consumption, there will be changes in frontal 
EEG activity. Lastly, it is hypothesized that TBZ will shift effort-related choice behavior, 
decreasing lever pressing and increasing chow intake, which will thus alter the pattern of frontal 
cortex EEG activity relative to baseline conditions. These results could lead to a greater 
understanding of the circuit mechanisms that underlie effort-based aspects of motivation, while 
providing preclinical animal data leading to the development of physiological biomarkers of 
exertion of effort that can be easily translatable to human clinical research.  
 
8.8 General Discussion and Conclusions 
 
Effort-related motivational dysfunctions such as anergia, lassitude and fatigue are 
hallmark symptoms of depression, parkinsonism, schizophrenia, multiple sclerosis, and other 
disorders. Unfortunately, the most commonly prescribed medications do not effectively treat 
these symptoms, and can sometimes exacerbate them (Fava et al. 2014). Preclinical models of 
effort-based decision making can be used to study the amotivation produced by some of the 




depression and other psychiatric disorders is aligned with the NIMH Research Domain Criteria 
(RDoC) initiative, which emphasizes the importance of characterizing the neural processes that 
underlie the development of specific psychiatric symptoms. Importantly, tasks that have been 
designed to measure effort-related decision making are important in assessing the therapeutic 
potential of novel pharmacological compounds for their ability to mitigate effort-related deficits 
in animals.  
Considerable evidence supports the role of DA in modulating motivational processes. 
Drugs that reduce central DA transmission demonstrate a tendency to disturb motivational 
functions in animals (Nunes et al. 2013; Randall et al. 2012, 2014; Yohn et al. 2015a,b) and in 
humans (Artaloytia et al. 2006; Frank 2009, 2010; Guay, 2010; Chen et al. 2012). Consistent 
with previous literature, the DA D2 antagonist haloperidol reduced high-effort responding on the 
FR5 feeding task, and shifted rats’ behavior from the high effort (lever pressing) to low effort 
(chow intake) alternative on the concurrent FR5/chow feeding choice task (Chapter 2). In several 
experiments, the VMAT-2 inhibitor TBZ was shown to alter effort-based choice on the 
FR5/chow feeding choice task (Chapters 3-5) and on a PROG lever pressing schedule (Chapter 
6). Reductions in lever pressing also were induced by administration of the pro-inflammatory 
cytokine IL-1β (Chapter 5). These findings have been validated by clinical studies of effort-
related decision making showing that depressed individuals demonstrate a reduced likelihood of 
selecting high effort alternatives (Treadway et al. 2012a; Yang et al. 2014).  
Numerous studies have shown that administration of classical DAT inhibitors are able to 
reverse the effects of TBZ (Nunes et al. 2013, Yohn et al. 2016a,b; Salamone et al. 2016b) and of 
pro-inflammatory cytokines (Yohn et al. 2016c), but these drugs tend to produce undesirable side 




The novel modafinil analogs (S)-CE-123 and (S, S)-CE-158 were able to reverse the motivational 
deficits induced by TBZ on the FR5/chow feeding choice task, increase PROG responding, and 
increase extracellular accumbens DA as measured by microdialysis (Chapter 3-4). In addition, 
the recently synthesized atypical DAT inhibitor CT-005404 reversed a suppression of lever 
presses produced by IL-1β, while also demonstrating the ability to reverse the effort-related 
effects of TBZ, increase PROG responding, and increase extracellular DA in nucleus accumbens 
(Chapter 5). Together, the findings from Chapters 3-5 serve as important preclinical evidence for 
atypical DAT inhibitor compounds in support of their potential utility as treatments for 
symptoms of fatigue and amotivation seen in depression, schizophrenia, multiple sclerosis, and 
other disorders. Future studies need to focus on the potential abuse liability of these compounds. 
As discussed above, pharmacological conditions such as the administration of DA 
depleting agents or antagonists, or pro-inflammatory cytokines, can induce a low-effort bias in 
rats (Salamone et al. 2016a,b,c; Yohn et al. 2016a,b,c), and these effects can be reversed by co-
administration of several drugs that facilitate DA transmission (Chapters 3-5). Despite a growing 
body of animal work demonstrating that the exertion of effort and selection high-effort options is 
dependent upon forebrain circuits that involve mesolimbic DA inputs to nucleus accumbens, 
ventral pallidum, amygdala, and prefrontal cortex (Salamone et al. 1991, 1994; 2007, 2016a,b, 
2018; Walton et al. 2003; Floresco and Ghods-Sharifi 2007; Mingote et al. 2008; Farrar et al. 
2008, 2010; Winstanley and Floresco 2016), potential physiological markers of low effort bias 
that can be readily translatable to human clinical research have not been elucidated. In light of 
this, Chapters 6-7 experiments employed a novel operant lever pressing task and EEG methods 
to aid in the development of physiological markers associated with altered DA transmission and 




high levels of  baseline lever pressing, causing rats to exhibit a breakpoint during a 30-minute 
session. TBZ shifted rats away from high-effort responding, reducing total number of lever 
presses, time of last response, and breakpoint on the modified PROG schedule (Chapter 6). The 
modified PROG lever pressing schedule developed in these experiments will be implemented in 
future studies of electrophysiological recordings in awake, behaving rats. In Chapter 7 
experiments, cortical EEG was measured in rats under baseline and DA depletion conditions 
(i.e., administration of TBZ). Our findings suggested that there are several notable differences in 
the cortical EEG markers associated with altered DA transmission in rats, which may ultimately 
contribute to our understanding of how DA transmission in the ventral striatum and 
striatopallidal circuits modulate cortical functions involved in motivational dysfunctions in 
humans. 
Finally, the aim of Appendix Experiments 1-3 was to investigate the effects of several 
non-dopaminergic drugs on effort-related choice behavior in rodents. Appendix Experiments 1 
demonstrated that the SERT inhibitor fluoxetine suppressed FR5/chow lever pressing in male 
and female rats. Furthermore, Appendix Experiments 1 and 2 demonstrated that the effort-related 
effects induced by drugs such as fluoxetine, haloperidol, tetrabenazine, and risperidone could not 
be reversed  by reversed by 5-HT2A or 5-HT2C antagonists, or the 5-HT2A inverse agonist 
pimavanserin. These findings have been corroborated by recent studies in our lab that have also 
shown the negative effects of serotonergic drugs on running wheel choice behavior. Lastly, the 
kappa opioid receptor antagonist BT was unable to reverse motivational impairments induced by 
tetrabenazine and risperidone on the concurrent FR5/chow feeding choice task. The present 




serotonin receptors or kappa opioid receptors in terms of their ability to reverse effort-related 
dysfunctions, further emphasizing the importance of DA in regulating effort-related functions. 
In summary, the findings from the experiments described above highlight the critical role 
of DA in effort-related choice behaviors. DA transmission exerts a bi-directional modulatory 
control over exertion of physical effort in rats performing on instrumental tasks. Moreover, the 
behavioral paradigms used throughout this body of work have demonstrated their utility as 
preclinical tools for studying effort-related motivational impairments and identifying potential 
treatments. The conclusions that can be drawn from these experiments will aid in the 
development of novel therapeutic strategies for motivational impairments and will contribute to 
the growing body of literature on biomarkers related to fatigue and anergia observed in numerous 




















Summary of Appendices 
Appendix Experiments 1-3 sought to assess the effects of several non-dopaminergic 
drugs on effort-related choice in rodents. Appendix Exp 1 demonstrated that the administration 
of serotonin (5-HT) transport inhibitors (SERT inhibitors or SSRIs) reduced lever pressing and 
did not affect chow intake, but that this effect could not be reversed by the administration of 
selective serotonin receptor inhibitors (5-HT2A or 5-HT2C). Appendix Exp 2 examined the 
effort-related impairments induced by various pharmacological agents such as fluoxetine, 
haloperidol, risperidone, pilocarpine, and tetrabenazine, and showed that the 5-HT2A inverse 
agonist pimavanserin was unable to reverse the effort-related effects of any of these drugs. 
Appendix Exp 3 examined kappa opioid receptor function in effort-related aspects of motivation 
by assessing a kappa opioid receptor antagonist for its ability to reverse the effects of 
tetrabenazine, or the effects of risperidone. Taken together, the negative drug reversal results 
from Appendix Exp 1-3 emphasize the importance of DA in the regulation of effort-related 
behaviors, suggesting the need to focus on dopaminergic manipulations in developing treatments 











Appendix 1: Investigation of SSRI-induced fatigue in effort-related choice tasks, and of 
several selective serotonin receptor antagonists as potential treatment strategies. 
 
1.1 Introduction 
Major depressive disorder (MDD) often includes symptoms such as retardation, fatigue, 
lassitude, loss of energy and effort-related deficits, which commonly affect motivational and 
psychomotor functions (Stahl 2002; Demyttenaere et al. 2005; Salamone et al. 2006; Treadway 
and Zald 2011; Treadway et al. 2012a; Fava et al. 2014). The severity of such effort-related 
symptoms in depression is highly correlated with problems in social function, employment, and 
treatment outcomes (Tylee et al. 1999; Stahl 2002), and it has been observed that these 
debilitating symptoms are highly resistant to treatment (Stahl, 2002; Nutt et al. 2007; Fava et al. 
2014). In fact, serotonin (5-HT) uptake inhibitors such as fluoxetine (FLX; Prozac) are relatively 
ineffective for treating motivational dysfunction, and can induce or exacerbate these symptoms 
(Daly et al. 2011; Padala et al. 2012; Stenman and Lilja 2013; Rothschild et al. 2014; Fava et al. 
2014). Effort-related motivational symptoms are present in other disorders in addition to 
depression, including bipolar disorder, schizophrenia, Parkinsonism, chronic fatigue syndrome 
and multiple sclerosis (Salamone et al. 2006, 2010, 2016b; Friedman et al. 2007; Tellez et al. 
2008; Green et al. 2015). For these reasons, it is critical to examine the facets of effort-related 
dysfunctions in animal models in order to improve upon the currently available treatment options 
for these disorders.  
The neural basis of the effort-related dysfunctions in psychopathology are still being 
characterized, nevertheless, considerable preclinical and clinical evidence implicates central 
dopamine (DA), basal ganglia, and related corticolimbic circuits (Rogers et al. 1987; Rampello et 
al. 1991; Brown and Gershon 1993; Hickie et al. 1999; Caligiuri and Ellwanger et al. 2000; 
Volkow et al. 2001; Schmidt et al. 2001; Brody et al. 2001; Salamone et al. 2006, 2016b; Tellez 
et al. 2008; Treadway and Zald 2011; Chong et al. 2015). In addition to DA, other 
neurotransmitters such as glutamate, GABA, and 5-HT have also been implicated in the 
pathogenesis of MDD (Cowen and Browning 2015; Milak et al. 2016; Zheng et al. 2016; 
Belujon and Grace 2017; Pan et al. 2018), but their distinct roles in the regulation of 
motivational/psychomotor symptoms have not been fully elucidated. In view of the severe 
disease burden presented by depression (Wittchen et al. 2011; Marcus et al. 2012), the 
prevalence of motivational symptoms such as anergia and fatigue in depression and other 
disorders, and the relative resistance of these motivational/psychomotor symptoms to many 
common drug treatments, it seems evident that this line of work will ultimately improve the 
outlook for patients suffering from these debilitating symptoms. 
 Over the past several decades, a considerable body of work has focused on characterizing 
the role of various neurotransmitters including dopamine (DA), 5-HT, norepinephrine (NE), 
adenosine, and GABA, in the exertion of effort and effort-related decision making (Salamone 
and Correa 2002; Salamone et al. 1991, 2002, 2007, 2009a,b). Behavioral tasks have been 
developed in animals to study effort-related functions in animals, including operant procedures 
with different work requirements, and tests of effort-related decision making that allow animals 
to choose between high-effort alternatives that lead to more highly valued rewards vs. low-effort 




involving operant behavior and T-maze performance have demonstrated that low doses of DA 
antagonists, as well as DA depletions or antagonism in nucleus accumbens, reduce the exertion 
of effort and alter effort-related choice, biasing animals towards low-effort alternatives 
(Salamone and Correa 2002, 2012a; Salamone et al. 2007, 2009a,b, 2012). It has been suggested 
that tests of effort-based decision making in rodents could be useful as models of the effort-
related motivational symptoms of depression (Salamone et al. 2003, 2006, 2007, 2012, 2015, 
2016a,b,c; Salamone and Correa 2012). Reduced selection of high-effort activities in rodents is 
induced by manipulations associated with depression, including stress (Shafiei et al. 2012; Bryce 
and Floresco 2016), the pro-inflammatory cytokines IL-1β and IL-6 (Nunes et al. 2014; Yohn et 
al. 2016c), and the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine (Nunes et 
al. 2013b; Randall et al. 2014; Yohn et al. 2015a,b). These observations are validated by clinical 
data demonstrating that people with major depression show a reduced likelihood of selecting 
high effort alternatives when assessed in tests of effort-related decision making (Treadway et al. 
2012a; Yang et al. 2014).  
Recent studies from the Salamone laboratory have focused upon the effort-related effects 
of drugs that block the transporters for DA (DAT), NE (NET), and 5-HT (SERT). The effort-
related effects of tetrabenazine can be reversed by co-administration of the antidepressant 
bupropion (Nunes et al. 2013b; Randall et al. 2014; Yohn et al. 2015a,c), which blocks DAT and 
NET, and also by the DAT blocker GBR12909 (Yohn et al. 2016a). However, the SERT 
inhibitors fluoxetine and escitalopram fail to reverse the effort-related effects of tetrabenazine, 
and instead tend to exacerbate them (Yohn et al. 2016a,b). Furthermore, evidence indicates that 
while DA exerts a bi-directional modulation over effort-related decision making, 5-HT does not. 
Increased selection of high-effort choices can be enhanced by augmenting DA transmission with 
administration of the catecholamine uptake blockers bupropion (Randall et al. 2015) and 
lisdexamfetamine (Yohn et al. 2016b), and the DAT inhibitors MRZ-9547 (Sommer et al. 2014), 
PRX-14040 (Yohn et al. 2016d), and GBR12909 (Yohn et al. 2016). In contrast, the SERT 
inhibitor fluoxetine reduces selection of high effort lever pressing in rats responding on a 
progressive ratio (PROG)/chow feeding choice task at doses that also decrease extracellular DA 
in nucleus accumbens (Yohn et al. 2016a,e). This is consistent with studies showing that SERT 
inhibitors decrease high-effort physical activities such as voluntary wheel running (Weber et al. 
2009; Claghorn et al. 2016).  
Although there are several behavioral tasks that have been used for decades to assess the 
effects of antidepressant drugs in rodents (e.g. swim test, tail suspension test), none of these 
procedures specifically targets effort-related decision making, and therefore they do not seem 
suited for studying the effort-related effects of SERT inhibitors. Moreover, since SERT 
inhibitors generally yield a positive profile in the traditional behavioral tests related to 
depression, yet these drugs are relatively ineffective at treating effort-related motivational 
symptoms in depressed people, it underscores the need to have behavioral tests in animals that 
specifically focus on the effort-related effects of drugs used to treat depression. Therefore, the 
goal of these studies was to determine if the 5-HT2C receptor mediates effort-related effects by 
studying the ability of 5-HT2A and 5-HT2C antagonists to reverse the effects of fluoxetine on 
effort-related decision making. It was hypothesized that: a) systemic administration of fluoxetine 
would induce an effort-related impairment in rats performing on the concurrent FR5/chow 
feeding choice task similar to its effects on PROG/chow lever pressing; b) the reduction in 




receptors, but not 5-HT2A receptors; and c) systemic administration of 5-HT2C receptors would 
increase high-effort PROG/chow lever pressing.  
 
1.2 Materials and Methods 
 
Animals  
Adult male, drug-naïve, Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were 
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats were 
obtained weighing 275–299 g at the beginning of the study, and were initially food restricted to 
85% of their free-feeding body weight for operant training. Rats were allowed modest weight 
gain throughout the experiment. Supplemental chow was provided as needed to maintain body 
weights throughout the study, with water available ad libitum. Animal protocols were approved 
by the University of Connecticut Animal Care and Use Committee, and followed NIH 
guidelines. 
 
Behavioral and Pharmacological Methods 
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm; Med 
Associates, Fairfax, VT). Sessions lasted 30 minutes a day for 5 days/week. First, rats were 
trained to lever press on a continuous reinforcement schedule to receive 45 mg high-
carbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for one week, then were shifted to the 
FR5 schedule. After 5 weeks of FR5 training, chow was introduced. During each FR5/chow 
feeding choice task session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000, 
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. Rats were 
trained on this FR5/chow feeding choice procedure for 5 weeks, after which drug testing began. 
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered 
during each session. 
All experiments used a within-groups (i.e., repeated measures) design, in which all 
animals received all treatment combinations in a randomly varied order. During the drug 
treatment phase, rats were run 5 days per week, with 4 days being baseline days, and one day per 
week (either Thursday or Friday) being the drug treatment day. In all of the studies listed below, 
fluoxetine (10.0 mg/kg, 12.5 mg/kg, or 15.0 mg/kg IP) was administered 90 min before testing. 
Experiment 1 was conducted to establish a dose/response curve for fluoxetine, in which male and 
female rats were administered vehicle or one dose of fluoxetine (5.0, 10.0, or 15.0 mg/kg) in a 
randomly varied order over the course of four weeks. For the drug reversal studies, in which one 
drug is given to induce a behavioral impairment, animals also received a second injection of 
various doses of either the 5-HT2A antagonist MDL 100907, or the 5-HT2C antagonist SB 242084 
or vehicle to attempt to reverse the effects of fluoxetine. Each reversal study would typically 
involve 5 combined drug treatments (e.g. vehicle/vehicle, fluoxetine/vehicle, and fluoxetine plus 






List of Drug Experiments: 
1. Effect of fluoxetine on effort-related choice. 
2. Effect of 5-HT2C antagonist SB 242084 on the effort-related effects of fluoxetine. 
3. Effect of 5-HT2A antagonist MDL 100907 on the effort-related effects of fluoxetine. 
4. Effect of SB 242084 on performance on the PROG/chow feeding choice task. 
5. Effect of MDL 100907 on performance on the PROG/chow feeding choice task. 
 
Data Analyses 
 Repeated measures analysis of variance (ANOVA) was used to determine the effect of 
drug treatment on lever pressing and chow intake in the behavioral pharmacology experiments. 
To determine if there were significant reversal effects, nonorthogonal planned comparisons were 
performed, using the overall error term to assess differences between each treatment and the 
control condition. The number of comparisons was restricted to the number of treatments minus 
one (Keppel, 1991). 
 
1.3 Results 
FLX (5.0-15.0 mg/kg) was administered to male and female rats prior to performance on 
the FR5/chow feeding choice task. In both groups, FLX significantly reduced lever pressing, but 
had no significant effect on chow intake. A treatment x sex repeated measures factorial ANOVA 
revealed a significant overall main effect of treatment on lever pressing [F(3,42)=29.323, 
p<0.001], but no effect of sex on lever pressing (p=n.s.), and no significant treatment x sex 
interaction [F(3,42)=0.307, p=n.s.] (Fig. 1A). Due to a non-significant interaction, non-
orthogonal planned comparisons were computed collapsed across male and female lever presses. 
It was shown that all three doses of FLX significantly reduced lever presses relative to the 
vehicle treatment [VEH vs. 5.0 mg/kg FLX, F(1,42)=16.747, p<0.001; VEH vs. 10.0 mg/kg 
FLX, F(1,42)=65.577, p<0.001; VEH vs. 15.0 mg/kg FLX, F(1,42)=107.601, p<0.001]. Dose of 






Figure 1. Effects of FLX on performance on the FR5/chow feeding choice task in male and 
female rats. Male (n=8) and female (n=8) rats were injected with vehicle or fluoxetine (5.0-15.0 
mg/kg IP). (A) Fluoxetine significantly reduced lever pressing at 5.0 mg/kg, 10.0 mg/kg, and 
15.0 mg/kg (*p<0.001) and (B) had no effect on chow intake (p=n.s.). 
 
 A set of reversal experiments were conducted to investigate the effects of 5-HT2C or 5-
HT2A receptor antagonists SB 242084 or MDL 100907 on the effort-related impairments induced 
by fluoxetine (10.0 mg/kg) in male and female rats. The experiments sought to assess the effects 
of SB 242084 (0.25-2.0 mg/kg) on fluoxetine-induced changes in performance on the concurrent 
FR5 lever pressing/chow feeding choice task. Repeated measures ANOVA demonstrated a 
significant overall main effect of treatment on lever pressing in males [F(5,40)=31.076, p<0.001] 
and females [F(5,40)=10.249, p<0.001] (Fig. 2A). Planned comparisons revealed a significant 
reduction of lever presses in the FLX plus vehicle condition compared to the vehicle plus vehicle 
condition in males [F(1,40)=82.101, p<0.001] and females [F(1,40)=23.883, p<0.001]. Co-
administration of FLX with SB 242084 did not produce a significant reversal from the FLX plus 
vehicle condition at any of the doses tested (p=n.s.). There was no significant overall effect of 











Figure 2. The effects of SB 242084 on fluoxetine-induced changes in performance on the 
concurrent FR5 lever pressing/chow feeding choice procedure in male and female rats. Male 
(n=8) and female (n=8) rats were injected with vehicle or fluoxetine (10.0 mg/kg IP) and vehicle 
or one of four doses of SB 242084 (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg IP). (A) 
Fluoxetine significantly reduced lever pressing (#p<0.001) and (B) had no effect on chow intake 
relative to vehicle, but there was no significant reversal with SB 242084 at any dose.  
 
The second reversal experiment was conducted to investigate the effects of the 5-HT2A 
receptor antagonist MDL 100907 on the effort-related impairments induced by fluoxetine (15.0 
mg/kg) in male and female rats on the concurrent FR5 lever pressing/chow feeding choice task. 
Repeated measures ANOVA demonstrated a significant overall main effect of treatment on lever 
pressing in males [F(5,25)=46.214, p<0.001] and females [F(5,25)=19.362, p<0.001] (Fig. 3A). 
Planned comparisons revealed a significant reduction of lever presses in the FLX plus vehicle 
condition compared to the vehicle plus vehicle condition in males [F(1,25)=46.214, p<0.001] 
and females [F(1,25)=55.168, p<0.001]. Co-administration of FLX with SB 242084 at any of the 
doses tested did not produce a significant reversal from the FLX plus vehicle condition (p=n.s.). 











Figure 3. The effects of MDL 100907 on fluoxetine-induced changes in performance on the 
concurrent FR5 lever pressing/chow feeding choice procedure in male and female rats. Male 
(n=6) and female (n=8) rats were injected with vehicle or fluoxetine (15.0 mg/kg IP) and vehicle 
or one of four doses of MDL 100907 (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg IP). (A) 
Fluoxetine significantly reduced lever pressing (#p<0.001) and (B) had no effect on chow intake 
relative to vehicle, but there was no significant reversal with MDL 100907 at any dose. 
 
Additional experiments investigated the ability of SB 242084 to increase lever pressing 
on the PROG/chow feeding choice task in male and female rats. Vehicle or one of four doses of 
SB 242084 (0.5-4.0 mg/kg) was administered to rats prior to task performance. Repeated 
measures ANOVA revealed that SB 242084 did not have a significant overall effect on lever 
pressing in males [F(4,28)=0.742, p=n.s.] or females [F(4,28)=0.514, p=n.s.] (Fig. 4A). In 
addition, there was no significant overall effect of treatment on chow intake (p=n.s.). Tests of 
between-subjects effects revealed a significant overall difference in chow intake between male 
and female rats [F(1,14)=146.536, p<0.001]. (Fig. 4B). 
 
   
Figure 4. The effects of SB 242084 on effort-related performance on the concurrent PROG lever 
pressing/chow feeding choice procedure in male and female rats. Male (n=8) and female (n=8) 
rats were injected with vehicle or one of four doses of SB 242084 (0.5 mg/kg, 1.0 mg/kg, 2.0 
mg/kg, 4.0 mg/kg IP). (A) Treatment with SB did not significantly affect lever pressing (p=n.s.) 
or (B) chow intake relative to vehicle (p=n.s.). Chow intake significantly differed between male 
and female rats (p<0.001). 
 
The fifth experiment in this series assessed the ability of MDL 100907 to increase lever 
pressing on the PROG/chow feeding choice task in male and female rats. Vehicle or one of four 
doses of MDL 100907 (0.5-4.0 mg/kg) was administered to rats prior to task performance. 
Repeated measures ANOVA revealed that MDL 100907 did not have a significant overall effect 
on lever pressing in males [F(4,28)=1.253, p=n.s.] or females [F(4,28)=0.802, p=n.s.] (Fig. 5A). 





Tests of between-subjects effects revealed a significant overall difference in chow intake 
between male and female rats [F(1,14)=43.131, p<0.001]. (Fig. 5B). 
 
  
Figure 5. The effects of MDL 100907 on effort-related performance on the concurrent PROG 
lever pressing/chow feeding choice procedure in male and female rats. Male (n=8) and female 
(n=8) rats were injected with vehicle or one of four doses of MDL 100907 (0.5 mg/kg, 1.0 
mg/kg, 2.0 mg/kg, 4.0 mg/kg IP). (A) MDL did not significantly affect lever pressing (p=n.s.) or 
(B) chow intake relative to vehicle at any of the doses tested (p=n.s.). Chow intake significantly 
differed between male and female rats (p<0.001). 
 
1.4 Discussion 
The purpose of Appendix 1 experiments was to evaluate the effort-related effects of the 
SERT inhibitor fluoxetine, and to assess two different selective 5-HT receptor antagonists for 
their ability to reverse fluoxetine-induced motivational impairments. Consistent with previous 
findings from our laboratory using the PROG/chow feeding choice task (Yohn et al. 2016e), 
fluoxetine administration caused a dose-dependent decrease in lever presses on the FR5/chow 
feeding choice task. The Yohn et al. (2016e) study was conducted in male rats, while the present 
experiment used both males and females. In contrast to the effects of DA antagonists or 
depletions on the FR5/chow task performance to produce compensatory increases in chow 
consumption, fluoxetine did not have any effect on the amount of chow consumed during the 
FR5/chow feeding choice task. Though the lack of compensatory chow intake is thought to be a 
result of possible appetite suppression effects, it is important to note that these effects were not 
simply due to the use of food reinforcement. Recent studies in our lab demonstrated that 
systemic fluoxetine administration dose-dependently decreases both running wheel activity and 
chow consumption in choice procedures in male and female rats (Presby et al., in preparation). In 
agreement with the data presented here, antagonism of 5-HT2C or 5-HT2A receptors did not 
reverse the fluoxetine-induced suppression of wheel running or chow intake, nor did they 
increase high-effort responding when administered alone to rats trained on the PROG/chow 





fluoxetine-induced effects is inconsistent with previous literature demonstrating that SB 242084 
blocked the rate decreasing effect of fluoxetine on lever pressing (Bauer et al. 2015), and also 
increased lever pressing (Martin et al. 2002). Antagonism of 5-HT2C receptors increased burst 
firing in ventral tegmental area (VTA) DA neurons (DiMatteo et al. 1999; DiGiovanni et al. 
1999), increased accumbens DA release (Visser et al. 2015), and blocked the decrease in DA 
neuron activity induced by the SERT inhibitor citalopram (Dremenecov et al. 2009), which 
would have suggested that blocking this receptor might have been able to reverse the effects of 
fluoxetine. This inconclusive pattern of effects may be due in part to possible off-target 
peripheral actions of fluoxetine and SB 242084 related to systemic administration. Thus, it may 
be beneficial to replicate these studies using intracranial administration of selective 5-HT 
antagonists into areas of the brain implicated in motivation and mesolimbic DA transmission 
such as the VTA. In view of the fact that SERT inhibitors are relatively ineffective at treating 
effort-related motivational symptoms of depression, and that these drugs often induce or 
exacerbate these debilitating symptoms, ongoing and future work in this area could contribute 
significantly to the understanding of the neurotransmitter interactions that underlie the 
motivational effects of antidepressants, and could foster the development of agents that would 




















Appendix 2: Assessment of pimavanserin in animal models of effort-related choice 
behavior: significance for treating motivational dysfunctions. 
 
2.1 Introduction 
Behavioral activation and effort-related processes are fundamental aspects of motivation. 
Considerable evidence from the basic neuroscience literature indicates that nucleus accumbens 
dopamine (DA) is an important component of the neural circuitry that regulates behavioral 
activation and effort-related aspects of motivation (Salamone et al. 2007, 2016a,b). Studies of 
behavioral activation and effort also are clinically relevant. In humans, symptoms such as 
anergia, psychomotor retardation, amotivation and fatigue reflect pathologies in behavioral 
activation. These symptoms are fundamental features of depression, Parkinson’s disease and 
schizophrenia (Tylee et al. 1999; Stahl 2002; Demyttenaere et al. 2005; Salamone et al. 2006, 
2007, 2012; Chong et al. 2015). Within the last few years, rodent procedures assessing effort-
related choice behavior have been developed into formal animal models that are useful for 
characterizing the effects of well-known and experimental therapeutic agents.   
Tests of effort-based choice behavior allow animals to select between a more preferred 
reward that can only be obtained by high exertion of effort vs. a low effort/low reward option. In 
our laboratory, several tasks have been developed for assessing effort-related choice behavior in 
rats. Our most commonly used task is an operant concurrent choice task that offers rats a choice 
between lever pressing to obtain a relatively preferred food (high carbohydrate pellets), vs. 
approaching and consuming a less preferred food (lab chow) that is concurrently available. 
Under non-drug conditions, rats lever pressing on a fixed ratio 5 (FR5) schedule typically get 
most of their food by lever pressing, and they eat only small amounts of chow. With rats 
performing on this task, pre-feeding to reduce food motivation was shown to suppress both lever 
pressing and chow intake (Salamone et al. 1991). In contrast, low-to-moderate doses of DA 
antagonists produced a very different pattern of effects. DA antagonists with varying degrees of 
receptor subtype specificity, including cis-flupenthixol, haloperidol, raclopride, eticlopride, SCH 
23390, SKF83566 and ecopipam, all decreased lever pressing for food but substantially 
increased intake of the concurrently available chow (Salamone et al. 1991, 2002; Nowend et al. 
2001; Sink et al. 2008). The low dose of haloperidol that produced this effect (0.1 mg/kg) did not 
alter food intake or preference in free-feeding choice tests (Salamone et al. 1991). In addition, it 
has been demonstrated that intra-accumbens administration of the muscarinic acetylcholine 
receptor agonist pilocarpine shifted rats’ behavior on the FR5/chow task to the low-effort bias, 
seen as a reduction of lever presses and increased selection of freely available chow (Nunes et al. 
2013b). Although DA antagonists and the muscarinic agonist pilocarpine have been shown to 
reduce FR5 lever pressing and increase chow intake, appetite suppressants such as fenfluramine 
and cannabinoid CB1 antagonists (Salamone et al., 2002; Sink et al. 2008) do not increase chow 
intake at doses that suppress lever pressing.  
In addition to the FR5/chow feeding task, a progressive ratio (PROG)/chow feeding 
choice task has been developed. With this task, the rats have a choice between lever pressing vs. 
approaching and consuming the freely available chow, however, the PROG lever pressing 
schedule is more demanding because the ratio requirement gets progressively higher throughout 




chow more than they do on the FR5/choice procedure, because the increasing PROG work 
demand makes the animals switch from lever pressing to chow intake once the ratio requirement 
gets high enough (Randall et al. 2012). As with the other effort-based tasks, administration of the 
DA antagonists haloperidol, ecopipam, and eticlopride all decrease selection of the high-effort 
PROG lever pressing at doses that do not impair chow intake (Randall et al. 2012, 2014).   
More recently, models have been established that assess the effects of the VMAT-2 
inhibitor tetrabenazine. This drug depletes DA by blocking vesicular storage, and tetrabenazine 
is useful for animal models because it produces depressive symptoms in people (Guay 2010).  At 
low doses that reduce extracellular DA and alter DA-related signal transduction in nucleus 
accumbens, tetrabenazine also alters effort-based choice in animals responding on multiple tasks, 
including the FR5/chow feeding choice task described above (Nunes et al. 2013), the 
PROG/chow feeding choice task (Randall et al. 2014), and the T-maze barrier choice task (Yohn 
et al. 2015a,b). Tetrabenazine induced these effort-related effects at doses that did not alter food 
intake, food preference, sucrose preference, hedonic reactivity to sucrose, or reference memory. 
Together with the other results reviewed above, these findings demonstrate that interference with 
DA transmission does not simply reduce appetite for food or food-related hedonia, but rather, 
alters effort-based choice and produces a bias away from high-effort activity towards low-effort 
activity. 
Over the last few years, several drugs have been assessed for their ability to improve 
effort-related performance in these models. The adenosine A2A receptor antagonists 
istradefylline, Lu AA47070, MSX-3 and MSX-4 have all been shown to reverse the effort-
related effects of DA antagonists and tetrabenazine across multiple tasks (Farrar et al. 2007, 
2010; Worden et al. 2009; Mott et al. 2009; Salamone et al. 2009; Nunes et al. 2010; Collins et 
al. 2011; Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015a). DA D1 receptor agonists also 
reversed the effort-related effects of DA antagonism and depletion in rats tested on the 
FR5/chow feeding choice and T-maze barrier choice tasks (Yohn et al. 2015b).  Recent studies 
demonstrated that the glycine uptake inhibitor bitopertin was able to reverse the effort-related 
effects of haloperidol (Yohn et al. 2017). In addition, several drugs that block DA uptake, 
including bupropion, GBR12909, lisdexamfetamine, PRX-14040, methylphenidate, and 
modafinil, all were able to reverse the effort-related effects of tetrabenazine (Nunes et al. 2013; 
Randall et al. 2014; Yohn et al. 2016a,b,c; Salamone et al. 2016). Moreover, in otherwise 
untreated rats that were tested on the PROG/chow feeding choice task, the DA transport 
inhibitors bupropion, GBR12909, lisdexamfetamine and PRX-14040 all were shown to increase 
selection of the high-effort PROG lever pressing and decrease choice of the low effort option 
(chow intake; Randall et al. 2015; Yohn et al. 2016b,c,d). These results demonstrate the 
feasibility of using tests of effort-based choice for preclinical characterization of compounds 
with different pharmacological profiles, and also emphasize the role of brain DA systems as a 
modulator of effort-related functions. This animal research demonstrating the involvement of DA 
systems in effort-related aspects of motivation is consistent with studies showing that effort-
based decision making in humans is related to DA transmission (Treadway et al. 2011; Wardle et 
al. 2012), and that motivational function can be improved in depressed patients by administration 
of drugs that increase DA transmission (Stotz et al. 1998; Papakostas et al. 2006). Furthermore, 
the use of effort-based tasks in rodents as models of human psychopathology is validated by 
studies showing that a low-effort bias on choice tasks is seen in human patients with major 




2013, 2015; Reddy et al. 2015) and Parkinson’s disease (Chong et al. 2015). Nevertheless, it is 
worth pointing out that these animal models have limitations, and do not directly model effort-
based tasks in human subjects suffering from depression, schizophrenia, Parkinson’s disease or 
other disorders. 
In contrast to the effects of drugs that act to increase DA transmission, drugs that block 
serotonin (5-HT) transport, such as the SSRIs fluoxetine and citalopram, failed to reverse the 
effects of tetrabenazine on FR5/chow feeding choice performance (Yohn et al. 2016a,b). 
Furthermore, fluoxetine and citalopram suppressed lever pressing in rats tested on the FR5/chow 
feeding choice task (Yohn et al. 2016a,b), and fluoxetine reduced PROG lever pressing after 
both acute and repeated administration (Yohn et al. 2016e). Fluoxetine also was shown to 
decrease extracellular DA in nucleus accumbens at a dose that suppressed PROG lever pressing 
(Yohn et al. 2016e). These results are consistent with human clinical studies reporting that SSRIs 
are relatively poor at treating motivational dysfunctions in depressed people (Papakostas et al. 
2006; Bell et al. 2013; Fava et al. 2014; Rothschild et al. 2014; Cooper et al. 2014). In fact, these 
drugs can actually worsen effort-related symptoms such as fatigue.   
Because of the widespread prevalence of motivational dysfunctions related to problems 
with behavioral activation and effort, which are evident across multiple disorders, it is critical to 
develop a line of preclinical research for assessing the effects of potential treatments. If 
elevations in 5-HT transmission due to uptake blockade are relatively ineffective at restoring 
normal motivational function, and in fact can impair effort-related processes, it is critical to study 
drugs that blunt 5-HT transmission to determine if they can exert pro-motivational effects. In 
view of the ability of pimavanserin to act as an inverse agonist at the 5-HT2A receptor, it is 
important to assess the effects of pimavanserin in animal models of effort-related choice 
behavior. Pimavanserin (also known as ACP-103) has been approved for human use in treating 
hallucinations and delusions associated with Parkinson’s disease (trade name: Nuplazid®). 
Previous research has shown that pimavanserin has anti-tremor effects in an animal model of 
Parkinsonian tremor (Vanover et al. 2008), but its effects on effort-related motivational processes 
are unknown.  
This project was undertaken determine if pimavanserin exert effects in animal models of 
effort-related choice behavior, and can reverse the effects of the SSRI fluoxetine and the 
antipsychotic drugs haloperidol and risperidone, as well as the DA depleting agent tetrabenazine, 
on performance of these tasks. In the initial experiments, pimavanserin was assessed for its 
ability to reverse the effects of the serotonin transport (SERT) inhibitor fluoxetine in rats tested 
on the FR5/chow feeding choice task, and additional experiments studied the ability of 
pimavanserin to reverse the effects of the DA D2 antagonist haloperidol, as well as the atypical 
antipsychotic risperidone, and the muscarinic agonist pilocarpine, on the FR5/choice procedure. 
Finally, pimavanserin and MDL 100907 were tested for their ability to reverse the effort-related 








2.2 Materials and Methods 
Animals  
Adult male, drug-naïve, Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were 
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats were 
obtained weighing 275–299 g at the beginning of the study, and were initially food restricted to 
85% of their free-feeding body weight for operant training. Rats were fed supplemental chow to 
maintain weight throughout the study, with water available ad libitum. Rats were allowed modest 
weight gain throughout the experiment. Animal protocols were approved by the University of 
Connecticut Animal Care and Use Committee, and followed NIH guidelines.  
 
Behavioral and Pharmacological Methods 
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm; Med 
Associates, Fairfax, VT). Sessions lasted 30 minutes a day for 5 days/week. First, rats were 
trained to lever press on a continuous reinforcement schedule to receive 45 mg high-
carbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for one week, then were shifted to the 
FR5 schedule. After 5 weeks of FR5 training, chow was introduced. During each FR5/chow 
feeding choice task session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000, 
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. Rats were 
trained on this FR5/chow feeding choice procedure for 5 weeks, after which drug testing began. 
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered 
during each session. 
All experiments used a within-groups (i.e., repeated measures) design. Thus, once 
animals were trained for a given experiment, all animals received all treatment combinations in a 
randomly varied order. During the drug treatment phase, rats were run 5 days per week, with 4 
days being baseline (drug-free) days, and one day per week (either Thursday or Friday) being the 
drug treatment day. All of the studies listed below (except Exp 3) are drug reversal studies, in 
which one drug is given to induce a behavioral impairment (12.5 mg/kg IP fluoxetine 90 min 
before testing, 0.1 mg/kg IP haloperidol 50 min before testing, 0.5 mg/kg IP risperidone 30 min 
before testing, and 1.0 mg/kg IP tetrabenazine 120 min before testing). Animals also received a 
second injection of various doses of pimavanserin or MDL 100907 to attempt to reverse the 
effects of the first drug. Each study would typically involve 5 combined drug treatments (e.g. 
vehicle/vehicle, haloperidol/vehicle, and haloperidol plus 3 doses of pimavanserin).  
 
List of Drug Experiments 
1. FR5/chow feeding with pimavanserin vs. fluoxetine  
2. FR5/chow feeding with pimavanserin vs. haloperidol  
3. FR5/chow feeding with risperidone (to determine effective dose)  
4. FR5/chow feeding with pimavanserin vs. risperidone 




6. FR5/chow feeding with pimavanserin vs. tetrabenazine 
7. FR5/chow feeding with MDL 100907 vs. tetrabenazine 
 
Data Analyses 
 Repeated measures analysis of variance (ANOVA) was used to determine the effect of 
drug treatment on lever pressing and chow intake in the behavioral pharmacology experiments. 
To determine if there were significant reversal effects, nonorthogonal planned comparisons were 
performed, using the overall error term to assess differences between each treatment and the 
control condition. The number of comparisons was restricted to the number of treatments minus 
one (Keppel, 1991). 
 
2.3 Results 
 A series of experiments were conducted to investigate the effects of the 5-HT2A inverse 
agonist pimavanserin on the effort-related impairments induced by various pharmacological 
challenges. The first set of experiments sought to assess the effects of pimavanserin on 
fluoxetine-induced changes in performance on the concurrent FR5 lever pressing/chow feeding 
choice task. Repeated measures ANOVA demonstrated a significant overall main effect of 
treatment on lever pressing [F(4,24)=25.603, p<0.001] (Fig. 1A), [F(4,20)=16.527, p<0.001] 
(Fig. 1C). There was no overall effect of drug treatment on chow intake in either experiment. 
Planned comparisons indicated that fluoxetine (12.5 mg/kg) significantly reduced lever pressing 
compared to the vehicle condition (p<0.001; Fig. 1A and 1C), but had no effect on chow intake 
(Fig. 1B, 1D). There was no significant reversal of lever pressing when pimavanserin was co-
administered at any dose. Furthermore, the route of administration (subcutaneous vs. 
intraperitoneal) had no effect on the ability of pimavanserin to reverse the fluoxetine-induced 
suppression of lever pressing. 
  Treatment (mg/kg)

























































Figure 1. The effects of pimavanserin on fluoxetine-induced changes in performance on the 
concurrent FR5 lever pressing/chow feeding choice procedure. (A,B) Fluoxetine and 
pimavanserin (subcutaneous; SC). Rats (n=7) were injected with vehicle or fluoxetine (12.5 
mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, or 10.0 mg/kg SC). (A) 
Fluoxetine significantly reduced lever pressing (*p<0.001) and (B) had no effect on chow intake, 
but there was no significant reversal with pimavanserin at any dose. (C,D) Fluoxetine and 
pimavanserin (intraperitoneal; IP). Rats (n=6) were injected with vehicle or fluoxetine (12.5 
mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, or 10.0 mg/kg IP). (C) 
Fluoxetine significantly reduced lever pressing (*p<0.001) from vehicle, and (D) had no effect 
on chow intake, but there was no significant reversal with pimavanserin at any dose. 
  
Figure 2 shows the effects of pimavanserin on haloperidol-induced changes in 
performance on the concurrent FR5 lever pressing/chow feeding choice procedure. Repeated 
measures ANOVA revealed a significant overall main effect of treatment on lever pressing and 
chow intake in all three experiments (Fig. 2A: [F(4,28)=13.575, p<0.001]; Fig. 2B: 
[F(4,28)=5.079, p<0.05]; Fig. 2C: [F(4,28)=22.012, p<0.001]; Fig. 2D: [F(4,28)=13.653, 
p<0.001]; Fig. 2E: [F(3,21)=66.199, p<0.001]; Fig. 2F: [F(3,21)=25.642, p<0.001]. Planned 
comparisons were performed and showed that haloperidol (0.1 mg/kg) significantly reduced 
lever pressing (p<0.001) and increased chow intake (p<0.001) in all three experiments (Fig. 2). 
There was no significant reversal of the haloperidol-induced effort-related effects on lever 
pressing or chow intake by pimavanserin at any dose, regardless of route of administration. 
Treatment (mg/kg)























































































































































































































Figure 2. The effects of pimavanserin on haloperidol-induced changes in performance on the 













pimavanserin (subcutaneous; SC). Rats (n=8) were injected with vehicle or haloperidol (0.1 
mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, or 10.0 mg/kg SC). (A) 
Haloperidol significantly reduced lever pressing (*p<0.001) and (B) increased chow intake 
(*p<0.001) from vehicle, but there was no significant reversal with pimavanserin at any dose. 
(C,D) Haloperidol and pimavanserin (intraperitoneal; IP). Rats (n=8) were injected with vehicle 
or haloperidol (0.1 mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, or 10.0 
mg/kg IP). (C) Haloperidol significantly reduced lever pressing (*p<0.001) and (D) increased 
chow intake from vehicle, but there was no significant reversal with pimavanserin. (E,F) 
Haloperidol and pimavanserin  (IP vs. SC) at a higher dose. Rats (n=8) were injected with 
vehicle or haloperidol (0.1 mg/kg IP) and vehicle or pimavanserin (20 mg/kg IP or SC). (E) 
Haloperidol significantly reduced lever pressing (*p<0.001) and (F) increased chow intake 
(*p<0.001) from vehicle, but there was no significant reversal with pimavanserin using either IP 
or SC routes of administration. 
 
The antipsychotic drug risperidone was administered to rats trained on the FR5/chow 
feeding choice procedure to evaluate its effects effort-related choice behavior, and to determine 
the effective dose to be used to induce a motivational deficit in pharmacological challenge 
reversal experiments. Repeated measures ANOVA showed a significant effect of treatment on 
lever pressing [F(5,35)=25.758, p<0.001] and chow intake [F(5,35)=11.525, p<0.001]. When 
administered alone, risperidone significantly reduced lever pressing at 0.25 mg/kg (p<0.001) and 
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Figure 3. The effects of risperidone when administered alone to rats on the concurrent FR5 lever 
pressing/chow feeding choice procedure. Rats (n=8) were injected with vehicle or risperidone 
(0.0313-0.5 mg/kg IP). (A) Risperidone significantly reduced lever presses at 0.25 mg/kg 










 In a fourth experiment, pimavanserin was assessed for its ability to reverse the 
suppression of lever pressing caused by risperidone. There was a significant overall main effect 
of drug treatment on lever pressing [F(4,60)=53.847, p<0.001], but no significant effect of drug 
treatment on chow intake [F(4,60)=0.636, n.s.]. Risperidone induced a significant reduction of 
lever pressing on the FR5/chow feeding choice task compared to the vehicle/vehicle condition 
(Fig. 4A), but had no effect on chow intake (Fig. 4B). Co-administration of pimavanserin (1.0-
10.0 mg/kg) with risperidone did not produce a significant reversal of the reduction in lever 
pressing at any dose. 
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Figure 4. The effects of pimavanserin on risperidone-induced changes in performance on the 
concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16) were injected with 
vehicle or risperidone (0.5 mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, 
or 10.0 mg/kg SC). (A) Risperidone significantly reduced lever pressing from vehicle/vehicle 
(*p<0.001) but there was no significant reversal with pimavanserin at any dose. (B) There was 
no significant effect of risperidone or pimavanserin on chow intake.  
 
 Figure 5 shows the effects of pimavanserin on pilocarpine-induced changes in 
performance on the concurrent FR5 lever pressing/chow feeding choice task. There was a 
significant overall main effect of treatment on lever pressing [F(3,21)=28.287, p<0.001], and no 
effect of drug treatment on chow intake [F(3,21)=0.656, n.s.]. Pilocarpine administration caused 
a reduction in lever pressing (p<0.001) (Fig. 5A), but did not affect chow intake (Fig. 5B). 
Pimavanserin did not cause a reversal of pilocarpine-induced suppression of lever pressing at 







    
Figure 5. The effects of pimavanserin on pilocarpine-induced changes in performance on the 
concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=8) were injected with 
vehicle or pilocarpine (1.0 mg/kg IP) and vehicle or one of two doses of pimavanserin (1.0 or 
10.0 mg/kg SC). (A) Pilocarpine significantly reduced lever pressing from vehicle/vehicle 
(*p<0.001) and (B) had no effect on chow intake. There was no significant reversal of the 
pilocarpine-induced suppression of lever pressing with pimavanserin at any dose. 
 
 The DA-depleting agent tetrabenazine was used to induce an effort-related impairment in 
rats on the FR5/chow feeding choice task in the final two experiments. As shown in Figure 6, a 
repeated measures ANOVA demonstrated a significant overall main effect of drug treatment on 
lever pressing [F(4,60)=45.831, p<0.001] and on chow intake [F(4,60)=16.782, p<0.001]. 
Tetrabenazine significantly reduced lever presses (p<0.001) (Fig. 6A) and increased chow intake 
(Fig. 6B) compared to the vehicle treatment. These effects were not attenuated by pimavanserin 
at any dose. 
 
     
Figure 6. The effects of pimavanserin on tetrabenazine (TBZ)-induced changes in performance 









with vehicle or tetrabenazine (1.0 mg/kg IP) and vehicle or one of three doses of pimavanserin 
(1.0, 5.0 mg/kg, or 10.0 mg/kg SC). (A) Tetrabenazine significantly reduced lever pressing 
(*p<0.001) and (B) increased chow intake (*p<0.001) from vehicle/vehicle, but there was no 
significant reversal of the tetrabenazine-induced effects on lever pressing or chow intake with 
pimavanserin at any dose. 
 
 The last experiment of the series assessed whether the tetrabenazine-induced effects on 
lever pressing and chow intake could be reversed by the co-administration of MDL 100907.  A 
one-way ANOVA revealed a significant reduction of lever presses when tetrabenazine and MDL 
were co-administered compared to the tetrabenazine plus vehicle treatment group 
[F(1,31)=4.458, *p<0.05] (Fig. 7A). Co-administration of tetrabenazine and MDL did not differ 
from the tetrabenazine plus vehicle treatment condition (Fig. 7B). 
 
 
      
Figure 7. The effects of MDL 100907 on tetrabenazine-induced changes in performance on the 
concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16) were injected with 
tetrabenazine (1.0 mg/kg IP) and MDL 100907 (1.0 mg/kg IP). (A) One-way ANOVA revealed a 
significant reduction of lever presses when TBZ and MDL were co-administered compared to 
the TBZ plus vehicle treatment group [F(1,31)=4.458, *p<0.05]. (B) Chow intake was unaffected 
[F(1,31)=0.753, n.s.].  
 
2.4 Discussion 
 Across all 6 reversal experiments, pimavanserin showed no signs of reversing the effects 
of fluoxetine, haloperidol, risperidone, pilocarpine, or tetrabenazine. It seems unlikely that these 
negative results were due a lack of range of doses tested, because depending upon the 
experiment, pimavanserin doses ranging from 1.0 mg/kg up to 20.0 mg/kg were used. 






results. These results are consistent with other data (Rotolo Ph.D. Dissertation Appendix 1) 
indicating that the selective 5-HT2A antagonist MDL 100907 and the 5-HT2B antagonist SB 
242084 also were ineffective in at improving performance in fluoxetine-treated rats tested on 
effort-based choice procedures. Experiment 7 showed that MDL 100907 also was unable to 
reverse the effects of tetrabenazine. Taken together, these results suggest that the tested drugs 
that act upon 5-HT2 family receptors were ineffective at reversing any of the drug-induced 
impairments in effort-based choice induced by a variety of different drugs with distinct 
pharmacological profiles (e.g. SERT inhibitor, DA antagonists, DA depleting agent, muscarinic 
agonist). The present results should be put into context by recognizing the limitations of the 
methods being used. The effort-based choice models employed may not predict accurately the 
effects of serotonergic drugs in human subjects suffering from psychiatric disorders like 
Parkinson’s disease, schizophrenia or depression. Nevertheless, these negative results serve to 
emphasize the important role that dopaminergic drugs have in modulating effort-based choice 
















Appendix 3: Assessment of the role of kappa opioid receptor function in animal models of 
effort-related choice behavior: significance for treating motivational dysfunctions. 
 
3.1 Introduction 
Individuals that suffer from major depressive disorder (MDD) and other psychiatric 
disorders often experience an array of symptoms affecting mood, cognition, and motivation. The 
most commonly used antidepressant drug therapies include selective serotonin reuptake 
inhibitors (SSRIs) and tricyclic antidepressants, but these drugs do not mitigate some of the most 
debilitating symptoms, and are often accompanied by negative side effects (Montgomery et al. 
1994; Li et al. 2016). Moreover, individuals that are treated with DA antagonists or depleting 
agents often experience effects such as depression, anergia and motivational dysfunctions (Frank 
2009, 2010; Guay, 2010; Chen et al. 2012; Kennedy et al. 2014). Drugs that inhibit the uptake of 
the dopamine (DA) transporter (DAT) have demonstrated clinical efficacy in reducing some of 
the physical symptoms of depression, but can be accompanied by adverse effects such as 
psychostimulant effects, psychosis, and abuse liability, limiting their therapeutic use. The 
drawbacks of the currently approved pharmacological treatments beg the need for the 
investigation of an alternative class of drugs that will more effectively treat symptoms of 
amotivation in humans. 
Since most of the widely prescribed antidepressants affect some aspect of monoamine 
transmission, there may be utility in assessing compounds in a distinct category for their safety 
and efficacy as treatments for depression. Recently, it has been noted that the endogenous opioid 
system has been implicated in some regulatory aspects of MDD symptoms. There are several 
different modulators of the endogenous opioid system that have been characterized by distinct 
structures and patterns of functional activity (Waldhoer et al. 2004; Guerrero et al. 2019). The 
kappa opioid receptor (KOR) has been identified as a key central nervous system modulator and 
is distributed throughout the brain, including in areas relevant in disorders such as depression 
and schizophrenia (Simonin et al. 1995; Mague et al. 2003; Carlezon et al. 2006; Ranganathan et 
al. 2012). Some preclinical and clinical evidence suggests that KOR antagonists have therapeutic 
value for stress- and mood-related symptoms of depression and anxiety disorders (Mague et al. 
2003; Shippenberg 2009; Lalanne et al. 2014), but the ability of this class of drugs to ameliorate 
symptoms of motivational dysfunction and fatigue have not been explored.  
Animal studies of effort-related choice behavior are being used to model effort-related 
motivational dysfunctions in humans. Our laboratory has developed several behavioral tasks in 
rodents that assess the role of DA, serotonin (5-HT), adenosine, and GABA in the exertion of 
effort and effort-related decision making (Salamone and Correa 2002; Salamone et al. 1991, 
2012). With these procedures, animals are offered a choice between high effort instrumental 
actions leading to highly valued reinforcers vs. low effort/low reward options. Several previous 
studies have shown that DAT inhibitors, including GBR12909, lisdexamfetamine, 
methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular 
monoamine transport inhibitor tetrabenazine, which blocks DA storage (Nunes et al. 2013, Yohn 
et al. 2016a,b,d; Salamone et al. 2016b). Other studies have demonstrated that SERT inhibitors 
such as fluoxetine (Prozac) and citalopram (Lexapro) are not effective at treating fatigue and 




many drugs that block DAT or SERT produce a number of undesirable side effects, there is a 
need to investigate novel alternative or adjunctive drug therapies, such as modulators of the 
endogenous opioid system, to aid in the treatment of effort-related symptoms.  
The purpose of these studies was to investigate the function of the KOR in effort-related 
aspects of motivation. Initial experiments sought to determine if a novel KOR antagonist 
(BlackThorn Therapeutics) can reverse impairments in effort-related choice behavior induced by 
the dopamine (DA) storage blocker tetrabenazine and the DA D2 receptor antagonist/5-HT2A 
receptor inverse agonist risperidone. Additional experiments investigated the effects of the 
benzodiazepine inverse agonist FG-7142 on effort-based choice as a comparison to the effects 
induced by DA depletion or antagonism. Finally, the ability of the KOR antagonist to reverse the 
effects of FG-7142 was assessed.  
 
3.2 Materials and Methods 
Animals  
Adult male, drug-naïve, Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were 
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats were 
obtained weighing 275–299 g at the beginning of the study, and were initially food restricted to 
85% of their free-feeding body weight for operant training. Rats were fed supplemental chow to 
maintain weight throughout the study, with water available ad libitum. Rats were allowed modest 
weight gain throughout the experiment. Animal protocols were approved by the University of 
Connecticut Animal Care and Use Committee, and followed NIH guidelines.  
 
Behavioral and Pharmacological Methods 
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm; Med 
Associates, Fairfax, VT). Sessions lasted 30 minutes a day for 5 days/week. First, rats were 
trained to lever press on a continuous reinforcement schedule to receive 45 mg high-
carbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for one week, then were shifted to the 
FR5 schedule. After 5 weeks of FR5 training, chow was introduced. During each FR5/chow 
feeding choice task session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000, 
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. Rats were 
trained on this FR5/chow feeding choice procedure for 5 weeks, after which drug testing began. 
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered 
during each session. 
All experiments used a within-groups (i.e., repeated measures) design. Thus, once 
animals were trained for a given experiment, all animals received all treatment combinations in a 
randomly varied order. During the drug treatment phase, rats were run 5 days per week, with 4 
days being baseline (drug-free) days, and one day per week (either Thursday or Friday) being the 
drug treatment day. Three of the studies listed below (Experiments 1, 2, and 4) are drug reversal 
studies, in which one drug is given to induce a behavioral impairment (1.0 mg/kg IP 
tetrabenazine 120 min before testing, 0.5 mg/kg IP risperidone 30 min before testing, and 6.0 
mg/kg IP FG-7142 30 min before testing). Animals also received a second injection of various 




attempt to reverse the effects of the first drug. Each study would typically involve 5 combined 
drug treatments (e.g. vehicle/vehicle, tetrabenazine/vehicle, and tetrabenazine plus 3 doses of 
KOR antagonist). Experiment 3 was conducted to establish a dose/response curve for the FG-
7142, in which animals were administered vehicle or one dose of FG-7142 (2.0, 4.0, 6.0, or 8.0 
mg/kg) in a randomly varied order over the course of five weeks. 
 
List of Drug Experiments: 
1. Effect of KOR antagonist on the effort-related effects of tetrabenazine.  
2. Effect of KOR antagonist on the effort-related effects of risperidone. 
3. Effect of FG-7142 on effort-related choice.  




 Repeated measures analysis of variance (ANOVA) was used to determine the effect of 
drug treatment on lever pressing and chow intake in the behavioral pharmacology experiments. 
To determine if there were significant reversal effects, nonorthogonal planned comparisons were 
performed, using the overall error term to assess differences between each treatment and the 
control condition. The number of comparisons was restricted to the number of treatments minus 
one (Keppel, 1991). 
 
3.3 Results 
1. Effect of KOR antagonist on the effort-related effects of tetrabenazine. A series of 
experiments were conducted to investigate the effects of a recently synthesized KOR antagonist 
(BlackThorn Therapeutics) on the effort-related impairments induced by various 
pharmacological challenges. The first experiment sought to assess the effects of the KOR 
antagonist on tetrabenazine-induced changes in performance on the concurrent FR5 lever 
pressing/chow feeding choice task. Repeated measures ANOVA demonstrated a significant 
overall main effect of treatment on lever pressing [F(4,56)=48.295, p<0.001] (Fig. 1A) and on 
chow intake [F(4,56)=21.927, p<0.001] (Fig. 1B). Planned comparisons indicated that 
tetrabenazine (1.0 mg/kg) significantly reduced lever pressing (p<0.001; Fig. 1A), and 
significantly increased chow intake (Fig. 1B) compared to the vehicle condition. There was no 
significant reversal of lever pressing when the KOR antagonist was co-administered at any dose, 





   
Figure 1. The effects of the KOR antagonist (BT) on tetrabenazine-induced changes in 
performance on the concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=15) 
were injected with vehicle or tetrabenazine (1.0 mg/kg IP) and vehicle or one of three doses of 
the KOR antagonist (3.0, 10.0, or 30.0 mg/kg P.O.). (A) Tetrabenazine significantly reduced 
lever pressing (#p<0.001) from vehicle. The KOR antagonist BT did not reverse the lever 
pressing impairment at any dose. (B) Tetrabenazine plus vehicle significantly increased chow 
intake compared to vehicle (#p<0.001). Planned comparisons indicated that when co-
administered, the KOR antagonist BT significantly reduced chow intake from tetrabenazine plus 
vehicle at 10.0 mg/kg (*p<0.05) and 30.0 mg/kg (**p<0.001).  
 
 2. Effect of KOR antagonist on the effort-related effects of risperidone. Figure 2 shows 
the effects of the KOR antagonist on risperidone-induced changes in performance on the 
concurrent FR5 lever pressing/chow feeding choice procedure. Repeated measures ANOVA 
revealed a significant overall main effect of treatment on lever pressing  [F(4,60)=27.824, 
p<0.001] (Fig. 2A) and chow intake [F(4,60)=17.350, p<0.001] (Fig. 2B). Planned comparisons 
were performed and showed that risperidone (0.5 mg/kg) significantly reduced lever pressing 
(p<0.001) and increased chow intake (p<0.001) compared to vehicle. There was no significant 
reversal of the risperidone-induced effort-related effects on lever pressing or chow intake by the 
KOR antagonist at any dose, although there was a trend towards a reversal at 10.0 mg/kg. BT did 







Figure 2. The effects of the KOR antagonist (BT) on risperidone-induced changes in 
performance on the concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16) 
were injected with vehicle or risperidone (0.5 mg/kg IP) and vehicle or one of three doses of the 
KOR antagonist (3.0, 10.0, or 30.0 mg/kg P.O.). (A) Risperidone significantly reduced lever 
pressing (#p<0.001) from vehicle. The KOR antagonist BT did not significantly reverse the lever 
pressing impairment at any dose, however, co-administration of 10.0 mg/kg BT and risperidone 
approached significance (†0.05<p<0.1). (B) Tetrabenazine plus vehicle significantly increased 
chow intake compared to vehicle (#p<0.001). Planned comparisons indicated that when co-
administered, the KOR antagonist BT significantly reduced chow intake from tetrabenazine plus 
vehicle at 10.0 mg/kg (*p<0.05) and 30.0 mg/kg (**p<0.001).  
 
 3. Effect of FG-7142 on effort-related choice. The benzodiazepine inverse agonist FG-
7142 was assessed for its effects on the FR5/chow feeding choice procedure (Fig. 3). Repeated 
measures ANOVA demonstrated a statistically significant overall effect of treatment on lever 
pressing [F(4,60)=80.872, p<0.001] (Fig. 3A). Planned comparisons revealed a significant 
reduction in lever presses compared to vehicle at all four doses of FG-7142 (2.0-8.0 mg/kg) 
(p<0.001). Repeated measures ANOVA was also used to assess the effect of FG-7142 on chow 
intake. Treatment with FG-7142 produced an overall significant effect on chow intake 







Figure 3. The effects of the benzodiazepine inverse agonist FG-7142 on effort-related choice 
behavior in rats. Rats (n=16) were injected with vehicle or FG-7142 (2.0-8.0 mg/kg IP) prior to 
performing on the concurrent FR5 lever pressing/chow feeding choice procedure. (A) FG-7142 
significantly reduced lever pressing (*p<0.001) from vehicle at all four doses. (B) FG-7142 
produced a significant overall effect on chow intake (p<0.05). Treatment with 2.0 mg/kg and 8.0 
mg/kg significantly increased chow intake relative to vehicle (**p<0.01, *p<0.05). 
 
 4. Reversal of the effort-related effects of the benzodiazepine inverse agonist FG-7142 by 
KOR antagonist. In the fourth experiment, the KOR antagonist was assessed for its ability to 
reverse the effort-related performance effects of the benzodiazepine inverse agonist FG-7142 in 
rats performing on the FR5/chow task (Fig. 4). Repeated measures ANOVA revealed a 
significant overall effect of treatment on lever pressing [F(4,60)=43.362, p<0.001] (Fig. 4A). A 
significant reduction in lever presses was produced by co-administration of 6.0 mg/kg FG-7142 
plus vehicle, compared to the vehicle plus vehicle condition. None of the three doses of the KOR 
antagonist were able to significantly reverse the FG-7142-induced suppression of lever presses. 







Figure 4. Effects of the KOR antagonist (BT) on FG-7142-induced changes in performance on 
the concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16) were injected 
with vehicle or FG-7142 (6.0 mg/kg IP) and vehicle or one of three doses of the KOR antagonist 
(3.0, 10.0, or 30.0 mg/kg P.O.). (A) FG-7142 significantly reduced lever pressing (#p<0.001) 
from vehicle. The KOR antagonist BT did not significantly reverse the lever pressing impairment 
at any dose (p=n.s.). (B) Drug treatment did not have an overall effect on chow intake (p=n.s.). 
 
3.4 Discussion 
The concurrent FR5/chow feeding choice task was useful for assessing the ability of the 
novel KOR antagonist to reverse the effects of the DA depleting agent tetrabenazine, the DA 
D2/5-HT2A inverse agonist risperidone, and the benzodiazepine inverse agonist FG-7142. In 
order to assess the effect of the KOR BT on FG-7142, it also was necessary to determine if FG-
7142 induced effort-related effects in rats performing on this task. In summary, the KOR 
antagonist was unable to reverse the suppression in lever pressing caused by tetrabenazine, 
risperidone, although it did reverse the increase in chow intake produced by these drugs. BT also 
failed to reverse the suppression of lever pressing induced by FG-7142. These data suggest that 
the KOR antagonist is not an effective treatment of effort-related dysfunction when administered 
on its own as measured by the FR5/chow feeding choice task. Nevertheless, it is possible that it 
could be tested in the future as a potential adjunct therapy in combination with dopaminergic 
compounds. Furthermore, previous research has demonstrated that the effects of other KOR 
antagonists can take up to hours or days (Guerrero et al. 2019), so it is possible that the time 
course of this more recently synthesized compound may need to be further elucidated in in vivo 
behavioral experiments. 
The third experiment provided the first examination of the effects of FG-7142 using a 
task that assesses effort-based choice. FG-7142 is a benzodiazepine inverse agonist that acts as 
an anxiogenic drug and produces signs of the stress response. Preclinical studies of the role of 
stressors in modulating aspects of motivational performance are important, because stress is 
generally seen as a factor in several psychopathologies. Previous research has shown that 





releasing hormone can produce a low effort bias in tests of effort-based choice (Shafiei et al. 
2012; Bryce and Floresco, 2016; Dieterich et al. 2020). In the present studies, FG-7142 
substantially decreased lever pressing, but did not significantly increase chow intake in the dose 
range tested. Nevertheless, and examination of the dose response curve for FG-7142 indicates 
that the lowest dose (2.0 mg/kg) produced a substantial reduction in lever pressing, and at that 
dose there was a tendency for most rats to show an increase in chow intake. Thus, future research 
should explore the possibility that low doses in the range of 1.0-3.0 mg/kg would in fact produce 
a significant shift from lever pressing to chow intake. 
Taken together, these experiments provide critical preclinical research that address the 
feasibility of using KOR antagonists to improve effort-related aspects of motivation in people 
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